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Abstract   
The  Spondyloarthritides  (SpAs)  are  a  group  of  related  inflammatory  disorders  that  share 
common clinical features and a genetic predisposing factor, the MHC class I gene HLA-B27. 
Rats transgenic for the human HLA-B27 and !2 microglobulin genes (B27-TG rats) develop a 
multisystem  inflammatory  disease,  offering  a  model  for  studying  SpA.  Several  lines  of 
evidence from both humans and rats suggest that intestinal inflammation and the commensal 
microbiota in the gut are important in disease development. The intestine is the site of entry for 
vast amounts of antigens, and the intestinal immune system has evolved to be tolerant towards 
harmless non-self antigens, but still retain the ability to mount protective immune responses 
against invading pathogens. Dendritic cells (DCs) are professional antigen presenting cells 
residing in the intestinal tissue at sites of antigen entry, and continuously migrate from the 
intestine into the mesenteric lymph nodes, via lymph, where they interact with naïve T cells. 
Hence, DCs have important role in maintaining the balance between tolerance and immunity in 
the intestine.  
The aim of this thesis was to investigate the roles of migrating intestinal lymph DCs (L-DCs) 
in  disease  development  in  the  B27-TG  rat.  These  DCs  were  collected  by  thoracic  duct 
cannulation  and  their  phenotype  and  functions  were  investigated.  In  addition,  mesenteric 
lymph node (MLN) and bone marrow derived DCs (BMDCs) were compared between B27-
TG and non-TG animals. 
B27-TG animals lack one of the three subsets of L-DCs, the MHCII
hi CD103
+ CD172a
lo cells, 
in the pseudo-afferent lymph, and the remaining L-DCs appear more activated. The proportion 
of this subset was also reduced in the MLNs of B27-TG animals. The CD172a
lo DC subset has 
been implicated in the induction and maintenance of intestinal tolerance, and thus lack of this 
subset could lead to breakdown in tolerance and to systemic disease. In addition, BMDCs 
cultured with mouse Flt3L survived less well than non-TG BMDCs, and this defect could be 
reversed by addition of the apoptosis inhibitor Q-VD into the cultures. This indicated there 
could be a defect in the development of B27-TG DCs from their bone marrow precursors. 
Furthermore, B27-TG BMDCs stimulated significantly less proliferation from naïve CD4
+ T 
cells than their non-TG counterparts in a mixed leukocyte reaction. In spite of this, more IL-
17F and less IFN-! were detected in the B27-TG BMDC-T cell co-cultures compared to non-
TG  DCs,  indicating  skewing  of  the  immune  response  from  Th1  to  Th17.  Together,  these 
results reveal previously unrecognised defects in HLA-B27
+ DCs both in vivo and in vitro, 
which could have a role on SpA disease pathogenesis. This opens up new exciting avenues of 
research for the future.      
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1.  Introduction 
1.1   Spondyloarthritides 
The  Spondyloarthritides  (SpAs)  are  a  group  of  inter-related  but  heterogeneous 
inflammatory disorders that share common genetic predisposing factors. These diseases 
also share some clinical features, however each disease in the group also has its own 
distinct features. Historically, it was suggested by Moll et al in 1974 that this group of 
diseases  indeed  form  their  own  group  of  related  disorders  separate  from  rheumatoid 
arthritis, and they were originally named as seronegative spondarthrides (1). Today, the 
term  spondyloarthritis,  or  spondyloarthritides  in  plural,  is  preferred.  The  SpA  group 
includes psoriatic SpA (PsSpA), reactive arthritis (ReA), arthritis related to inflammatory 
bowel disease (SpA-IBD), a subgroup of juvenile idiopathic arthritis, undifferentiated SpA 
(uSpA) and ankylosing spondylitis (AS), which is the most common and most studied 
member of the group (Figure 1.1). Common clinical features, described in the original SpA 
publication (1) and expanded more recently (2-4), include sacroiliitis with inflammatory 
back pain, peripheral arthropathy, enthesitis, extra-articular or extra-spinal involvement, 
including that of the eye, heart, lung, and skin, and the absence of rheumatoid factor and 
subcutaneous nodules. In addition, all the SpA diseases share a common genetic factor, the 
major histocompatibility (MHC) class I gene HLA-B27 (5). The prevalence rate for the 
combined SpA diseases in the general population is estimated to be roughly the same as for 
RA, ranging from 0.3 % to 1.9 % depending on the population studied and the methods 
used (6, 7).  
Juvenile 
SpA 
Undifferentiated 
SpA 
Reactive 
arthritis 
Acute anterior 
uveitis 
Psoriatic 
Arthritis 
Arhtitis 
associated with 
Ulcerative colitis/ 
crohnʼs disease 
Ankylosing Spondylitis 
Figure 1.1. Diseases belonging to the SpA group. Modified From 
the ASAS slide collection, http://www.asas-group.org, open access.  
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SpA  patients  can  be  divided  into  two  groups  based  on  their  symptoms:  1)  patients 
presenting with axial SpA, characteristic of AS, or 2) patients presenting with peripheral 
symptoms only. Thus, two different diagnostic classification criteria have been developed 
recently by the Assessment of Spondyloarthritis International Society (ASAS) to be able to 
identify patients presenting with or without axial symptoms as having SpA (8). For axial 
SpA, the inclusion criteria are back pain for at least three months and a young age (<45), 
combined with either sacroiliitis or HLA-B27 positivity combined with other classical SpA 
features  (Figure  1.2.).  Peripheral  SpA  inclusion  criteria  are  arthritis,  enthesitis  and 
dactylitis, combined with one or two additional SpA features (Figure 1.2.). These two 
criteria can be combined by dictating that all patients presenting with back pain (with or 
without  peripheral  features)  follow  the  assessment  for  axial  SpA,  whereas  for  patients 
manifesting  with  only  peripheral  symptoms,  the  ASAS  criteria  for  peripheral  SpA  are 
followed. 
As the diseases belonging to the SpA family vary greatly in their symptoms and all of them 
have some specific characteristics not necessarily present in the other members of the SpA 
family, it is not possible to describe all of them in great detail within the scope of this 
thesis. Thus, I will mostly concentrate on ankylosing spondylitis, as it is the archetypal 
disease of the family and it is also the most studied. Information about the other members 
of the SpA family will be given when relevant, and can also be found in several other 
publications (2-4, 9-11).  
In patients with ≥3 months back pain (w/ or 
w/o peripheral manifestations) and age of 
onset <45 years 
Sacroilitis on 
imaging plus ≥1 
SpA feature 
HLA-B27 plus ≥2 
other SpA 
features 
 
SpA features 
!  Inﬂammatory back pain 
!  Arthritis 
!  Enthesitis (heel) 
!  Uveitis 
!  Dactylitis 
!  Psoriasis 
!  Crohnʼs/ Ulcerative colitis 
!  Good response to NSAIDs 
!  Family history for SpA 
!  HLA-B27 
!  Elevated CRP 
OR 
In patients with peripheral manifestations 
only 
Arthritis or enthesitis or dactylitis  
plus: 
 
≥1  SpA feature 
!  Uveitis 
!  Psoriasis 
!  Crohnʼs/ ulcerative colitis 
!  Preceding infection 
!  HLA-B27 
!  Sacroilitis on imaging 
OR 
≥2  other SpA features 
!  Arthritis 
!  Enthesitis 
!  Dactylitis 
!  Inﬂammatory back pain ever 
!  Family history of SpA 
Figure 1.2. SpA assessment 
Combined use of the Assessment of SpondyloArhritis Society (ASAS) 
criteria for axial and peripheral SpA in the entire SpA population. Modified 
from (8).  
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1.1.1  Epidemiology of AS 
The most common diagnosis for patients presenting with axial symptoms only is AS, and 
its prevalence among adults has been estimated to be between 0.2 and 0.9 % according to 
studies carried out in Berlin and France (6, 7). Ankylosing spondylitis generally affects 
younger people, as 80 % of AS patients present with their first symptoms before the age of 
30 and less than 5 % older than 45 years (12). Unlike many other autoimmune diseases, 
AS  affects  men  more  often  than  women  with  the  ratio  of  about  2-3:1.  Overall  the 
prevalence of AS in Europe is estimated to be 0.1 - 1.4 % and the incidence of the disease 
is between 0.5-14 people per 100,000 people per year (13). 
1.1.2  Pathogenesis and genetics of SpA 
In spite of vigorous research, the exact genetic and environmental triggers of AS, or other 
SpAs,  are  not  known.  In  1973  two  groups  reported  independent  findings  of  a  strong 
association between the MHC class I molecule HLA-B27 and AS (14, 15). However, after 
three decades of research the functional role of HLA-B27 in SpA disease pathogenesis is 
still obscure. Through twin studies it has been established that AS has a strong genetic 
component; monozygotic twins have concordance rate of 63 % compared with a dizygotic 
concordance rate of 12.5 % (16). Overall, it has been estimated that genetic factors account 
for over 90 % of AS disease susceptibility with the rest being attributed to random, but 
widespread,  environmental  factors  (16).  It  is  now  commonly  accepted  that  the  overall 
contribution of HLA-B27 to the AS susceptibility is 30-40 %; the rest are attributed to other 
genes within and outside the MHC locus such as IL-23 receptor (IL-23R) and endoplasmic 
reticulum aminopeptidase (ERAP1), which have been proposed to contribute 9 % and 26 
%, respectively, to disease susceptibility (Table 1.1) (10). Even though other genes have 
been linked to AS, HLA-B27 remains by far the most strongly associated with about 90-95 
% of AS patients being positive for the HLA-B27 gene (14, 17). Other SpA diseases also 
show a strong association with HLA-B27 as about 70 % of Caucasian reactive arthritis 
patients are positive for HLA-B27, as well as 60-70 % of psoriatic spondylitis patients and 
50-60 % of patients presenting with SpA-IBD (10). 
  HLA-B27 
HLA-B27 is a class I MHC gene expressed by all the nucleated cells in the body. It is a 
relatively  common  subtype  of  MHC  class  I,  with  on  average  7-8  %  of  Caucasians 
expressing  it  (18).  Despite  being  very  closely  linked  to  the  development  of  SpA,  as  
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discussed  above,  fewer  than  5  %  of  HLA-B27
+  individuals  in  the  general  population 
develop AS or other SpAs (7, 19). However, there is a strong familiar heritability as first 
degree relatives of AS patients have 5-16 times greater chance of developing AS than 
HLA-B27
+ individuals in the general population (20). The low percentage of HLA-B27
+ 
people developing SpA suggests there are other factors, genetic or environmental, affecting 
the risk of developing the disease. Indeed, as mentioned HLA-B27 only accounts for about 
30-40 % of disease susceptibility, with other genes inside and outside the MHC locus 
together  with  environmental  factors  accounting  for  the  rest.  Thus,  for  the  disease  to 
develop, a certain genetic background may be required as well as environmental factors to 
trigger it. Also, at present over 80 subtypes of HLA-B27 have been defined (21), some of 
which confer disease susceptibility more strongly than others (22). Some are so rare it has 
not been possible to link them to AS or other SpAs.  
The B*2705 allele is thought to be the parent molecule for all the other subtypes, and 
together with B*2704 and B*2702 subtypes it accounts for almost all HLA-B27-positive 
north European Caucasians (23). These three alleles are also the two most strongly disease 
associated alleles (23). Several other HLA-B27 subtypes have also been associated with 
AS, but more weakly than B*2705 and B*2704. These other subtypes are believed to have 
developed  from  B*2705  through  population  migration,  as  different  ethnic  populations 
carry different mixture of HLA-B27 subtypes (16, 24, 25). B*2706 and B*2709 have been 
reported not be associated with AS, and even though some cases of AS have been reported 
on people with this background, it is thought that these alleles are at most very weakly 
associated (26-28). The variability in the mixture of HLA-B27 subtypes seen in different 
populations might be the result of evolution and in response to environmental stresses. 
This variability may have been maintained through natural selection by local infectious 
diseases, as has been shown to be the case to other HLA antigens (29). Indeed, HLA-B27 
has been shown to confer protection towards viral infections such as Epstein-Barr virus 
and herpes simplex virus type 2 (29). Furthermore, HIV progression has been shown to be 
slower in HLA-B27
+ individuals (29).  
As mentioned above, no definite role for HLA-B27 in SpA disease pathogenesis has been 
defined.  However,  several  hypotheses  try  to  address  this  issue:  (a)  The  Arthritogenic 
peptide theory hypothesises that HLA-B27 presents a distinct peptide repertoire, where 
some  of  the  peptides  might  be  molecular  mimics  of  self-antigens,  which  would  cause 
immune reaction against self; (b) HLA-B27 misfolds and contributes to inflammation by 
activating a series of intracellular events known as the unfolded protein response; and (c)  
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HLA-B27 forms a homodimer on the cell surface, and this serves as an activating ligand for 
natural killer cells. All these theories are discussed in detail later in this chapter. 
  Association with genes other than HLA-B27 
Traditionally, genetic studies of diseases have been hypothesis led; that is, a suspect gene 
or genes are selected, and it is then investigated whether they are differentially expressed 
between healthy controls and patients. In recent years genetic studies have changed as the 
technology and knowledge of how to carry out studies investigating the whole genome 
have expanded. These genome wide association studies (GWAS) are carried out without 
any underlying hypothesis, using the whole genome of affected individuals and healthy 
controls.  Following  initial  analysis,  differentially  expressed  genes  are  identified  and 
subsequently verified by more traditional methods of Q-PCR, for example. Use of these 
GWAS studies to study AS patients have led to the identification of several additional 
genes linked to the disease (Table 1.1). Of these, ERAP1 and IL-23R have been studied 
most, and their association has also been verified in other independent studies (30). ERAP1 
is  an  intracellular  molecule  expressed  in  the  endoplasmic  reticulum  (ER),  and  is 
ubiquitously expressed throughout the body. The role of ERAP1 in AS pathogenesis is 
unclear, but it is thought it could be involved through one or both of its two different 
functions. First, ERAP1, together with ERAP2, trims peptides destined for loading onto 
MHC I molecules to a correct length (31), and it could be that this function is defective in 
AS  patients,  leading  to  disruption  in  antigen  presentation  on  MHC  class  I  molecules. 
Supporting this theory, ERAP1
-/- mice have been shown to be more prone to infection with 
the  intracellular  parasite  Toxoplasma  gondii  due  to  defective  presentation  of  parasite 
antigen on MHC class I molecules (32). The second role proposed for ERAP1 is to cleave 
proinflammatory cytokine receptors, such as IL-1R2, TNFR1 and IL-6R", from the cell 
surface and thus create soluble receptors with potential to bind their respective ligands and 
attenuate the effect of these cytokines (33-35). However, these data have been obtained 
using in vitro cell lines and no in vivo data are available to support this latter function of 
ERAP1. 
Another gene found to be associated with AS in the GWAS study was IL-23R. Unlike 
ERAP1, which has not been found to be associated with other diseases, single-nucleotide 
polymorphisms (SNPs) in the gene encoding IL-23R have also been linked to IBD (36), 
psoriasis (37) and more recently to psoriatic arthritis another disease of the SpA family 
(38). IL-23R is a heterodimeric receptor for the cytokine IL-23. It is composed of IL- 
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12R#1 chain, a component of IL-12 receptor complex, and a specific IL-23R chain (39). 
The IL-12R#1 receptor binds to janus kinase (Jak) family member Tyk2, whereas IL-23R 
associates  with  Jak2  (39).  Signalling  through  the  receptor  complex  leads  to 
phosphorylation  of  Jaks,  and  they  in  turn  phosphorylate  tyrosine  residues  in  the 
intracellular portions of the receptor subunits. STATs (signal transducers and activators of 
transcription) in turn bind to these phosphorylated tyrosine residues (39). In humans IL-
23R is expressed on activated/memory T cells, natural killer (NK) cells, and at low levels 
on  activated  macrophages  and  dendritic  cells  (DCs)  (40).  In  mice  it  is  expressed  by 
activated  macrophages,  bone  marrow  derived  DCs  and  activated  T  cells  (40).  These 
activated T cells expressing IL-23R were found to be a novel CD4
+ helper T cell subset, 
named  Th17,  which  produce  the  cytokine  IL-17  (41,  42).  Th17  cells  have  raised 
considerable research interest lately as they have been indicated to have a pathological role 
in many animal models of autoimmune diseases, such as collagen induced arthritis and 
experimental autoimmune encephalomyelitis (43, 44), as well as in many human diseases 
such as RA, IBD and psoriasis (45). These cells are discussed in detail later in this chapter. 
One IL-23R SNP, R381Q, has been found to confer protection from several inflammatory 
diseases, and in a recent publication it was shown that memory CD4
+ and CD8
+ T cells 
from healthy people carrying this SNP mutation showed decreased IL-23-dependent IL-17 
and  IL-22  production  relative  to  individuals  with  WT  IL-23R  (46).  In  addition,  this 
phenomenon was associated with a lower percentage of circulating Th17 cells. These data 
indicate,  perhaps,  that  non-protective  mutations  could  work  in  the  opposite  manner, 
increasing the numbers of circulating Th17 cells. There is, however, no direct evidence for 
a role for IL-23R mutations in SpA pathogenesis. Indeed, it is not currently known whether 
the disease-associated variants of IL-23R cause gain or loss function. However, several 
genes associated with IL-23R signalling have been linked to AS, thus indicating that IL-
23R can indeed have a role in SpA pathogenesis. These genes include: 1) IL-12B, which 
encodes the 40-kd (p40) chain, a component of both IL-12 and IL-23; in the latter, it is 
paired  with  a  19-kd  protein  (p19);  2)  caspase  recruitment  domain  9  (CARD-9),  which 
encodes a major signaling intermediate in the pathway whereby fungal products induce IL-
23 production from DCs; and 3) STAT-3 (24). STAT3 is a key transcription factor in 
IL23R signaling, and loss-of-function mutations of STAT3 cause failure of development of 
Th17  lymphocytes,  resulting  in  Job’s  (hyper-IgE)  syndrome,  which  is  associated  with 
severe, recurrent fungal and bacterial infections (47).  
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Table 1.1. Genes linked to development of AS, and the relationship of these genes to 
psoriasis and IBD, using GWAS studies (modified form (5)).  
 
Gene 
 
Function  Associated with 
   
Ankylosing 
spondylitis 
Psoriasis 
Inflammatory 
bowel disease 
HLA-B  Ag presentation  Yes  --  -- 
ERAP1  Aminopeptidase  Yes  Probable  -- 
IL23R  Cytokine receptor  Yes  Yes  Yes 
TNFRSF1A  Cytokine receptor  Probable  --  Yes 
TRADD  Signalling  Probable  --  -- 
TNFSF15  Inflammatory cytokine  Probable  --  Yes 
IL1A  Inflammatory cytokine  Probable  --  -- 
IL1R2  Cytokine receptor  Probable  --   -- 
CARD9  Innate immune defence  Probable  --  -- 
ANTRX2  Vascular morphogenesis  Probable  --  -- 
 
1.1.3  Role for intestinal microbiota in SpA pathogenesis? 
The role of intestinal inflammation and microbiota in SpA pathogenesis has long been 
under  debate.  It  is  reported  that  25-70  %  of  SpA  patients  display  signs  of  intestinal 
inflammation,  and  moreover,  6-13  %  of  these  patients  eventually  develop  overt  IBD. 
Furthermore, 50 % of HLA-B27
+ IBD patients develop AS, compared with 1-10 % of 
HLA-B27
+ individuals in the general population (48). Also, as mentioned above, both IBD 
and  AS  have  additional  shared  genetic  factors,  such  as  IL23R  polymorphisms,  further 
suggesting that these two diseases might have shared pathogenic mechanisms. Thus, I will 
briefly  discuss  evidence  linking  intestinal  inflammation,  and  especially  the  intestinal 
microbiota, to the development of SpA. 
In  several  studies  a  role  for  the  intestinal  microbiota  in  AS  development  has  been 
suggested,  but  no  concrete  evidence  have  been  found.  In  ReA,  a  subgroup  of  SpA, 
peripheral joint inflammation in genetically predisposed individuals has been shown to be 
triggered  by  particular  bacterial  gut  infections,  such  as  Salmonella  typhimurium, 
Campylobacter  jejuni,  Yersinia  enterocolitica  and  Shigella,  and  antigens  from  these 
bacteria have also been found in the joints of these patients (49). About 20 % of these ReA 
patients will eventually develop AS, providing a link for the role of gut inflammation in 
SpA. In addition, there is some evidence to support the role of intestinal bacteria Klebsiella  
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in  AS  (reviewed  in  (50)),  although  in  some  cases  these  observations  have  been 
controversial; they have proved difficult to replicate, and in addition the studies carried out 
have been relatively small. Nonetheless, higher titers of antibodies against these bacteria 
were found in the serum of AS patients compared to RA patients or healthy controls (50). 
Additionally, elevated levels of antibodies against K. pneumoniae were associated with a 
higher degree of gut inflammation in Finnish patients with axial AS (51); and in a study 
from 1980, cross-reactivity between antisera against a specific isolate of Klebsiella and 
HLA-B27 itself was also reported (52). To support the role for bacterial infections in AS 
pathogenesis, it has also been noted that HLA-B27 shares an unusually high degree of 
sequence similarity with proteins derived from gram-negative bacteria (53, 54), possibly 
lending support for the hypothesis of arthritogenic peptide presentation described above.  
1.1.4  Treatment of SpA 
There is no cure for SpA, but several treatments can be used to alleviate the symptoms 
(reviewed in (55). Conventional anti-rheumatic drugs, such as sulfasalazine, methotrexate 
and leflunomide have no effect on the axial or enthesopathic features of SpA, but have 
some effects on peripheral arthritis and other extra-articular features such as psoriasis, 
uveitis and IBD. The most commonly used treatment of SpA is anti-tumour necrosis factor 
(TNF)-" therapy. It has been shown to reduce general symptoms such as fatigue, and 
improve the overall function and quality of life. However, TNF-" therapy appears to halt 
joint destruction, but has no effect on the formation of new bone regularly observed in 
SpA. Anti-TNF-" therapy is not effective for all patients, and thus several therapies are 
either under trial or being developed. For example, B cell therapy with rituximab, shown to 
be effective in RA, was shown not to have a similar efficacy in SpA as in RA. T cell 
targeted  therapies,  such  as  efalizumab  (anti-CD11a/LFA-1),  alefacept  (anti-LFA3)  and 
abatacept (CTLA-4-Ig), have not been successful in the treatment of SpAs. Based on the 
newly suggested role for Th17 cells in SpA pathogenesis, antibodies against IL-6 (Th17 
differentiation) and IL-17 (effector cytokine) are currently being trialled. 
1.2  Dendritic cells 
 DCs  have  several  roles  in  immune  regulation  in  several  locations  in  the  body.  As 
professional  antigen  presenting  cells  (APCs),  they  are  responsible  for  the  induction  of 
antigen specific immune responses by T cells. However, they also have important roles in 
induction and maintenance of peripheral tolerance. Because DCs have such a big role in  
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the immune system, it is possible they could be involved in the pathogenesis of SpA. Thus, 
in this section I take a closer look at DCs and their interaction with other immune cells, 
and their role in immune regulation in general terms. As has been mentioned above, the 
intestinal immune system seems to also have an important role in the pathogenesis of SpA, 
and hence the intestinal immune system and in particular intestinal DCs are discussed in 
greater detail in their own section. 
1.2.1  What is a dendritic cell? 
DCs are highly specialised cells of the immune system present in most tissues and organs 
of the body, where they act as phagocytic cells continuously sampling their environment. 
The first descriptions of DCs were published in 1973 by Ralph Steinman’s group, when 
they found cells with a unique morphology in murine lymph nodes (LNs) and Peyer’s 
patches (PP) (56), and a few years later in mouse spleens (57). These cells were named 
dendritic cells due to the visible “dendrites” these cells possess. DCs can also sample 
antigen, either self- or foreign, from the tissues where they reside, and migrate out of the 
tissues via lymphatic vessels and into organised lymphoid tissues, where they act as APCs 
capable of activating cells of the adaptive immune system. In fact, DCs were also found to 
be unique in their ability to induce naïve T cell proliferation in allogeneic mixed leukocyte 
reactions (MLRs) (58). Thus, whilst DCs can act as a link between the innate and adaptive 
immune systems, they also have an additional role in the induction and maintenance of 
peripheral tolerance. All of these functions of DCs will be discussed in more detail in the 
sections that follow. 
1.2.2  DC classification 
Not only are DCs unique regarding their function and phenotype, many would also say 
they are a uniquely heterogeneous group of cells – reflecting their many diverse functions 
and  physical  locations  within  the  body.  This  heterogeneity  poses  many  challenges  to 
researchers, the first of which is classification. Traditionally, DCs have been referred to as 
either  myeloid  DCs  or  plasmacytoid  DCs  (pDCs),  as  it  was  thought  that  all  DCs  are 
derived from myeloid precursors. However, as discussed below, DCs can be derived from 
both  myeloid  and  lymphoid  bone  marrow  precursors,  another  unique  DC  feature,  thus 
making the traditional classification inaccurate. Using a more modern approach DCs are 
first divided into either conventional (cDCs) or non-conventional DCs. Conventional DCs 
arise from pre-DC precursors and have classical DC functions, and can be further divided 
into migrating and resident DCs. Migrating DCs reside in peripheral tissues, such as skin  
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and intestine, and upon acquiring antigen they are able to migrate to draining LNs, where 
they interact with T cells. Resident DCs, on the other hand, reside in the lymphoid organs 
such  as  spleen,  thymus  and  LNs,  and  lack  migratory  function.  Non-conventional  DCs 
include  pDCs,  which,  although  derived  from  the  same  common  myeloid  progenitors 
(CDPs)  as  cDCs,  are  distinguished  from  cDCs  by  their  unique  ability  to  secrete  large 
amounts of IFN upon activation. Also it has been recently shown that DCs can be derived 
in vivo and in vitro from monocytes under specific conditions both in steady state and 
under inflammatory conditions; these DC subsets are also classified as non-conventional 
DCs. Subsets of DCs belonging to these various groups are discussed later on this section. 
1.2.3  Cytokines in DC development: evidence from in vitro and in vivo 
studies 
Because  DCs  are  such  a  heterogeneous  group  of  cells,  details  of  their  complex 
developmental pathways have only recently started to emerge. In addition, as is common, 
most of what is known about DC development at the moment is derived from studies 
carried out in the mouse, and in some cases in humans. In the rat, not much information is 
available, and thus at this point we can only assume that DC development is similar in 
mice  and  rats.  However,  what  is  known  is  that  all  DCs,  like  other  leukocytes,  are 
differentiated from hematopoietic stem cells in the bone marrow (BM), which requires the 
integration  of  environmental  signals  surrounding  the  cell.  These  signals  include  for 
example  cytokines  or  growth  factors,  which  can  act  either  locally  in  the  immediate 
microenvironment,  or  they  can  act  distantly  by  traveling  in  the  bloodstream  or  lymph 
vessels from the site where they were produced. Here, cytokines and growth factors most 
commonly associated with DC development, granulocyte-macrophage colony stimulating 
factor  (GM-CSF),  fms-like  tyrosine  kinase  3  ligand  (Flt3L)  and  macrophage-colony 
stimulating factor (M-CSF), are discussed. 
DCs cultured from bone marrow (BMDCs) are often used in experiments due to the rarity 
and difficulty of obtaining DCs in vivo or ex vivo. Two main cytokines used to generate 
DCs in vitro from BM cells, are GM-CSF and Flt3L. GM-CSF was the first cytokine 
described to be capable of supporting DC differentiation in vitro (59). Addition of this 
cytokine, with or without the cytokine IL-4, to murine monocyte or bone marrow cultures 
leads to generation of high numbers of BMDCs, which were thought to be the in vitro 
equivalent  of  steady  state  cDCs.  However,  these  cells  are  both  functionally  and 
morphologically different from cDCs isolated ex vivo (60); they are larger, contain more 
granules  and  also  produce  higher  amounts  of  TNF-"  and  nitric  oxide  (iNOS)  after  
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stimulation  than  cDC  (61).  Similar  cells  were  also  identified  in  rat  BMDC  cultures 
supplemented with IL-4 and GM-CSF (62). In vivo, cells with a similar phenotype were 
first discovered in spleens of mice 1-2 days after infection with Listeria monocytogenes; 
these were named TNF-" and iNOS producing DC (Tip-DC) (61). Furthermore, GM-CSF-
deficient mice or mice lacking the GM-CSF receptor have only a very slight decrease in 
splenic and LN cDCs compared to wild type mice (63). Another factor factoring against 
the role for GM-CSF in steady state DC development is the fact that GM-CSF levels are 
undetectable in the blood in the absence of inflammation (64), and thus it is unlikely it 
could drive differentiation of monocytes under non-inflammatory conditions. These data 
derived from both in vitro and in vivo animal studies have led researchers to consider these 
GM-CSF-dependent cells likely to be monocyte derived cells resembling the inflammatory 
in vivo tip-DCs.  
In contrast to BMDCs grown with GM-CSF, rat or mouse BM cells but not monocyte 
cultures, supplemented with Ftl3L give rise to both pDCs and cDCs resembling steady 
state DC populations (60, 65, 66). In addition, Flt3L or Flt3 receptor knock out mice have 
severely reduced DC numbers in spleen, LN and thymus (67, 68). In vivo, injection of 
Flt3L to mice or humans leads to massive expansion of cDCs, pDCs and myeloid cells, but 
not B or T lymphocytes (69-71). Unlike GM-CSF, Flt3L is also readily detected in the 
serum even in the absence of inflammation (72).  
M-CSF null mice, or mice deficient in M-CSF receptor have severe problems in monocyte 
development in early life and lack some macrophage subsets (73). Total DC numbers are 
reduced in these animals, however they also present with reduced spleen size, which could 
explain the lower DC numbers observed. In addition, splenic DC subsets are present in 
their expected number and density, thus suggesting that M-CSF is not needed for steady-
state DC development from DC precursors, nor from monocyte precursors.  
Taken together, these data indicate that Flt3L is essential for the development of cDCs and 
pDCs under steady state conditions, whereas GM-CSF and M-CSF are not. 
1.2.4  DC ontogeny and life cycle 
The development of DCs from bone marrow precursors is an active field of study, and 
much is still not known. Here I seek to give a brief summary of what is known about DC 
development and ontogeny thus far, with the intentional omission of precursors prior to  
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lymphoid and myeloid precursors. DC development has also been recently discussed in 
several reviews (73-75).  
Two distinct cell lineages can be recognised in the bone marrow: myeloid and lymphoid 
lineages. Common myeloid progenitor (CMP) cells gives rise to monocytes, macrophages, 
granulocytes, megakaryotes and erythrocytes, whereas B, T and natural killer (NK) cells 
differentiate from the common lymphoid progenitor (CLP). DCs are unique, as it has been 
shown that they can be derived from both myeloid and lymphoid lineages. However, about 
90  %  of  DCs  in  all  compartments,  except  for  thymus,  are  derived  from  the  myeloid 
precursors. A very simplified picture of DC development in the mouse, which probably 
also  takes  place  in  rats,  is  provided  in  Figure  1.3.  CMPs  give  rise  to  monocyte-DC 
progenitors (MDP), which have the potential to differentiate into monocytes, or into the 
common DC progenitor cell (CDP). This is dependent on the signals provided: it is thought 
that  presence  of  growth  factor  M-CSF  instructs  MDP  to  produce  monocytes,  whereas 
Flt3L  drives  differentiation  of  CDPs.  Consequently,  all  cells  following  the  DC 
differentiation  pathway  express  the  receptor  for  Flt3L,  Flt3,  whereas  its  expression  is 
downregulated on cells following the monocyte differentiation pathway.  
CDPs in turn can give rise to both pDCs and a cell type called pre-DC, which is the 
immediate precursor for cDCs. Monocytes, pDCs and pre-DCs leave the BM and travel 
vial blood to peripheral tissues, where pre-DCs differentiate into tissue resident DCs, and 
monocytes into macrophages. In addition to giving rise to resident splenic and LN DCs, it 
has also been shown that pre-DCs are precursors for all CD103
+ DCs in non-lymphoid 
tissues such as skin, lung, kidney and intestine, and also for some CD103
$ DCs in those 
organs.  As  mentioned  above,  monocytes  can  also  give  rise  to  DCs  under  some 
circumstances. This is thought to occur under inflammatory conditions, when monocytes 
are exposed to the inflammatory cytokine GM-CSF. However, in rats it has been shown 
that CD43
hi CCR2
lo CX3CR1
hi monocytes, corresponding to mouse Ly6C
lo monocytes, 
can give rise to some DC subsets even in steady-state (76).      
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Figure 1.3. Development of DCs from BM precursors – a simplified view 
In the BM, common myeloid precursors (CMP) give rise to macrophage-DC precursors (MDP). DC 
potential is retained in all CMPs and common lymphoid progenitors (CLPs), and is restricted to 
progenitors expressing Flt3 receptor (green receptor on cells). MDPs in turn give rise to both 
monocytes and common DC precursors (CDP). In addition, CLPs are thought to be able to give rise 
to CDPs as well. 
Monocytes leave the bone marrow (BM) and under influence of M-CSF give rise to macrophages in 
the peripheral tissues (blue receptor denotes M-CSF receptor). However, it is also believed that 
monocytes can be induced to become inflammatory DCs under inflammatory conditions under the 
influence of GM-CSF (denoted by red arrows, and red GM-CSF receptor).  
CDP in the BM give rise to both pDCs and to classical DC precursors (Pre-DCs). pDCs exit the 
bone marrow, circulate in the blood and can enter the peripheral tissues. Pre-DCs also exit the 
bone marrow, but it is not certain whether they circulate in blood, or immediately home to peripheral 
tissues where they give rise to the various cDC subsets under the guidance of the local 
microenvironment. It is believed that Flt3L directs the development of DCs from MDP downwards. 
The dotted lines demonstrate additional developmental pathways that may lead to development of 
cDCs. 
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1.2.5  Subsets of dendritic cells  
As  noted  above,  DCs  can  be  classified  into  several  groups  and  subgroups.  However, 
almost all the groups contain several subsets of DCs. In this section I will introduce some 
of these DC subsets belonging to these groups; most of the information comes from studies 
with mice, but I will also incorporate elements of what is known about rat and human DCs. 
  Conventional DCs 
Conventional  DCs  are  present  in  most  tissues  of  the  body,  including  internal  organs, 
lymphoid  tissues  and  mucosal  surfaces.  However,  as  cDCs  are  relatively  scarce  in 
peripheral tissues and difficult to isolate, most research has focused on cDCs present in 
lymphoid tissues such as spleen and LNs. Mouse splenic DCs were originally divided into 
two subsets according to the expression of the surface CD8"" homodimer (77); CD8""
+ 
and CD8""
$ (referred to as CD8
+  and CD8
$, respectively). CD8
+ cells are also DEC 205
+ 
CD11b
lo  CD172a
lo,  whereas  CD8
$  cells  are  DEC  205
$  CD11b
+  and  CD172a
+. 
Furthermore, it was found that splenic CD8
$ DCs could be divided into two additional 
populations according to expression of CD4: CD8
$ CD4
+ and CD8
$ CD4
$ (DN, double 
negative). CD8
+ splenic DCs are all negative for CD4 (78). These same DC subsets can 
also be found in mouse LNs (79). In addition to displaying different surface markers, in the 
steady state these subsets of DCs are also found in different areas within the lymphoid 
organs: CD8
+ DCs are mainly found in the T cell areas, whereas CD8
$ DCs reside in the 
marginal zones (80). However, upon stimulation CD8
$ cells are able to migrate into the T 
cell areas (81).  
CD8
+ and CD8
$ cells also differ in their functions, although the CD8
$ DCs are not as well 
characterised as CD8
+ DCs. DN DCs have been shown to be poor stimulators of CD8
+ T 
cells in vitro and instead they have been shown to prime OVA-specific OTII CD4
+ T cells, 
which secrete IL-10 and suppress the immune response via a transforming growth factor 
(TGF)-! dependent mechanism (82). However, when DN DCs were stimulated with Toll-
like  receptor  (TLR)  9  agonist  CpG,  they  were  converted  from  tolerogenic  DCs  into 
immunogenic DCs and induced development of CD4
+ Th1/Th17 T cells, and were able to 
stimulate efficient OVA specific CD8
+ T cell responses (83). CD8
$ CD4
+ DCs were able to 
prime CD8
+ T cells as well as CD8
+ DCs (83). This could mean that under steady-state 
conditions DN DCs have a role in tolerance induction, but upon TLR stimulation they 
revert to an immunogenic phenotype. CD8
+ DCs, on the other hand, have a key role in 
viral immunity and in inducing immunity against intracellular pathogens especially in the  
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spleen and LNs. Splenic CD8
+ DCs are more efficient at phagocytic uptake of apoptotic 
cells (84), and more importantly they have been shown to be much more efficient at cross-
presenting both soluble and cell-bound antigens on MHC class I compared with other 
splenic DC subsets (85, 86). As a consequence, it has been observed that in vivo CD8
+ DCs 
are better at activating CD8
+ T cells, whereas CD8
$ DCs are more efficient at activating 
CD4
+ T cells. In addition, upon activation with TLR ligands and when stimulated with 
either CD40 or with inflammatory cytokines, CD8
+ DCs produce high levels of bioactive 
IL-12p70 (87, 88). IL-12 production, together with presentation of exogenous antigens on 
MHC class I make CD8
+ DCs capable of driving development of both Th1 T cells and 
cytotoxic T-cell (CTL) responses from CD8
+ T cells. CD8
+ DCs have also been shown to 
produce anti-inflammatory cytokine TGF-! in the steady state (89), suggesting a role for 
this  DCs  subset  in  tolerance  as  well  and  immunity.  Indeed,  it  has  been  indicated  that 
splenic CD8
+ DCs are more efficient than their CD8
$ counterparts at inducing forkhead 
box  P3  (FoxP3)
+  regulatory  T  cells  from  FoxP3
$  precursors  without  the  presence  of 
supplemental TGF-!, both in vitro and in vivo (89). Furthermore, CD8
+ DCs have been 
shown to participate in the induction of peripheral self-tolerance by capturing self-antigens 
and presenting them to naïve CD4
+ and CD8
+ T cells using the cross-presentation pathway 
(90). 
Human  DCs  are  much  less  well  characterised  than  murine  DCs  due  to  the  limited 
availability of human lymphoid tissues for study, and due to rarity of these cells. Unlike 
mouse DCs, human DCs can be found in the blood, and much work has been conducted to 
find out if the human blood derived DCs could be compared to the mouse CD8
+ and CD8
$ 
subsets. Human blood DCs comprise about 1 % of all peripheral blood mononuclear cells 
(PBMCs), and they can be characterised as negative for lineage markers (CD3, 14, 15, 19, 
20, 56) and some are positive for MHC class II (HLA-DR) (91), although the usefulness of 
this marker is under debate. Human DCs, like mouse DCs, can be divided into pDCs and 
conventional  DCs;  pDCs  are  defined  as  CD11c
$  CD123
+  CD304
+,  whereas  cDCs  are 
CD11c
+ CD123
$. Additionally, cDCs can be divided into CD141
+ (BDCA-3), CD16
+ and 
CD1c
+ (BDCA-1) subsets (92). Given that human DCs do not express CD8", correlation 
of mouse and human DC subsets has been difficult. Recently, however, progress has been 
made in understanding of the relationship of DCs from these two species. First of all, 
genome-wide expression profiling revealed similarities in the genetic signatures of human 
CD141
+ DCs and mouse CD8
+ DCs, and with human CD1c
+ and mouse CD8
$ DCs (93). 
In addition, the human CD141
+ subset shares some phenotypic similarities with the mouse 
CD8
+  subset,  such  as  expression  of  TLR3  (94,  95),  c-type  lectin  9A  (CLEC9A)  (96),  
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nectin-like  molecule  2  (NECL2)  (97)  and  the  chemokine  receptor  XCR1  (98,  99). 
Recently, functional studies form several groups have revealed more similarities between 
these two DC subsets by demonstrating that, like murine CD8
+ DCs, human CD141
+ DCs 
show  more  efficient  cross-presentation  capabilities  than  other  DC  subsets  (98-101). 
Furthermore, the CD141
+ DC subset has also been shown to expand in vivo after Flt3L 
injection (97), as do the mouse CD8
+ DCs (discussed above). In addition to blood, human 
CD141
+  DCs  have  also  been  found  in  the  spleen,  bone  marrow,  tonsils  and  LNs, 
suggesting a similar distribution pattern to mouse CD8
+ DCs (97, 100, 102).  
Similar to human DCs, rat DCs do not express CD8", and the subsets are not very well 
defined. Rat peripheral tissue DCs have been identified in the intestine, lungs and liver. 
However, most of these studies have carried out using histological sections and different 
subsets have not been identified. However, in spleen and LNs, three subsets of DCs have 
been identified; two cDC subsets identified as CD103
lo CD11b
+ CD4
+ CD172a
+ (CD4
+) 
and CD103
hi CD11b
+ CD4
$ CD172a
$ (CD4
$), and pDCs identified as CD103
$ CD11b
$ 
CD4
+ CD172
+ (103). CD4
+ DCs have been shown to have better spontaneous survival in 
culture  compared  to  CD4
$  DCs,  but  survival  of  both  cell  types  was  enhanced  by 
stimulation  with  TLR  agonists  (103).  In  addition,  CD4
+  DCs  exhibited  spontaneous 
maturation after overnight culture, as measured by CD86 expression, whereas CD4
$ DCs 
required  TLR  stimulation  for  their  maturation.  However,  CD4
$  DCs  were  shown  to 
produce more IL-12p40 after TLR stimulation compared to CD4
+ DCs. Regarding their 
capacity to induce proliferation of T cells, both DC subsets were equally capable of driving 
CD4
+ T cell proliferation, but whereas CD4
$ DCs induced Th1 type T cells, CD4
+ DCs 
drove  non-polarized  T  cell  differentiation.  CD4
+  DCs  were  also  shown  to  be  better 
stimulators of CD8
+ T cells compared to CD4
$ DCs.  
In addition to blood derived DC subsets described above, LNs also contain DCs that have 
arrived via afferent lymph from peripheral tissues. The phenotype of these cells depends 
on the tissue the LN drains, and thus DCs found in the LNs draining the skin are different 
from those found in the mesenteric lymph nodes (MLNs) that drain the intestine. Most 
information concerning migrating DCs has been derived from studies involving murine 
DCs migrating from the skin. In the steady state, five subsets of DCs can be identified in 
the skin dermis and epidermis, and they differ in their expression of CD207 (langerin), 
CD11b and CD103 (104). Epidermal DCs called Langerhans cells (LC) are all CD207
hi, 
whereas dermal DC populations express less CD207 and also include cells negative for this 
marker (104).  All five populations have also been suggested to migrate from the skin to  
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the skin draining cutaneous lymph node (CLN) even in the absence of inflammation (105). 
In humans, corresponding LC populations of CD207
+ CD11b
+ DCs can be identified in the 
skin, but understandably less in known about the migratory behaviour of these cells (105). 
As was mentioned above, DCs also migrate from the intestine to the MLN. In rats, these 
migrating  intestinal  lymph  DCs  (L-DCs)  consist  of  three  subsets  that  share  some 
phenotypical  characteristics  with  the  CD4
+  and  CD4
$  DCs  found  in  the  spleen  and 
described above, and have also shown to exhibit different functions. These DCs, together 
with the recently described murine L-DCs, are discussed in section 1.3. 
1.2.6  Migration of dendritic cells 
As  mentioned  above,  immature  DCs  reside  at  the  sites  of  pathogen  entry,  where  they 
sample and collect antigen. Subsequently, they migrate out of the tissues and into draining 
LNs through the lymphatic system (reviewed in (106)). This migration occurs both in 
steady  state  and  under  inflammatory  conditions,  however  it  is  increased  under 
inflammatory conditions compared to steady state. To detect invading pathogens or other 
foreign antigens, DCs carry pathogen recognition receptors (PRRs) on their surface, which 
recognise  conserved  pathogen  associated  molecular  patterns  (PAMPs)  shared  by  large 
groups of potentially pathogenic microorganisms. Best known among the PRRs are TLRs, 
which  have  evolved  to  recognise  a  large  variety  of  both  viral  and  bacterially  derived 
antigens.  Innate  recognition  of  pathogens  by  TLRs  and  other  PRRs  has  recently  been 
reviewed (107), and will not be discussed here further. Upon recognition of pathogenic 
antigens,  DCs  start  to  express  more  MHC  molecules  on  their  surface,  as  well  as 
upregulating their expression of co-stimulatory molecules, leading to maturation. Activated 
DCs migrate out of the tissue, and into the draining LNs via lymph in a CCR7 dependent 
manner.  Lymphatic  vessels  drain  all  peripheral  tissues,  and  the  lymph  flow  is 
unidirectional from the periphery towards the heart. Eventually, lymphatic vessels from the 
abdominal viscera join the thoracic duct, from which lymph and its contents return to the 
circulation. Given that very few DCs are detected in the efferent lymph leaving the LNs, it 
is thought that once DCs have arrived in the LNs, the vast majority of DCs do not travel 
any further but die there. This contrasts with lymphocytes, which after interacting with 
DCs leave the LNs and return to the circulation.  
Direct investigation of migrating DCs involves either cannulation of afferent lymphatics in 
bigger animals, or on rats and mice a two-stage surgical method is used. This requires 
removal of draining LNs prior to cannulation and collection of the thoracic duct pseudo- 
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afferent lymph, as described in materials and methods. Using these techniques, migrating 
DCs have been detected in the skin draining lymph of cows (108), sheep (109) and pigs 
(110, 111) , as well as in the intestinal lymph of rats, mice (112, 113) and pigs (114). From 
these studies, it has been observed that migration of dendritic cells from the periphery to 
the LNs is continuous and occurs even in the absence of inflammatory stimulation. It has 
also been shown to be independent of intestinal flora, as demonstrated by cannulation of 
germ-free rats where DC migration can still be observed (115). Once in the LNs, DCs 
present antigen to lymphocytes and this interaction leads to either activation or tolerance of 
the cells with which they interact (116). DCs migrating in the steady state can carry self-
antigens  or  antigens  derived  from  commensal  bacteria  in  the  case  of  intestine,  and 
presentation of these antigens to T cells without inflammatory stimulus leads to induction 
or maintenance of peripheral tolerance. The role of intestinal DCs in inflammation and 
tolerance will be discussed in detail later in this chapter.  
As  investigation  of  migrating  DCs  involves  surgical  procedures,  it  could  be  that  the 
surgery  induces  a  low  level  of  inflammation  that  drives  migration  of  DCs.  However, 
studies conducted in cattle, where lymph can be collected for several weeks, indicate that 
the  surgical  procedure  does  not  affect  the  number  or  phenotype  of  the  DCs  as  their 
characteristics remain stable for duration of the lymph collection (117). In addition, DC 
migration  from  the  periphery  to  LN  can  be  enhanced  in  the  cannulated  animals  by 
proinflammatory stimuli, such as skin contact sensitization (118), i.v. administration of 
TLR4 agonist LPS (119) or oral administration of a TRL7/8 agonist R848 (120). This 
increased DC migration results in peripheral tissues becoming almost completely devoid of 
DCs, and this effect is dependent on TNF". 
Migration of DCs from the periphery into the LNs is regulated by chemokine receptor 
CCR7.  DCs  in  peripheral  tissues  exist  in  an  immature  state,  and  upon  encountering 
inflammatory signals they rapidly mature. This maturation is also linked to upregulation of 
CCR7 and downregulation of CCR6 (121). The crucial role for CCR7 in DC migration was 
revealed when mice deficient in CCR7 were investigated, and it was noted that there was a 
defect in DC migration into LNs (122), and furthermore, CCR7 deficient DCs failed to 
migrate when transferred into wild type recipients (123).  
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1.2.7  DC interactions with immune cells 
Interactions  between  DCs  and  other  cells  of  the  immune  system  are  crucial  for  the 
induction  of  effective  immune  reactions,  as  well  as  for  development  of  peripheral 
tolerance. It is therefore important to understand the biology of the DC : T cell interactions 
in order to gain greater understanding of the role DCs can have in disease pathogenesis. In 
this section, interactions of DCs with both CD4
+ and CD8
+ T cells are briefly reviewed.  
  CD4
+ T cells 
CD4
+ T cells have critical roles during adaptive immune responses, including helping B 
cells to produce antibodies, recruitment and activation of CD8
+ T cells, as well as attracting 
other  effector  cells  such  as  macrophages  and  neutrophils.  These  diverse  functions  are 
mirrored in the heterogeneity of the CD4
+ effector T cell populations, which all have a 
variety of functions. Four main lineages currently recognised are Th1, Th2, Th17 and 
regulatory T cells, and these populations differ in their cytokine production and function 
(124). Recently, however, it has been suggested there is much more plasticity in the CD4
+ 
T cell populations than previously thought, with cells of one subset being able to acquire 
the cytokine profile of another subset, at least in vitro, and to some extent in vivo (125, 
126). For the purpose of this brief review, the traditional lineage commitment models are 
discussed, but this picture may change in the future as new data emerge. As all the CD4
+ T 
cell subsets share the same early activation events, these are first discussed, followed by a 
brief introduction to each of the different subsets. 
As the development of activated effector cells under non-inflammatory conditions could 
harm the host, their differentiation is tightly regulated. Thus, CD4
+ T cells need at least 3 
different  types  of  signal  for  full  differentiation  into  effector  cells  (127).  The  first 
interaction, or signal 1, is provided by DCs expressing exogenously derived peptides on 
their  MHCII  molecules,  which  are  recognised  by  the  T  cell  receptor  complex  of  a 
particular T cell clone. This interaction leads to activation of the naïve, non-committed 
CD4
+ T cell, but does not lead to proliferation or commitment to a specific lineage. The 
same DC, from whom the T cell acquired signal 1, also delivers signal 2. This involves 
ligation of co-stimulatory molecules such as CD80 and CD86 on the mature DC with 
activating  CD28  or  inhibitory  CTLA-4  on  the  T  cell,  leading  to  activation  of  specific 
signalling  pathways  on  the  T  cell.  The  mechanisms  behind  the  balancing  act  between 
activating and inhibiting signals delivered by the above mentioned two receptors have been 
recently elegantly described (128). In addition to these interactions, ligation of CD40 or 4- 
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1BB on DC by CD40 ligand or 4-1BBL, respectively, on T cells leads to bi-directional 
signalling, where ligation of these molecules leads to activating signals being directed to 
both DC and T cell (129). Signal 1 and 2 together lead to production of the cytokine IL-2 
by the T cell, which is needed for the survival and proliferation, or clonal expansion, of the 
CD4
+ T cells. T cells that receive either only signal 1, without signal 2, or cells that only 
receive co-stimulatory signal 2, are not activated but instead enter a state of anergy (130). 
These  anergic  cells  continue  to  circulate,  but  do  not  subsequently  respond  to  specific 
antigen even when it is presented to them by an APC expressing co-stimulatory molecules. 
These events provide a mechanism to maintain peripheral self-tolerance, required because 
not all self-reactive T cells are deleted in the thymus during development. Thus, DCs as 
APCs have an important role in the shaping of early immune response. 
Mediators, such as chemokines or cytokines, secreted by DCs provide signal 3, and this 
directs the differentiation of CD4
+ T cells into different lineages (124). There are currently 
four recognised CD4
+ T cell lineages: Th1, Th2, Th17 and Tregs. Th1 and Th2 cells were 
the  first  ones  discovered  in  1986  by  Mosmann  and  Coffman,  who  demonstrated  the 
existence  of  two  CD4
+  T  cell  types,  Th1  and  Th2,  which  differed  in  their  cytokine 
secretion profiles (131, 132). Th1 cells produce IFN-!, which is important for macrophage 
activation  and  clearance  of  intracellular  pathogens,  such  as  viruses  and  intracellular 
bacteria. In addition, Th1 cells can also activate naïve CD8
+ T cells to become cytotoxic T 
lymphocytes (CTLs). In contrast, Th2 cells are involved in allergic responses and produce 
IL-4,  IL-5,  IL-10  and  IL-13,  which  have  key  roles  in  IgE  production,  eosinophil  and 
basophil recruitment and clearance of extracellular pathogens, such as helminths. These 
two cell types also require different cytokines for their differentiation; Th1 cells require 
cytokines IL-12 and IFN-!, which are derived from DCs or other innate cells, whereas Th2 
cells need IL-4, whose initial source is not entirely clear. As the response develops, IFN-! 
produced by Th1 cells, or IL-4 produced by Th2 cells create a positive feedback loop, 
further driving the differentiation of these effector cells. The development of one or the 
other effector subset is driven by the DCs, which can be activated by different microbial 
stimuli to drive differentiation of the most suitable effector cell type.  
It has been observed that Th1 cytokine IFN-! expression in target tissues correlates with 
clinical signs in both experimental autoimmune encephalomyelitis (EAE) and collagen-
induced arthritis (CIA), and treatment with polyclonal antibodies against IL-12 in both of 
these disease models works as a therapy (133, 134). Thus, for a long time Th1 cells were 
thought to be the main T cell subset driving the pathology in several animal models of T  
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cell  mediated  autoimmune  diseases.  However,  this  view  was  challenged  when  data 
emerged  showing  that  mice  deficient  for  several  molecules  in  the  Th1  differentiation 
pathway, such as IFN-!, IL-12p35 or IL-12 receptor #2 were not protected from EAE and 
CIA but rather were more susceptible (135-137). These observations led researchers to 
believe there could be another cell type independent of Th1 that is responsible for the 
induction of disease pathogenesis in these models. IL-12 is a dimer formed by two chains: 
p40 and p35, and in 2000 a novel cytokine chain, p19, was discovered that shared the p40 
chain with IL-12 (138). This novel cytokine was named IL-23, and it is predominantly 
produced by activated dendritic cells and macrophages, especially in the gut (139). Cua 
and colleagues discovered that it was IL-23 rather than IL-12 that was responsible for 
induction of EAE by comparing IL-23p19 deficient mice to IL-12p35 deficient mice (140). 
Furthermore, in a follow-up publication they also showed that IL-23 expands a specific 
subset of IL-17A (referred to as IL-17) producing CD4
+ T cells in EAE that are capable of 
transferring disease into naïve WT recipients (43). Since these original observations, a 
wealth  of  data  has  emerged  linking  these  IL-17  producing  T  cells,  named  Th17,  to 
pathogenesis  in  several  experimental  animal  models,  as  well  as  human  autoimmune 
diseases such as RA, psoriasis and IBD (for review see (141)). In addition, it has been 
observed  that  AS  patients  have  increased  number  of  circulating  Th17  cells  as  well  as 
increased  IL-17  levels  in  the  serum  (142,  143).  Furthermore,  Th17  cells  have  been 
indicated to have a pathological role in the animal model for SpA, where rats transgenic 
for the human HLA-B27 gene have more Th17 cells in mesenteric and popliteal lymph 
nodes as well as in arthritic joints, than non-transgenic animals (144). This SpA animal 
model is discussed in detail in a later section of this chapter. 
Differentiation of Th17 cells from naïve mouse T cells requires cytokines TGF-! and IL-6, 
produced by a variety of cell types such as DCs, and these cytokines in turn upregulate 
expression of IL-23R on the surface of these T cells (145, 146). The precise function of IL-
23 on Th17 cells is still elusive but it is thought that it is required for proliferation and 
survival of differentiated Th17 cells, as shown by the observation that IL-23p19 deficient 
mice have limited number of Th17 cells (43), and that treatment of mice with IL-23p19 
neutralising antibody inhibits development of EAE (147). Initial reports about human Th17 
cells suggested that, in contrast to mice, it was not possible to create human Th17 cells 
using TGF-! and IL-6. Instead, it was suggested that a combination of IL-1#, IL-6 and/or 
IL-23 was needed for the differentiation of IL-17 producing cells from CD4
+ peripheral 
blood T cells (148, 149). However, it was noticed that the culture medium used for the in 
vitro experiments contained TGF-#. Thus, when TGF-# free medium was used together  
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with  naïve  T  cells  derived  from  cord  blood,  it  was  indeed  shown  that  TGF-#  is  also 
required for the differentiation of human Th17 cells (150, 151).  
Th17 cells produce a variety of cytokines in addition to their signature cytokine IL-17A. 
These include other members of the IL-17 family, such as IL-17F, IL-21 and IL-22, as well 
as TNF-". These cytokines produced by Th17 cells have been proposed to have a role in 
protection against extracellular bacteria, protozoa and fungi, and in addition they have 
been shown to be key mediators of chronic inflammation in several experimental animal 
models of diseases such as rheumatoid arthritis, multiple sclerosis, inflammatory bowel 
disease  and  psoriasis  (reviewed  in  (152)).  In  addition,  as  discussed  earlier,  IL-23R 
polymorphisms have been linked to several inflammatory disorders. Interestingly, Th17 
cells  have  also  been  shown  to  produce  GM-CSF,  which  is  critical  for  their  pro-
inflammatory functions (153, 154). For example, GM-CSF was shown to induce IL-23 
production by APCs. Like the other T helper subsets, development of Th17 cells is tightly 
regulated, and it has been reported Th1 and Th2 cytokines IFN-# and IL-4 both inhibit IL-
17 production as well as the differentiation of Th17 cells (41, 42).  
There is also a reciprocal relationship between Th17 cells and regulatory T cells, another 
CD4
+ T cell type. There are two types of regulatory T cells: Natural regulatory T cells 
(nTregs)  develop  in  the  thymus  from  CD4
+  T  cells  as  a  separate  population,  whereas 
inducible Tregs (iTregs) can be generated from naïve CD4
+ T cells in the periphery (155). 
There is considerable overlap between these two populations, and as of yet no reliable 
surface markers have been found to distinguish iTregs from nTregs. Despite differences in 
the origins of these cells, most Tregs secrete anti-inflammatory IL-10 and/or TGF-!, which 
can inhibit T cell responses, and thus these cells are important in tolerance and control of 
inflammatory  responses.  Similarly  to  Th17  cells,  differentiation  of  iTregs  from  naïve 
precursors  requires  TGF-! (156). This  induces  the  expression  of  the  Treg  specific 
transcription  factor  FoxP3  on  these  cells,  which  is  required  for  the  induction  and 
maintenance of iTregs in the peripheral immune compartment. However, in the presence of 
IL-6, the Treg specific developmental pathway is stopped and instead these T cells develop 
into Th17 cells as previously discussed. Many cell types produce TGF-#, and it has broad 
inhibitory effects on the whole immune system. Thus under non-inflammatory conditions 
it could be that generation of iTregs is favoured, whereas under inflammatory conditions 
where  IL-6  production  is  induced,  inflammatory  Th17  cells  would  be  produced.  In 
addition,  retinoic  acid,  a  vitamin  A  metabolite,  can  drive  generation  of  Tregs  while 
inhibiting  the  differentiation  of  Th17  cells.  Retinoic  acid  is  primarily  produced  by  
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intestinal CD103
+ DCs, and it is thought to act directly on naïve T cells by enhancing 
TGF-#  signalling  while  inhibiting  IL-6  signalling  (157,  158).  This  provides  further 
evidence for the crucial role DCs in general, and specifically in the intestine, play in the 
initiation and regulation of various T cell responses.  
  CD8 
In contrast to CD4
+ T cells, CD8
+ T cells show less heterogeneity in their differentiation. 
Current knowledge suggests that upon activation, all CD8
+ T cells become CTLs, which 
migrate to their instructed peripheral target sites and kill their target cells. This role is 
particularly  important  in  defence  against  intracellular  pathogens,  like  viruses  and 
intracellular bacteria. For example, virus-infected cells can express viral proteins derived 
from  virus  replicating  inside  them  on  their  MHCI,  which  the  CTLs  recognise.  As 
uncontrolled activity of CTLs could be destructive, their activation is very tightly regulated 
and naïve CD8+ T cells need more co-stimulatory activity to drive the development of 
effector CTLs compared to CD4
+ T cell differentiation. There are two ways in which this 
can be achieved, with or without CD4
+ T cells help. In inflammatory conditions, DCs are 
activated by binding of PAMPs derived from viruses and bacteria to their TLRs, leading to 
maturation  (107).  Mature  DCs  express  all  necessary  co-stimulatory  molecules  and  can 
directly  stimulate  CD8  T  cells  to  synthesize  IL-2,  which  drives  proliferation  and 
differentiation of CD8 CTLs. However, this type of CD8 T cell stimulation only occurs in 
some specific settings, and most often the DC alone is not able to induce CD8 T cell 
differentiation. The extra help required is provided by CD4
+ effector T cells recognising 
their cognate antigen on the surface of the same DC, which leads to upregulation of co-
stimulatory molecules on the DC (159). Especially important for this interaction is the 
CD40 on DCs that interacts with CD40L on T cells, leading to upregulation of CD80 and 
CD86 molecules on the DC (160). These activated DCs are then able to stimulate CD8 T 
cell differentiation. This mechanism of action is referred to as licensing of DCs by the CD4 
effector T cells. After differentiation, effector CTLs proliferate and dramatically increase 
in  numbers.  This  phase  is  referred  to  as  the  effector  phase,  which  leads  to  pathogen 
clearance. This activity is followed by the contraction phase, where most effector CTLs die 
and leave behind only a small population of long-lived memory cells. These memory cells 
are maintained at stable levels for several years, so that in case of pathogen re-exposure, 
they can mount a rapid recall response. CD4 T cell help for CTL differentiation seems to 
play a critically important role in the formation of these long lived memory CTLs. Memory 
CTL cells derived from CD4 competent mice were able to mount an effective immune  
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response  when  transferred  into  CD4  deficient  hosts,  whereas  memory  CTL  from  CD4 
deficient mice transferred into CD4 competent mice did not (161, 162). 
1.3  The Intestinal Immune system 
The  intestinal  immune  system  is  the  largest  and  most  complex  of  all  the  immune 
compartments in the body. It is the site of entry for vast amounts of antigens, including 
harmless  antigen  from  food  alongside  harmful  pathogenic  bacteria.  In  addition,  the 
intestinal  system  is  a  home  to  a  large  colony  of  commensal  bacteria,  which,  whilst 
harmless, are still seen as foreign by the immune system. Thus, the intestinal immune 
system has evolved to ignore, or be tolerant, towards harmless non-self antigens, but still 
retain the ability to mount protective immune responses against invading pathogens. A 
break in tolerance can result in hypersensitivity reactions against either food antigens or 
commensal bacteria, as demonstrated by coeliac disease and Crohn’s disease. As has been 
discussed  in  the  above  paragraphs,  DCs  as  professional  APCs  have  a  central  role  in 
inducing immune responses throughout the body, so it not surprising that they have an 
important role in maintaining the balance between tolerance and immunity in the intestine. 
Lymphoid tissues in the intestine are referred to as gut-associated lymphoid tissue (GALT) 
and  it  consists  of  both  non-organised  and  organised  lymphoid  tissue  sites.  The  non-
organised  tissues  contain  aggregations  of  effector  lymphocytes  and  are  scattered 
throughout the epithelium and lamina propria (LP). In adult humans the single layer of 
epithelial cells, which make up the epithelium lining the lumen of the gut, covers an area 
of about 200-400 m
2. It absorbs nutrients and fluids, but it also acts as a barrier between 
the environment and the inside of the body, and as such it forms the largest entry site for 
pathogens. Thus, the epithelium contains immune cells acting as the first line of defence 
against  invading  pathogens.  These  cells  are  antigen-experienced  T  lymphocytes  called 
intraepithelial lymphocytes (IEL), and it has been demonstrated using parabiotic mice that 
they do not seem to recirculate (163). Many IELs express the molecule CD103 (integrin 
"e) that binds E-cadherin on the epithelial cells and is important for their localisation (164, 
165). The various types of IELs have different functions but as a whole they have been 
indicated to: condition and repair the epithelial barrier; control the growth and turnover of 
the epithelium; contain cytoplasmic granules for cytotoxic activity; and secrete various 
inflammatory cytokines such as IFN-!, IL-2, IL-4 and IL-17 (166).  
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DCs  can  be  found  in  the  LP,  which  unlike  the  epithelium  contains  several  different 
populations in addition to DCs such as macrophages, CD4
+ and CD8
+ T cells, plasma cells 
and eosinophils (167). In addition to the lamina propria, DCs can be found in the organised 
lymphoid  tissues,  sites  of  induction  of  immune  reactions  (168).  Intestinal  organised 
lymphoid  tissues  include  MLNs,  Peyer’s  patches  (PP)  and  isolated  lymphoid  follicles. 
MLNs, like other LNs of the body, are highly organised structures allowing circulating 
naïve T cells to interact with their cognate antigen on DCs, which have arrived from the 
periphery (169). This interaction can lead to either tolerance or induction of immunity, and 
this will be discussed in more detail below. PPs, like MLNs, are organised into separate B 
and T cell areas, and they are primarily responsible for the induction of T cell dependent 
IgA  responses  (167).  DCs  are  found  in  the  submucosa  along  the  length  of  the  small 
intestine,  and  they  are  separated  from  the  gut  lumen  by  a  single  layer  of  specialised 
epithelial cells called follicle-associated epithelium (FAE). Under the FAE layer an area 
called sub-epithelial dome (SED) can be found, which also further separates the B and T 
cell areas from the lumen. DCs can be found both in the SED and around the B and T cells 
areas.  
The  intestine  is  an  immunologically  active  organ,  and  due  to  its  constant  exposure  to 
numerous antigens it is in a constant state of low-grade inflammation. However, this rarely 
results  in  overt  inflammation  and  disease  because  of  sophisticated  homeostatic 
mechanisms, in which DCs play important roles.  
1.3.1  DCs of the intestinal system  
Like in other parts of the body, several intestinal subsets of CD11c
hi DCs can be identified 
in the intestine, including both cDCs and plasmacytoid DCs. In the mouse, PPs contain 
CD8
$ CD11b
+ DCs that are found mainly in the SED (170), and preferentially secrete IL-
10  and  induce  Th2  type  responses  (171).  In  contrast,  CD8
+  CD11b
lo  DCs  are  mainly 
located in the T cell rich areas of the PP, whereas a third subset of double negative CD8
$ 
CD11b
$ DCs can be found in both areas (170). Both of the latter mentioned subsets have 
been reported to produce mainly IL-12 and drive the differentiation of IFN-! producing T 
cells (171). Uniquely, DCs in PP express a chemokine receptor CCR6, which has been 
shown to be required for their recruitment of DCs into the FAE upon entry of pathogenic 
invading Salmonella typhimurium (172). In addition, upon activation PP DCs also start to 
express chemokine receptor CCR7 enabling them to migrate to the interfollicular T cell 
areas (170).  
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The same three subsets found in the PP can also be detected in small intestinal LP of mice, 
however in the LP the majority are of the CD8
$ CD11b
+ subset (173). In addition, most LP 
DCs  express  CD103,  and  these  CD103
+  DCs  consist  of  both  CD8
$CD11b
+  and  CD8
+ 
CD11b
$ subsets, which are functionally different (174). CD103
+ DCs are the only subset 
shown to be able to imprint gut homing molecules CCR9 and "4#7 on T and B cells, and to 
induce FoxP3 expression on naïve T cells (175). These functions are dependent on retinoic 
acid, and the role of CD103
+ DCs in tolerance induction will be discussed below. It was 
reported that another DC population present in the LP was able to extend dendrites through 
the epithelial layer, and thus directly sample the antigen content within the intestinal lumen 
(170). These cells were later reported to express high levels of the chemokine receptor 
CX3CR1 (176, 177). However, it was recently shown that CX3CR1
hi cells do not migrate 
in the lymph to the MLNs, a hallmark DC function, and are poor stimulators of T cells 
(112). In addition they were found to express the macrophage marker F4/80 but not CD103 
(178). Thus, these CX3CR1
hi cells are now generally accepted to be macrophages rather 
than  DCs.  Intriguingly,  another  heterogeneous  population  of  MHCII
+  CD11c
+  cells 
expressing intermediate levels of CX3CR1 (CX3CR1
int CD103
$) were found in the LP, 
and these appeared distinct from the CX3CR1
hi cells (112, 179). In addition to these cDC 
populations, LP in mice also includes a population of MHCII
lo B220
+ pDCs (173). 
Human intestinal DCs are poorly characterised. In the MLN, a population of CD103
+ DCs 
have  been  recognised,  which  share  similar  functions,  such  as  induction  of  CCR9 
expression on T cells, with the equivalent mouse CD103
+ DCs (180). In the colonic lamina 
propria,  MHCII  (HLA-DR)
+  CD11c
+  LIN
$  (CD3,  14,  16,  19,  20,  26)  DCs  have  been 
recognised, and they were shown to make up less than 1 % of all colonic LP mononuclear 
cells. These DCs were shown to migrate out of colonic biopsies in culture, be able to 
stimulate proliferation of T cells, and upregulate expression of co-stimulatory molecules 
upon TLR stimulation (181, 182).  More recently, a CD1c
+ subset of MHCII
+ CD11c
+ 
LIN
$ DCs was recognised in the small and large intestinal LP, and this population also 
included some CD103
+ cells (183).  
The DC populations in the LNs of mice have been discussed above, and the same subsets 
can also be found in the MLN. These are: CD8
$ CD4
+ CD11b
+, CD8
+ CD4
$ CD11b
$, 
CD8
$ CD4
$ CD11b
+ and an additional CD8
$ CD4
$ CD11b
$ subset. MLN also contain DCs 
expressing CD103, and these DCs include both CD8
+ and CD8
$ populations. CD103
+ DCs 
have unique functions, such as induction of gut homing molecules on T cells and induction 
of FoxP3
+ T regulatory cells, as has been discussed elsewhere. The number of CD103
+  
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DCs is reduced in the MLNs of CCR7 deficient mice (174), leading to idea that most 
CD103
+ cells found in the MLN have migrated there via lymph, whereas CD103
$ DCs are 
blood derived. CD103 seems to be a conserved marker between species, as CD103
+ DCs 
can also be found in the MLNs of rats and humans (180). 
Until recently it has not been possible to directly examine the phenotype of murine DCs 
arriving  to  the  MLN  from  the  intestine.  However,  we  have  adopted  the  cannulation 
techniques, successfully used to study rat migrating DC populations, for use with mice. 
Using this technique it was determined in our laboratory that the majority of mouse lymph 
MHCII
+ CD11C
+ L-DCs express CD103, with two distinct populations observed: CD8
+ 
CD11b
$ and CD8
$ CD11b
+ subsets, which can also be detected in the LP (Dr Vuk Cerovic, 
manuscript in preparation). Surprisingly, some CD103
$ CD8
$ cells were also observed 
within the MHCII
+CD11c
+ gate, with the majority also expressing CD11b. These cells 
have been shown to be able to prime both naïve CD4
+ and CD8
+ T cells, and to have 
normal DC characteristics. Thus, this new information challenges the view that CD103
$ 
DCs observed in the MLNs would have all arrived there via blood. Further investigation 
into the functional differences between these subsets is on going.  
Using the cannulation technique in the rat, three subsets of MHCII
+ CD103
+ DCs can be 
identified in the lymph. These subsets differ in their expression of CD11b and CD172a: 
CD172a
hi  CD11b
lo  (referred  to  as  CD172a
hi),  CD172a
int  CD11b
hi  (CD172a
int)  and 
CD172a
lo  CD11b
int  (CD172a
lo).  It  is  difficult  to  directly  compare  these  subsets  to  the 
mouse  ones,  as  rat  DCs  do  not  express  CD8,  and  no  good  rat-specific  anti-CD11c 
antibodies have been developed. In addition, CD4 is co-expressed with CD172a in the rat 
whereas in the mouse the three L-DC subsets all express only very low levels of CD4, and 
CD172a is co-expressed with CD11b (Dr Vuk Cerovic, manuscript in preparation). It is 
possible that in the rat there are also some CD103
$ L-DCs (personal observations), but 
these have not been further investigated.  
In the steady state, DCs carry self-antigens and antigen derived from commensal bacteria 
or food proteins. Upon arrival in the LNs they present these to naïve T cells, in the absence 
of co-stimulatory signals, and induce immunological tolerance towards the antigens they 
carry. Paradoxically, CD172a
hi, CD172a
int and CD172a
lo L-DC subsets in the rats have 
been shown to induce strong proliferation and IFN-! production from naïve CD4
+ T cells 
in MLR reactions in steady state (177), suggesting that at least in in vitro even steady state 
DCs are capable of T cell activation. There were some differences between the three L-DC  
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subsets,  as  the  CD172a
hi  and  CD172a
int  populations  were  shown  to  promote  stronger 
proliferative responses than the CD172a
lo population (177), suggesting that the CD172a
lo 
population might be less immunogenic. In addition, the CD172a
lo subset was shown to 
contain cytoplasmic apoptotic DNA and cytokeratins restricted to epithelial cells (115). 
These CD172a
lo DCs were also shown to be present in PPs, MLNs and LP, but not in other 
tissues. Together, these data  indicate that this subset is carrying antigen from apoptotic 
epithelial cells from the intestine into the MLN (115).  The cytoplasmic inclusions were 
also observed in the absence of normal microbiota in gnotobiotic rats, thus suggesting that 
the CD172a
lo subset might be involved in the induction and maintenance of tolerance to 
intestinal  antigens.  In  spite  of  these  differences  observed  between  steady-state 
CD172a
hi/CD172
int  and  CD172a
lo  subsets,  all  three  L-DC  subsets  induced  comparable 
proportions of CD25
+ FoxP3
+ Treg cells to divide in the absence of inflammatory stimuli 
(184).  
Under inflammatory conditions, the number of DCs migrating from the periphery to LNs 
increase, and they also upregulate their expression of co-stimulatory molecules. Arrival of 
these DCs in the LN results in T cell proliferation and activation. When TLR7/8 agonist 
R848 was orally fed to rats, it was observed that the the migration of all three subsets 
increased 30-50 fold (120). However, the DC subsets responded differently to in vivo R848 
stimulation, as only the CD172a
hi and CD172
int subsets upregulated expression of CD25 
(185). Furthermore, in vitro studies demonstrated that CD172a
hi and CD172a
int, but not 
CD172a
lo cells, were shown to express TLR8 receptor and respond to R848 stimulation 
(185). Differences between CD172a
hi and the CD172a
int subsets have also been observed. 
In response to in vitro R848 stimulation the CD172a
hi L-DCs included a higher proportion 
of CD25
+ cells than the CD172
int cells, and CD172a
hi subset was also the only subset 
secreting IL-6 and IL-12p40 ex vivo (185). In addition, oral admininistration of another 
antigen, heat labile E. coli enterotoxin, was shown to promote CD25 expression on the 
CD172a
hi subset as well as increasing the ability of these DCs to induce naïve T cell 
proliferation in MLRs (186).  
Some intestinal cell populations have been described to be hyporesponsive to stimulation 
with TLR4 ligand LPS (187). When rats were given LPS i.v., the number of migrating L-
DCs did increase, but the DCs did not show signs of activation, as they failed to upregulate 
CD80 and CD86 (188). Furthermore, L-DCs were shown to be hyporesponsive to TLR4  
ligand LPS in vitro (188). This function was later shown to be restricted to TLR4, as L-
DCs responded to stimulation with TLR2 and TLR9 ligands Pam3Cys and CpG in vitro, as  
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shown by upregulation of CD25, co-stimulatory molecules CD80 and CD86, as well as an 
increase in the production of cytokines IL-6 and IL-12p40 by all three subsets of DCs 
(189). However, it was observed that the CD172a
lo subset was the only one increasing 
production  of  TNF-"  after  stimulation  with  both  TLR  ligands  (189).  The  above 
experiments do demonstrate that the CD172a
lo subset does behave differently from the 
other two L-DC subsets, however, when these experiments were carried out no reagents 
were available to assess whether CD172a
lo L-DCs induced a truly tolerogenic phenotype 
on the T cells. However it should not be forgotten that real differences were noted in the 
ability of CD172a
lo L-DCs to induce proliferation of naïve T cells compared to the other 
two subsets.  
1.3.2  Intestinal DC antigen uptake and migration 
Several theories have been proposed to describe how the intestinal DCs acquire antigen. 
The  best  understood  method  is  via  specialised  enterocytes  called  microfold  (M)  cells 
situated  in  the  FAE  of  PPs  (167).  FAE  itself  differs  from  the  normal  epithelial  layer 
covering the intestine as it has lower levels of digestive enzymes and a less pronounced 
brush border. M cells, on the other hand, completely lack microvilli as well as the thick 
layer of mucus otherwise covering the surfaces of the intestinal lumen. These features are 
designed to allow easier access for antigens through the M cells. DCs are present both in 
the epithelium directly associated with M cells and in the dome regions directly below. In 
addition,  LP  DCs  can  acquire  antigen  through  the  epithelial  layer  in  a  yet  unknown 
mechanism. It is, for example, possible that the LP CX3CRI
hi cells, that extend dendrites 
into the lumen to sample antigen (177), could transfer antigen to the DCs in the LP.  
DCs carrying antigen migrate either to local T and B cell areas in the PP, or to the MLN 
via afferent lymphatics. It is not yet clear if DCs from PPs migrate to the MLNs, or if they 
just act locally. In the MLN, DCs interact with T cells and induce either activation or 
tolerance, mechanisms of which will be discussed in the next section. The vast majority of 
DCs die in the MLN as only a few can be detected in the efferent lymph leaving the LNs. 
The migration of DCs from the intestine to the MLN is constitutive; in steady state, every 
day about 8x10
5 DCs, from the total pool of about 7-24 million intestinal DCs, migrate out 
(186).  DCs  in  the  lymph  have  upregulated  their  expression  of  MHCII,  but  not  the 
expression of costimulatory molecules, and thus migrating DCs are described as semi-
mature (190).   
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1.3.3  Immunity vs. tolerance  
Induction of protective immune responses in the gut is important for host survival, and as 
has  been  discussed  DCs  are  closely  involved  in  this.  DCs  have  been  indicated  to  be 
involved in the induction of immune reactions against a variety of pathogens, including 
bacteria,  viruses  and  parasites  (reviewed  in  (191).  CD103
+  intestinal  DCs  have  been 
proposed  to  have  many  unique  features,  and  they  are  important  in  both  induction  of 
immune responses as well as in tolerance. They were first found to be uniquely capable of 
inducing gut homing molecules "4!7 and CCR9 on the T and B cells that they interact with 
in  the  MLN,  as  well  as  inducing  FoxP3  expression  on  naïve  T  cells  (174,  192-194). 
Activated effector lymphocytes expressing CCR9 and "4#7 exit the MLN to the blood, 
where they circulate and eventually home back to the intestinal sites, as directed by CCR9 
and "4#7 ligands. "4#7 ligand mucosal addressin cell-adhesion molecule 1 (MAdCAM1) is 
expressed by the vasculature of mucosal tissues, whereas small intestinal epithelial cells 
express  the  CCR9  ligand  CCL25.  These  functions  of  the  CD103
+  mucosal  DCs  are 
dependent on the vitamin A metabolite retinoic acid, which can be produced by CD103
+ 
DCs  that  express  the  necessary  retinaldehyde  dehydrogenase  enzymes  needed  for  the 
conversion. Retinoic acid, together with TGF-# has also been implicated in antibody class-
switching from IgM to IgA by B cells (195). IgA antibodies are the dominant antibody 
class produced in the intestine, and have an important role in the protection against harmful 
pathogens. 
Despite being very effective at inducing immunity towards a variety of pathogens under 
inflammatory conditions, in the steady state intestinal DCs induce tolerance towards self- 
or food antigens as well as towards commensal microbiota. The best-studied model of 
tolerance is oral tolerance. In oral tolerance, antigen delivered via the oral route induces 
systemic unresponsiveness, revealed when animals are re-challenged in peripheral tissues 
with  the  same  antigen.  The  mechanisms  behind  this  phenomenon  are  not  completely 
understood, but it is known that T cells, commensal bacteria and DCs all play a role. DCs 
have been shown to induce peripheral tolerance using two mechanisms: induction of T cell 
anergy/deletion, and through generation of Tregs. Recently, it was shown that constitutive 
ablation  of  DCs  in  mice  led  to  spontaneous  fatal  autoimmunity,  demonstrating  the 
importance of DCs in maintaining immunological tolerance (196). Furthermore, expansion 
of DCs using Flt3L led to increased oral tolerance after feeding of soluble proteins (197). 
Many  factors  can  contribute  to  the  induction  of  tolerogenic  properties  on  DCs:  the  
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maturation stage of the DC, subsets, nature of the microbial stimuli and environmental 
cues from the local microenvironment. These will be briefly discussed below.  
As  has  been  discussed  earlier  in  this  chapter,  immature  DCs  promote  tolerogenic 
responses,  whereas  mature  DCs  promote  immunogenic  responses.  Under  steady  state 
conditions, DCs predominantly adopt an immature phenotype, with the expression of some 
MHCII, but only low levels of costimulatory molecules. Often these immature DCs carry 
self-antigens, and interaction of these DCs with T cells can lead to anergy or deletion of 
self-reactive T cells or induction of Tregs in vivo (198-201). Maturation of DCs leads to 
upregulation of MHCII and costimulatory molecule expression and induce T cell activation 
and differentiation.  
The site of tolerance induction can play a role as well. Antigen can gain access to DCs 
through M cells in the PPs, or the antigen can be transported by DCs to the MLN via 
lymph, where it is presented to the local T cells. PPs were originally considered to be the 
main site for tolerance induction, but this view has been challenged by more recent studies 
observing induction of oral tolerance in PP deficient intestines (202-204). Thus, the MLN 
is  now  considered  the  main  site  for  oral  tolerance  induction.  Supporting  this,  it  was 
recently observed that tolerance could not be induced in mice from which MLNs were 
removed (205). In addition, in the same study it was found that oral tolerance could not be 
induced in CCR7 deficient mice, where the migration of DCs from the intestine to the 
MLNs is impaired.  
As described above, mucosal CD103
+ DCs have many unique features and can be found 
both in the LP and the MLNs of mice, rats, and humans. One of their functions is to 
convert dietary vitamin A into retinoic acid in a two-step process. This process involves 
enzymatic oxidation of retinol by retinaldehyde dehydrogenase (ALDH), with the major 
isoform expressed by DCs being retinaldehyde dehydrogenase 2, encoded by the Aldh1a2 
gene (206). Compared to DCs from many other tissues, as well as to colonic CD103
+ DCs, 
murine  small  intestinal  LP  and  MLN  CD103
+  DCs  express  higher  level  of  Aldh1a2 
mRNA, display increased ALDH activity and induce enhanced retinoic acid signalling in 
responding T cells (206). Under steady state conditions, retinoic acid expressing CD103
+ 
DCs promote Treg conversion from naïve T cells, together with TGF-#  (discussed earlier) 
(157, 193, 207). Interestingly, retinoic acid has also shown to be able to inhibit the TGF-# -
dependent generation of inflammatory Th17 cells, even in the presence of IL-6 (158, 208).  
 
46 
In addition to its effects on T cells, retinoic acid promotes generation of IgA producing B 
cells (195). 
Another molecule produced by LP CD103
+ DCs is indoleamine 2,3 dioxygenase (IDO), 
which catalyses amino acid tryptophan from the environment, leading to generation of 
toxic metabolites. These can inhibit generation of effector T cells and induce Treg cells, 
and inhibition of IDO in vivo results in defective oral tolerance (209). It has been shown 
recently that although the generation of gut homing Tregs take place in the local MLN, and 
involves antigen presentation by DCs, full maturation of these cells does not take place in 
the MLN, but requires Tregs to migrate into the intestinal mucosa. In the gut mucosa Tregs 
undergo a second round of expansion, which is directed by IL-10 producing CX3CR1
+ 
macrophages,  suggesting  an  intriguing  cooperation  in  the  maintenance  of  tolerance  by 
different mucosal cell types (210). The functions of CD103
+ DCs seems to be conserved 
between  species,  as  human  CD103
+  DCs  show  similar  characteristics  to  their  mouse 
counterparts (180). 
How do intestinal CD103
+ DCs acquire their tolerogenic phenotype? It is now believed 
these  DCs  are  not  generated  from  specialised  precursors,  but  that  the  local 
microenvironment in the intestine directs these cells to become tolerogenic. These factors 
can involve intestinal commensal bacteria and interaction with intestinal epithelial cells 
(IEC)  as  well  as  other  leukocytes  (reviewed  in  (175,  206).  IECs  can  produce  several 
immunomodulatory factors, such as TGF-#, retinoic acid, thymic stromal lymphopoietin 
(TSLP),  and  GM-CSF,  and  the  production  of  these  molecules  can  be  enhanced  by 
interactions between IEC and commensal bacteria. Supporting this, addition of exogenous 
retinoic  acid,  GM-CSF  +  IL-4  or  supernatant  from  cultured  IECs  can  program 
inflammatory BMDCs or monocyte derived DCs to become tolerogenic (211, 212). IEC 
supernatant can promote generation of CD103
+ DCs from human CD103
$ cells, and these 
conditioned CD103
+ DCs inhibit development of Th1 and Th17 cells (212, 213). TSLP 
was found to be one of the molecules in the human IEC supernatants responsible for the 
generation  of  tolerogenic  DCs.  Intriguingly,  some  commensal  bacteria  seem  to  favour 
induction of Tregs, while other suppress Tregs and induce inflammatory Th17 cells. For 
example,  colonization  of  germ-free  mice  with  human  commensal  Bacteroides  fragilis 
induces  development  of  FoxP3
+  Tregs,  and  polysaccharide  A  (PSA)  derived  from  B. 
fragilis mediates the conversion of CD4
+ T cells into FoxP3
+ Tregs that produce IL-10 
(214). It was also noted that both induction of Tregs and IL-10 production were dependent 
on TLR2 signalling. Some helminths can also promote differentiation of regulatory T cells  
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(215). Whereas some commensals promote induction of Tregs, colonization of the small 
intestine of mice with segmented filamentous bacteria leads to appearance of CD4
+ Th17 
cells producing IL-17 and IL-22 in the lamina propria (216). Furthermore, it has been 
shown that DNA from intestinal flora can signal through TLR9, promoting effector T cell 
induction  while  suppressing  Tregs  (215,  217).  These  results  indicate  that  commensal 
bacteria exert complex effects on DCs, which shape the immune response by inducing 
generation of effector cells or regulatory T cells depending on the signals DCs receive 
from the environment. 
All  in  all,  intestinal  dendritic  cells  need  to  make  constant  decisions  about  whether  to 
induce  inflammation  or  tolerance  in  response  to  particular  antigens.  Several  unique 
features  make  the  intestinal  immune  system  geared  towards  generation  of  tolerogenic 
responses, and a breakdown in this tolerance can lead to overt inflammatory reactions or 
autoimmunity. In fact, it has been shown both in humans and mice that DCs can have 
protective or immunogenic roles in several diseases, including inflammatory bowel disease 
and celiac disease (168) and rheumatoid arthritis (218). 
1.4  B27-TG rats 
When  the  strong  genetic  link  between  HLA-B27  and  AS  was  discovered  in  1973, 
researchers were curious to learn whether HLA-B27 alone was responsible for AS disease 
pathogenesis. When the technology to create transgenic mammals became available in the 
mid 1980’s, mice transgenic for the human HLA-B27 and human !2 microglobulin (!2m) 
genes  were  among  the  first  ones  generated.  However,  despite  expressing  a  functional 
HLA-B27 gene, no evidence of spontaneous inflammatory disease was reported in these 
mice (219-221), although it was observed that the transgenic mice were more susceptible 
to Yersinia enterocolitica infection (222). As several classical models of chronic arthritis, 
such as adjuvant arthritis, occur in rats but not in mice, it was thought that rats would 
provide a better model for the HLA-B27 induced disease as well. 
1.4.1  Disease phenotype in B27-TG rats 
With the idea that rats might provide a better model for HLA-B27-dependent disease, in 
1989  Joel  Taurog  generated  rats  transgenic  for  the  human  HLA-B27  and  human  !2m 
genes (B27-TG rats) (223). These transgenic animals were created by randomly inserting 
both HLA-B27 and !2m DNA fragments into the rat genome, and assessing which of the  
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founders had integrated both genes in the genome and also expressed them as proteins on 
the  cell  surface.  Several  lines  on  the  LEW  background  and  one  line  on  the  F344 
background fulfilled both requirements, and these lines differed in their copy number of 
the incorporated genes (Table 1.2). It was then observed that some, but not all, lines of 
these transgenic animals developed a spontaneous inflammatory disease. The development 
of the symptoms seemed to correlate with the gene copy number: the more copies of the 
gene the animals had, the more likely they were to develop disease symptoms. In addition, 
it  was  observed  that  the  level  of  HLA-B27  mRNA  and  HLA-B27  surface  expression 
seemed to increase as the rats got older and displayed more disease symptoms. It has also 
been noted that HLA-B27
+ AS patients express higher level of HLA-B27 on the surface of 
their  PBMCs  than  HLA-B27
+  healthy  controls,  suggesting  that  the  level  of  HLA-B27 
expression correlates with disease symptoms (224).   
Table 1.2. HLA transgenic rat lines 
Line  HLA gene 
HLA copy 
number 
β2m copy 
number 
Original 
strain 
Other 
strains 
Disease 
21-4H  B*2705  150  90  LEW 
F344, DA, 
SD 
Yes 
21-3  B*2705  20  15  LEW   
In 
homozygotes 
25-6  B*2705  7  7  LEW    No 
21-4L  B*2705  6  6  LEW  PVG  No 
33-3  B*2705  55  66  F344  LEW, PVG  Yes 
195-2  B*2705  9  17  F344 
F344 
rnu/rnu 
No 
120-4  B*0702  26  5  LEW    No 
 
The  disease  in  these  transgenic  animals  has  shown  little  variation  since  they  were 
developed, and the main symptoms are (adapted from (225)): 
1.  Inflammatory gastrointestinal disease, in most cases affecting the colon and cecum; 
stomach and small intestine are affected with a variable distribution and frequency 
2.  Inflammatory peripheral arthritis, mostly in the tibiotalar and tarsal joints 
3.  Inflammatory and fibrotic spinal lesions (rare, and not investigated in detail) 
4.  Variety of skin lesions, such as psoriasiform dermatitis, folliculitis, alopecia and 
nail dystrophy 
5.  Orchitis and epididymitis  
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6.  Carditis (has not been investigated in detail) 
 
Not  all  symptoms  mentioned  above  are  present  in  all  the  transgenic  lines  used  for 
research, and not all have been followed up since the original description of the rats. For 
example, spinal lesions and carditis are not well characterised in this model. The two main 
lines  of  transgenic  rats,  33-3  (F344)  and  21-4H  (LEW),  both  present  with  intestinal 
inflammation,  arthritis,  nail  and  skin  symptoms  and  genital  lesions  (226).  Intestinal 
inflammation is the first symptom to occur, with the onset in both female and male rats of 
the 33-3 line around age of 5 weeks (226). In males, this is followed by development of 
skin and nail lesions, arthritis and genital lesions, with gradual increase in the percentage 
of animals affected from age 10 weeks. By 36 weeks, all the animals are affected by 
intestinal symptoms, about 80 % with skin and nail lesions and arthritis and at least 60 % 
by genital lesions. In female animals, the disease course is slightly different with later 
onset of arthritis and fewer skin- and nail-lesions. By 36 weeks, all the females are also 
affected by intestinal inflammation, about 60 % with arthritis, but only about 20 % present 
with skin and nail lesions.  
As  can  be  seen,  many  of  the  spontaneously-arising  HLA-B27-dependent  disease 
characteristics in the rats represent symptoms observed across the whole range of HLA-
B27-linked SpA diseases in humans, such as skin symptoms present in psoriatic SpA, and 
gastrointestinal disease observed especially in AS and IBD-SpA. Thus, these transgenic 
animals offer a good model for human SpA.  
1.4.2  Factors affecting disease development in B27-TG animals 
Development of spontaneous disease in the B27-TG animals suggests that the HLA-B27 
and  !2m  genes  alone  are  capable  of  driving  the  development  of  SpA.  But,  as  it  was 
observed that a very high copy number of HLA-B27 and !2m genes were needed for the 
disease to develop in the animals, it was suggested that the disease was caused by the 
insertion of human transgene in the rats, irrespective of the gene. Thus, rats transgenic for 
another human MHC class I molecule, HLA-B7, which is not associated with any human 
disease, were created and named line 120-4 (Table 1.2). These animals also have a high 
copy number of the human transgene, but they do not show any signs of spontaneous 
disease  development,  which  is  why  these  animals  today  serve  as  useful  controls  in 
experiments where B27-TG animals are used. In humans HLA-B27 is responsible for only 
about  30-40  %  of  disease  susceptibility,  with  other  genes  and  environmental  factors  
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contributing the rest, whereas in rats HLA-B27 seems to be able to drive the development 
of spontaneous inflammatory disease on its own. However, the disease in transgenic rats is 
also strain dependent. The 33-3 line, originally on the F344 background, shows normal 
disease development when backcrossed to both PVG and LEW backgrounds (225, 227), 
but when the F344 B27-TG rats are backcrossed to the DA strain, the animals exhibit a 
strikingly reduced disease phenotype (225). In addition, it was also noticed that the surface 
expression of the two transgenes was lower on the disease resistant DA.33-3 rats than on 
the susceptible F344.33-3 animals. This difference in the susceptibility of different rats 
strains for SpA phenotype also hints that, as in humans, additional genetic factors are 
required for SpA disease development. However, it has not been possible to identify the 
factors on rats of the DA strain that confer protection from the disease.  
Environmental factors also play a role in development of disease in the B27-TG animals. 
This was made especially clear by Joel Taurog’s group, when they encountered an extreme 
change in the disease phenotype in one of their barrier rooms (225). In this instance, the 
33-3 line on an F344 background developed an accelerated disease, with rats at weaning 
presenting with symptoms normally present at about 3 months of age, including severe 
diarrhoea. DA.33-3 animals housed in the adjacent rack had been completely symptom 
free  until  then,  but  eventually  they  also  developed  severe  bowel  inflammation  and 
diarrhoea.  This  observation  suggests  that  whatever  factors  offer  protection  in  the  DA 
background, they can be overcome by some, in that case unknown, environmental factors.  
As discussed before, there has been much interest in the role of intestinal factors in the 
pathogenesis of SpA in humans. Whereas the above-mentioned isolated observation does 
not provide direct evidence for the role of intestinal factors in disease development, other 
studies performed using these animals provide more reliable and consistent observations. 
Perhaps  the  most  convincing  evidence  linking  the  intestinal  microbiota  to  disease 
development on the B27-TG animals was acquired when B27-TG animals on 33-3 and 21-
4H backgrounds were re-derived in a germ-free environment. Surprisingly, no gut or joint 
inflammation was observed in either of the strains used (228). However, skin and male 
genital lesions were still present and not affected by the germ-free environment, suggesting 
that these two symptoms could be a direct consequence of transgene expression, whereas 
the  development  of  joint  and  intestinal  inflammation  is  dependent  on  additional 
environmental  factors.  Supporting  this,  upon  transferring  the  animals  from  germ-free 
environment  into  a  specific  pathogen-free  environment,  they  developed  the  complete 
disease phenotype (228). Furthermore, it was subsequently shown that it was possible to  
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induce the disease phenotype in germ-free animals by giving them a specific cocktail of 
bacteria  including  the  anaerobic  species  Bacteroides  vulgatus  (229).  This  same  group 
elaborated on their earlier observations and showed that reconstitution with this species 
alone, but not with E. coli, was sufficient to induce colitis in germ-free B27-TG animals 
(230). Regarding the intestinal microbiota in B27-TG animals, it has also been observed 
that the cecal content of E. coli and Enterococcus rise in parallel with disease activity 
(231). It was mentioned earlier that there has been much controversy regarding the role of 
Klebsiella bacteria in AS pathogenesis. This bacterium does not appear to be relevant for 
the disease in rats, as no evidence for the presence of these bacteria was found when cecal 
bacteria from B27-TG rats were studied (231).  
1.4.3  Immunological considerations  
The immunological mechanisms driving disease in the B27-TG animals have been of great 
interest to researchers, and much has been learned since the model was developed. Here, 
the main points are briefly discussed. 
After the generation of the B27-TG animal model, researchers were interested to discover 
which  cells  were  responsible  for  disease  induction  in  the  animals.  One  of  the  first 
experiments to try to elucidate this was performed by Joel Taurog’s group, where either 
LN or bone marrow BM cells were transferred from disease prone 21-4H and 33-3 lines to 
lethally irradiated non-transgenic recipients (232). All the recipients of B27-TG BM cells, 
but not LN cells, developed disease symptoms. In addition, transfer of non-transgenic BM 
cells  to  lethally  irradiated  B27-TG  33-3  animals  with  established  disease  resulted  in 
disappearance of skin lesions and diarrhoea. In the same publication, it was also observed 
that  there  was  an  increased  presence  of  B27
bright  CD4
dim  OX42
+  (CD11b)  cells  with 
monocyte-macrophage morphology in the peripheral blood of the animals that developed 
disease symptoms. The percentage of these cells also increased with disease progression. 
Thus, the authors concluded that BM derived hematopoietic precursors are required for 
disease development, and that these cells could be dendritic cells, or cells of the monocyte 
lineage. 
HLA-B27 is an MHC class I molecule involved in antigen presentation to CD8
+ T cells. 
Thus,  despite  the  findings  above  indicating  that  BM-derived  non-lymphoid  cells  are 
needed for disease development, it is likely that other cell types are involved as well. 
Following the above observations, Taurog’s group were interested to discover whether T  
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cells are required for the development of disease in these animals (233). They performed a 
series of elegant experiments involving the use of B27-TG 33-3 rats crossed with nude 
animals, which lack T cells. First, it was observed that these nude B27 transgenic animals 
remained healthy, suggesting that T cells are indeed required for the disease progression. 
Supporting this, transfer of BM from nude 33-3 animals into non-transgenic recipients did 
induce disease in the recipients. By transferring either total LN cells or LN cells enriched 
for either CD4
+ T cells or CD8
+ T cells into nude 33-3 recipients, it was surprisingly 
observed that CD4
+ cells induced a more pronounced disease in the recipients than CD8
+ 
cells. However, in both cases the induced disease was mild, and thus this observation has 
been followed up more recently using two different approaches. First, disease prone rats 
from 21-4H and 33-3 lines underwent thymectomy, and subsequent in vivo treatment with 
anti-CD8" (OX-8) antibody to deplete CD8"#
+ T cells (234). These animals developed a 
disease comparable to control animals, suggesting that CD8
+ T cells are not required for 
the disease pathogenesis. However, long-term treatment of B27-TG animals with OX8 
antibody led to a less severe arthritis compared with non-treated animals. There are other 
CD8" expressing cells in the rat that are not thymically derived, such as NK cells and 
monocytes, and thus it could be that depletion of these cells is responsible for the effects 
seen using the long-term treatment. To address this question more specifically, recently a 
new model was developed where rats with a mutation in the CD8" chain were backcrossed 
to LEW.33-3 transgenic line (235). This led to generation of transgenic animals with no 
surface  expression  of  either  CD8"  or  CD8#.  Supporting  the  earlier  observations,  no 
difference in either the onset of disease or the phenotype was seen when comparing CD8 
deficient  CD8"
-/-  animals  to  CD8"
-/+  littermates  with  normal  CD8  surface  expression. 
From  the  above  observations  it  can  be  concluded  that  normal  MHC  class  I  antigen 
presentation to CD8
+ T cells does not seem play a significant role in HLA-B27 driven 
disease development. And as it was noted in one of the experiments that CD4
+ T cells 
derived from disease prone animals were sufficient to induce disease in nude 33-3 animals, 
and  that  hematopoietic  BM  derived  cells  were  needed,  it  has  been  suggested  that 
interactions between dendritic cells and monocytes and CD4
+ T cells have a central role in 
the development of inflammatory disease in the B27-TG rat model. 
DCs are APCs that are uniquely capable of activating naïve CD4
+ T cells, a cell type, as 
noted above, that was able to transfer disease to non-TG recipients. Recently, there have 
been several publications suggesting a role for DCs in the SpA animal model. When B27-
TG animals were backcrossed to nude rats, creating 33-3 B27-TG rats that lack T and B 
cells, it was observed that these animals did not develop spontaneous disease. When non- 
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TG MLN cells were transferred to these nude 33-3 B27-TG animals, the donor non-TG 
cells were capable of inducing colitis in the recipient animals (236). This suggests that an 
additional HLA-B27 expressing cell type present in the recipient animals is needed for the 
disease induction on nude 33-3 animals, together with lymphocytes. As this cell type needs 
to be capable of activating and instructing the immune response, DCs were implicated. 
Furthermore, several additional observations support the role for DCs in SpA pathogenesis 
in the animal model: 
•  Splenic dendritic cells from B27-TG animals exhibit reduced capability to stimulate 
allogeneic T cells responses (237). 
•  Reduced and altered formation of T cell-DC conjugates has been observed when using 
B27-TG DCs (237, 238). 
•  Deficient cytoskeletal dynamics on B27-TG DCs leads to reduced DC mobility and 
impacts the formation of immunological synapse with T cells; and reduced expression 
of surface MHC class II, which in turn leads to increased apoptosis of B27-TG splenic 
DCs (239). 
•  Splenic DCs from B27-TG rats have been shown to induce more Th17 T cells when 
compared to non-TG DCs (144).  
 
Thus, several defects in splenic and LN DC behaviour have been identified in the B27-TG 
animal  model.  However,  given  the  mounting  evidence  for  the  role  of  intestinal 
inflammation in the pathogenesis of both human SpA and B27-TG animal model, it is 
surprising  that  only  a  few  studies  have  been  conducted  using  DCs  from  more 
physiologically relevant sites, such as the MLN or the intestine. This is likely to be due, at 
least  in  part,  to  the  lack  of  reliable  DC  markers  in  the  rat.  Therefore,  several  issues 
regarding DC function in SpA still need further research and clarification. 
1.4.4  HLA-B27 driven mechanisms of disease 
As was mentioned earlier in this chapter, the association between HLA-B27 and SpA is 
well  established.  However,  the  functional  role  this  molecule  has  in  disease  induction 
remains unclear. Several theories have been proposed to explain the pathogenic role of 
HLA-B27,  including  presentation  of  arthritogenic  peptides,  aberrant  folding  of  surface 
heavy chains, and HLA-B27 misfolding. These are described briefly below.  
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1.4.5  Presentation of arthritogenic peptides 
Presentation  of  arthritogenic  peptides  by  HLA-B27  is  sometimes  referred  to  as  the 
molecular mimicry theory. It is thought that HLA-B27 may present peptides arising from 
degradation of endogenous proteins to CD8
+ T cells, and the sequence similarity between 
microbial and self-antigens might lead to break in tolerance and lead to autoimmunity. In 
support of this theory, HLA-B27 was shown to present a peptide derived from its own 
molecule, which was shown to be highly homologous to a peptide derived from Chlamydia 
trachomatis  (240).  This  peptide  is  a  natural  ligand  to  HLA-B27  subtypes  strongly 
associated with SpA, namely B*2705, B*2704 and B*2702, but not to weakly associated 
B*2706 and B*2709 (240). Furthermore, peptides derived from cartilage or bone-related 
proteins  were  shown  to  be  possible  ligands  to  HLA-B27,  and  a  high  number  of  the 
peptides binding HLA-B27 shared a homology to bacterial sequences (241). It has also 
been shown that self-peptide derived from vasoactive intestinal peptide 1 (VIPR1) show 
homology to an Epstein-Barr derived peptide when bound in a non-conventional way to 
B*2705. B*2709 can only bind this peptide in a conventional way, and when presented in 
this conformation, VIPR1 peptide does not share the sequence similarity with Epstein-Barr 
virus.  Thus,  the  authors  hypothesise  that  individuals  with  B*2705  allele  could  have 
circulating  self-reactive  T  cells  that  have  escaped  the  central  tolerance  in  the  thymus, 
which can induce cross-reactivity to self-antigens (242, 243). This theory is also supported 
by the fact that reactive arthritis, a subtype of SpA, is triggered either by genitourinary 
infections  with  Chlamydia  trachomatis  or  by  gram-negative  enterobacteria  such  as 
Shigella,  Salmonella,  Yersinia  or  Campylobacter  species  (244),  and  thus  HLA-B27 
presenting peptides from these pathogens could lead to induction of immunity towards 
self-antigens and thus to autoimmunity. Furthermore, 10-20% of HLA-B27
+ patients with 
reactive arthritis develop AS in the space of 10-20 years (245).  
In favour of this theory, a single amino acid substitution from aspartate in the disease 
conferring allele B*2705 to histidine in B*2709 leads to loss of association with AS (246). 
This mutation is in the antigen-binding region of the molecule, which suggests that the 
disease-conferring alleles might bind unique set of peptides, supporting the theory that 
B*2705 binds a unique set of peptides that can induce disease development. However, 
some cases of SpA have been identified in individuals carrying the B*2709 allele, thus 
undermining the credibility of this particular piece of evidence. In addition, none of the 
above  mentioned  pathogens  have  been  noted  as  being  causative  agents  in  SpA.  Also, 
studies from B27-TG rats indicate that CD8
+ T cells are not needed for the induction of  
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disease, whereas CD4
+ T cells are (see section 1.4.3), further suggesting that HLA-B27 
might not have a traditional antigen presenting role in the disease pathogenesis of SpA. 
Thus, the absence of autoantibodies and scarce evidence for HLA-B27 restricted T cell 
responses could raise the questions whether SpA is a genuine autoimmune disease driven 
by B and T cells. Other theories discussed below suggest that HLA-B27 could have a role 
in triggering innate immune responses rather than in antigen presentation, thereby arguing 
for a more autoinflammatory rather than autoimmune origin for the disease.  
1.4.6  HLA-B27 misfolding in the ER 
It has been noted that the HLA-B27 molecule has some unusual features outside of its role 
in presenting antigens. Notably, HLA-B27 has been shown to have a tendency to misfold 
inside cells, in the endoplasmic reticulum (ER). The ER is a sub-cellular organelle, where 
proteins are assembled and correctly folded before transit to the cell surface or to other 
organelles. This process is dependent on chaperones and other molecules that assist in 
protein folding and is under strict quality control, which limits accumulation of protein 
aggregates by ensuring fidelity of transcription and by selectively degrading unfolded or 
misfolded proteins (247). Altered ER homeostasis may lead to accumulation of protein 
aggregates that can be detrimental to cell survival, and lead to an ER “stress response” or 
“unfolded protein response” (UPR) (247). The UPR can trigger three kinds of protective 
cellular responses: (i) up-regulation of ER chaperones, e.g. BiP which assist to refold the 
proteins;  (ii)  downregulation  of  protein  translation  and  (iii)  degradation  of  misfolded 
proteins by the proteasome in a process called ER associated degradation (ERAD) (247). If 
these  three  protective  measures  fail  to  resolve  the  ER  stress,  it  may  lead  to  NF-$B 
activation  and  upregulation  of  host  defence  mechanisms  or,  if  stress  is  prolonged,  to 
apoptosis or autophagy (247). 
HLA-B27 is an unusual molecule in that it has been shown to undergo slower protein 
folding and greater cytosolic accumulation than other MHC class I molecules, even in the 
presence of a normal supply of peptide and !2m (248). The unpaired Cys
67 residues in the 
peptide-binding region of the molecule appear to allow HLA-B27 heavy chains to dimerise 
when they are reassembled in the absence of  !2m (249). Supporting this, in the B27-TG 
rats, the B27 molecule has shown prolonged binding to the BiP chaperone suggesting that 
misfolding is taking place (250). In contrast, the HLA-B7 allele, which is not linked to 
disease,  did  not  show  any  evidence  of  misfolding  when  expressed  in  rat  cells  (251).  
 
56 
Further  evidence  for  HLA-B27  misfolding  comes  from  work  with  the  transgenic  rats 
where  it  was  noted  that  macrophages  activated  with  IFN#  showed  evidence  of  UPR 
whereas there was no evidence of UPR in macrophages derived from non-transgenic rats 
or  from  B7-TG  rats  (250).  In  this  same  study,  it  was  found  that  tissue  from  the 
gastrointestinal tract of B27-TG rats showed signs of UPR, unlike other tissues such as 
spleen and thymus where this effect was not seen. More recently, it was also shown that 
BM  macrophages  from  B27-TG  rats  produced  more  IL-23p19  than  macrophages  from 
non-TG animals when stimulated with LPS (252). In the same study it was found that IL-
23p19 and IL-17 mRNA were increased in the colon of B27-TG rats compared to non-TG 
animals, and most of these transcripts were localised in the LP of the rats. LP cells were 
divided into lymphocytes and APCs (DCs and macrophages) according to CD11b and 
FSC/SSC characteristics. It was found that there was an increase in the expression of BiP 
in  the  CD11b
+  APCs  from  B27-TG  animals,  and  these  cells  also  showed  increased 
expression of IL-23p19 compared to other cell populations observed. The increase in the 
IL-17 expression was noticed mostly in the CD4
+ TCR"!
+ lymphocytes. The authors name 
these  CD11b
+  cells  macrophages.  However,  some  of  these  cells  could  be  LP  DCs, 
populations of which also express CD11b. This would fit with other data from B27-TG rats 
showing defects in the DC populations, discussed above. In concordance with rats, human 
monocyte derived macrophages from AS patients were also noted to produce increased 
amounts IL-23 compared to cells from healthy individuals (253). However, no increase 
was noted in expression of ER stress molecules CHOP or BiP.  
The propensity of HLA-B27 molecules to misfold and activate UPR may lead activation of 
proinflammatory NF-$B pathways and thus to antigen-independent activation of NK cells, 
T  cells  and  macrophages  via  cytokines,  such  as  IFN-!  and  IL-12,  secreted  from  the 
stressed  cells.  For  example,  DCs  would  be  ideally  placed  to  drive  these  inflammatory 
responses. Not only can they activate T cells, it has also been noted that DCs can interact 
with and activate NK cells. However, there is little or no evidence of UPR or ER stress in 
human SpA cells, so it is still unclear how important this mechanism is for the human 
disease development. 
1.4.7  Aberrant folding of surface heavy chains 
In  1999  Allen,  RL  et  al  showed  that  HLA-B27  molecules  can  form  homodimeric  or 
heterotrimeric structures on cell surfaces (249). The HLA-B27 molecule normally consists 
of !2-microglobulin (!2m), which together with "3 domain supports peptide binding to  
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the groove formed by "1 and "2 domains. HLA-B27 has an unusual feature of having an 
unpaired cysteine residue (Cys
67) in its "1 domain. In their publication Bird, LA et al 
demonstrated that HLA-B27 was able to form heavy chain homodimers on the cell surface 
that  were  dependent  on  Cys
67  but  free  of  !2m.  These  disulfide-bridged  homodimeric 
complexes did not seem to derive from the ER but seemed to originate from cell surface 
heavy chain/!2m/peptide complexes that have lost !2m, and is was proposed they were 
formed either on the surface or in the endoplasmic vesicles during transport to the surface 
(254). However, these observations were carried out using HLA-B27 transfected B cell 
lines in vitro, and it is possible that on other cells, like DCs, some of the surface complexes 
are  formed  intracellularly  in  the  ER  and  then  circulated  to  the  cell  surface.  Indeed, 
complexes staining with HC10 antibody, that recognises B27 dimers, are found both in the 
surface and within the cell in B27-TG rat splenocytes and DCs (255). HC10 staining has 
also revealed surface homodimers to be present in other cell types both from AS patients 
and from HLA-B27 transgenic rats (255, 256).  
As it has been shown that CD8
+ T cells are not necessary for disease induction, at least in 
HLA-B27  transgenic  rats,  it  raises  a  question  about  which  cells  are  driving  disease 
pathogenesis. Hill Gaston showed that CD4
+ T cells are capable of directly recognising 
forms of mutated HLA-B27 (257), and the authors conclude that these abnormal forms 
could arise as a result of infection and thus CD4
+  T cells might play a pathogenic role in 
spondyloarthropathies. Furthermore, MHC class I restricted CD4
+ T cell lines have been 
isolated both from humans (258) and mice (259) supporting this argument. The mechanism 
for this interaction is not fully understood but the CD4 co-receptor is thought to play a role. 
In addition to CD4
+ T cells, NK cells are also capable of binding to HLA-B27 molecules. 
NK cells have both inhibitory and activatory receptors on their surface, and these belong to 
the  family  of  killer  cell  immunoglobulin-like  receptors  (KIRs)  (260).  Inhibitory  KIRs 
(KIR2/3DL) have long cytoplasmic tails, and incorporate two immunoreceptor tyrosine 
inhibitory motifs (ITIMs). Stimulatory KIRs (KIR2/3DS) have shorter cytoplasmic tails 
and  they  interact  with  immunotyrosine  activation  motifs  (ITAMs).  NK  cell  activation 
occurs  as  a  result  of  the  overall  sum  of  the  inhibitory  and  activating  signals  the  cell 
receives. Some populations of T cells, mostly a small population of CD8 memory effector 
cells, also express KIRs (261). KIR
+ CD4 T cells are scarce on healthy individuals, but are 
expanded  in  circumstances  where  chronic  T  cell  activation  occurs,  such  as  in  some 
autoimmune diseases (262, 263).  
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Kollnberger, S et al showed that NK cell receptor KIR3DL2 is capable of binding to HLA-
B27  homodimers  independent  of  the  bound  peptide  sequence  (264).  Co-culture  of 
KIR3DL2  NK  cells  with  HLA-B27  transfected  cells  expressing  B27  dimers  leads  to 
inhibition of IFN-! production by NK cells, whereas co-culture with HLA-B7 transfected 
cells did not affect IFN-! production (264). Interestingly, KIR3DL2 expressing CD4 T 
cells are expanded in the peripheral blood of patients with HLA-B27 associated SpA, and 
have been shown to account for almost 30 % of memory effector CD4 T cells in these 
patients (265). Ligation of KIR3DL2 with B27 dimers was shown to inhibit activation 
induced cell death of KIR3DL2 expressing leukocytes from patients, and thus binding of 
B27 dimers to KIRs could promote survival of proinflammatory NK and T cell population 
in SpA patients (237). Intriguingly, RA patients also have an expanded population of KIR 
expressing T cells, but no preferential expansion of KIR3DL2
+ is seen (265, 266). More 
recently, it was also noted that co-culture of KIR3DL2
+ CD4
+ T cells with a cell line 
expressing B27 homodimers induced survival, proliferation and IL-17 production from the 
T cells (267).  Furthermore, IL-17 producing KIR3DL2
+ CD4
+ T cells were expanded in 
the blood and synovial fluid of SpA patients. KIR3DL2
+ CD4
+ T cells from SpA patients 
also produced more IL-17 ex-vivo than KIR3DL2
+ T cells from healthy controls. These 
observations  are  interesting  as  they  again  enforce  the  observations  about  possible 
importance of Th17 cells in the pathogenesis of SpA, and offer an additional explanation 
for the role of HLA-B27 in SpA pathogenesis.  
1.5  Hypothesis and aims 
DCs act between innate and adaptive arms of the immune system, and thus have a crucial 
role as orchestrators of the immune response. Nowhere is this role more pronounced than 
within the intestinal immune compartment, where DCs have to be capable of directing 
protective  immune  responses  against  pathogens,  but  must  also  maintain  tolerance  to 
harmless  antigens.  Defects  in  the  maintenance  of  peripheral  tolerance  for  commensal 
bacteria  or  food  antigens  can  lead  to  disease,  as  demonstrated  in  coeliac  disease  and 
Crohn’s disease. Intestinal inflammation has also been linked to several HLA-B27-linked 
human  SpA  diseases.  The  most  convincing  evidence  for  a  link  between  intestinal 
inflammation  and  systemic  disease  comes  from  the  HLA-B27  transgenic  rat  model  of 
disease, where animals reared in germ-free conditions fail to develop the disease.  
Taking into account the central role of DCs in intestinal immune homeostasis, and the 
mounting evidence for the role of intestinal inflammation in systemic disease, I sought to  
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investigate the role of intestinal DCs in the pathogenesis of B27-TG rat model of SpA. 
DCs continuously migrate from peripheral intestinal sites to the MLNs, and these DCs can 
be collected by thoracic duct cannulation. Due to lack of reliable DC markers in the rat, 
investigation of DCs from B27-TG animals had mostly been limited to LNs, BMDCs and 
splenic DCs. Using our unique surgical method, I was, for the first time, able to investigate 
DCs migrating from the intestines to the MLNs in this animal model. I hypothesised that 
there  would  be  a  defect  in  the  migrating  intestinal  DCs,  leading  to  development  of 
systemic inflammatory disease in these animals. 
In the first results chapter (Chapter 3), I describe the disease in the transgenic animals we 
used; this is important because the animals were backcrossed to the PVG strain to enable 
collection of L-DCs. The expression of HLA-B27 in the animals is also characterised in 
this chapter. Chapter 4 contains data describing the migrating intestinal lymph DCs from 
B27-TG,  B7-TG  and  non-TG  animals.  These  findings  are  extended  in  chapter  5  by 
studying  similar  DC  populations  in  the  animals’  MLNs.  In  chapter  6  I  describe  data, 
obtained by studying the functions of BM-derived DCs from B27-TG and non-TG rats, 
and  argue  that  the  DC  defect  in  the  B27-TG  rats  is  systemic,  and  may  contribute  to 
pathology in these animals. In the final chapter I describe two possible models that will try 
to explain the events that could lead to development of inflammatory disease in both B27-
TG animals and the human SpA.       
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2.  Materials and methods 
2.1  Animals 
Rats transgenic for human HLA-B27 and #2 microglobulin genes (B27-TG) on the F344 
background  (F344/NTac-Tg(HLA-B2705,  #2M)33-3Trg)  were  purchased  from  Taconic 
Inc. (Hudson, NY) and bred under licence. Subsequently, these animals were backcrossed 
to a PVG strain (PVG/OlaHsd; Harlan, UK), and animals used for in vivo experiments 
(Chapter 4) are from generations F3-F5, whereas animals used for in vitro experiments 
(Chapter  5-6)  are  F7  and  up.  Hemizygous  B27-TG  animals  were  crossed  with  non-
transgenic PVG rats, and all offspring were screened for the presence of HLA-B27 gene 
using  a  FITC  conjugated  anti-human  HLA-B27  antibody.  Non-transgenic  age-matched 
littermates were used as controls, as well as rats transgenic for human HLA-B7 gene (B7-
TG), which were kindly provided by Maxime Breban (Université René Descartes, Paris, 
France). B7-TG animals were also backcrossed to a PVG strain as above. At the time of in 
vivo experiments B7-TG animals were F2-F3 progeny, and for in vitro data they were F3-
F4. DA rats used for T cell proliferation experiments were purchased from Harlan, UK. All 
rats were used at the age of 8-24 weeks, except for mesenteric lymphadenectomy (MLNX), 
where rats were 5-6 weeks old. 
Animals were bred and maintained under specific pathogen-free conditions at the Central 
Research Facility of University of Glasgow. All procedures were performed under licenses 
obtained from the UK Home Office. 
2.2  Surgical procedures 
These  have  previously  been  described  in  detail  (268),  but  a  brief  description  is  given 
below.  
Male rats of 5-6 weeks of age were used for MLNX. Animals were shaved and treated with 
subcutaneous  analgesics  Carprofen  (Rimadyl;  Pfizer)  and  Buprenorphine  (Vetergesic; 
Reckitt Benckiser Healthcare); both diluted 1:10, and dose rates 0.1 ml/100 g and 0.15 
ml/100  g,  respectively).  Anaesthesia  was  induced  by  inhalation  of  isoflurane  (Abbot 
Laboratories Ltd) and a small midline incision (about 2 cm) was made in the skin and 
along the linea alba. Intestines were externalised through this incision, and the chain of 
mesenteric lymph nodes was removed, along with any isolated lymph nodes visible near  
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the cecum. The intestines were replaced, and the wound was closed using a continuous 
stitch for the muscle layers, and metallic clips for the skin. Animals were placed in a 
recovery cage for a few hours, after which they were moved to normal cages. 
A polyurethane cannula (3fr, Harvard Apparatus, UK) was prepared in advance for the 
second part of the surgery. The cannula was first rinsed with acetone using a 5ml syringe 
and  23G  needle,  followed  by  10-minute  incubation  with  5  %  (v/v)  3-
aminopropyltriethoxysilane.  After  10  minutes,  the  cannula  was  again  rinsed,  first  with 
acetone and then with PBS, and finally the cannula was filled with Heparin (Wockhardt 
UK) and left at 4ºC overnight.  
A minimum of 5 weeks after MLNX, when the lymphatics had re-anastomosed, animals 
were  subject  to  a  second  round  of  surgery.  The  animals  underwent  laparotomy  under 
inhalation anaesthesia, and the prepared cannula was inserted into the thoracic duct. The 
cannula was externalised between the shoulder blades of the rats, and inserted through a 
metal tube attached to a Covance harness (Harvard Apparatus). Animals wore this harness 
for the entire duration of the lymph collection. For the first 24h after surgery, animals were 
placed  in  a  Bollman  restraining  cage  and  received  i.v.  saline.  After  24h,  they  were 
removed to a normal cage for further 24 or 48 hours of lymph collection.  
2.3  Histology 
For histochemical analysis, tissues were collected from animals under terminal anaesthesia 
and immediately fixed in neutral buffered formalin. Formalin-fixed tissues were processed 
by James Reilly and Shauna Kerr (University of Glasgow; Institute of Infection, Immunity 
and Inflammation) using a Shandon Citadel 1000 tissue processor (ThermoFisher) and 
embedded in paraffin wax using a Shandon Histocentre 3 (ThermoFisher) for subsequent 
sectioning  using  a  Shandon  Finesse  325  (ThermoFisher).  Sections  were  cut  at  5  µm 
thickness and floated on distilled water at 40°C in a Tissue Floatation Bath (ThermoFisher) 
to stretch and remove any wrinkles/folds from the section. Sections were then adhered to 
Polysine microscope slides (VWR).  
Paraffin-embedded sections were incubated at 60°C on a Hotplate (ThermoFisher) for at 
least  35  minutes  to  soften  the  paraffin  wax.  They  were  then  incubated  in  xylene 
(ThermoFisher) for 10 minutes to remove the wax, followed by 5-minute immersions in 
100 %, 90 % and 70 % ethanol, and finally a 5-minute immersion in running tap water to  
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hydrate the tissue. Slides were then stained as follows: immersion in haemotoxylin (Sigma) 
for 2 minutes; immersion in running tap water until water runs clear; two short immersions 
in 1 % acid/alcohol (ThermoFisher); rinse in running tap water; immersion in Scotts Tap 
Water  Substitute  (CellPath,  UK)  for  30  seconds;  rinse  in  cold  running  tap  water; 
immersion in eosin (Sigma) for 2 minutes; rinse in running tap water; immersion in 70% 
ethanol for 30 seconds; immersion in 90 % ethanol for 1 minute; immersion in 100 % 
ethanol for 3 minutes x 2; immersion in xylene for 3 minutes first, and then left in for 30 
minutes. Slides were then allowed to air-dry before glass coverslips were mounted onto the 
sections  using  DPX  mountant  (VWR)  and  air-dried  for  at  least  an  hour.  Images  were 
obtained  using  a  light  microscope  (Olympus  BX11)  with  an  x10  objective  and  were 
analysed and archived using cell^B software (Olympus, Southend-on-Sea, UK). 
2.4  Cell culture reagents 
Where indicated, cells were cultured in complete media consisting of: RPMI 1640 medium 
supplemented  with  5  %  FBS,  2  mM  L-glutamine,  100  U/ml  penicillin,  100  µg/ml 
streptomycin and 50 µM 2-mercaptoethanol (all Invitrogen, UK).  
Medium was supplemented with one or several of the following, as described in the text: 
10 % supernatant from mFlt3L producing CHO cell line prepared in house (see section 
2.5), or 100 ng/ml recombinant human Flt3L (Hatfield, UK); recombinant rat GM-CSF 
(100 ng /ml) or Pan Caspase OPH Inhibitor Q-VD (0.01-10 µM, as indicated; both from 
R&D  systems),  Thapsigargin  (0.4  -  400  nM,  Sigma)  or  Salubrinal  (1-15  µg/ml; 
Calbiochem). 
2.5  Generation of Flt3L culture supernatant 
Mouse  Flt3L  transfected  Chinese  hamster  ovary  (CHO)  cells  were  grown  in  flasks  in 
ProCHO4 media (Lonza) supplemented with 1x ProHT (Lonza), 2 mM L-glutamin, 100 
U/ml penicillin and 100 µg/ml streptomycin (all Invitrogen) until confluence was achieved. 
Supernatant was harvested from the flasks, and filtered through a 0.2 µM filter (Millipore). 
The filtered supernatant was aliquoted and placed at -20°C until use.  
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2.6  Isolation of peripheral blood cells for HLA-B27 
genotyping by FACS 
To determine whether the rats carried the HLA-B27 gene, offspring were tested at weaning 
(about 4 weeks of age) by FACS. Animals were anaesthetised using inhalation anaesthetic, 
and their tail veins were nicked using a scalpel blade. About 200 µl of blood was collected 
into 1.5 ml tubes containing 5 µl of heparin (5000 U/ml), and mixed thoroughly. 100 µl of 
blood  was  transferred  into  15  ml  tubes,  and  the  RBCs  were  lysed  using  ammonium 
chloride solution (Stem Cell Technologies) at a ratio of 1:10 v/v. Cells were washed twice 
using complete media or FACS buffer, and resuspended in 200 µl of FACS buffer for 
staining. Antibody specificities and concentrations can be found in Table 2.1. 
2.7  Isolation of thoracic duct leukocytes 
Thoracic duct leukocytes were collected from animals on ice in PBS supplemented with 10 
mM EDTA and 20 U/ml heparin. They were passed through a 40 µm cell strainer (BD 
Biosciences),  and  RBCs  were  lysed  with  Red  Blood  Cell  Lysing  Buffer  Hybri-Max 
(Sigma) for 3 minutes at room temperature and washed with complete media. Cells were 
either directly stained and analysed by flow cytometry, or enriched for L-DCs using anti-
CD103 MACS beads (Miltenyi Biotec) (see section 2.9). On occasion, cells were stained 
and further purified by FACS sorting using BD Aria cell sorter. 
2.8  Isolation of MLN and spleen cells 
MLNs and spleens were collected from rats in serum free RPMI, cut into small pieces and 
digested using DNase (50 µg/ml) and liberase (0.4 Wunsch units/ml; both Roche) for 45 
min in a shaking incubator set at 37°C. After this, cells were passed through a 40 µm cell 
strainer, washed and stained with antibodies and analysed by flow cytometry. On occasion, 
MLN cells were first enriched for CD103 using magnetic beads, and then further stained. 
2.9  Enrichment of cell populations using magnetic 
beads 
Dendritic cells were enriched from thoracic duct lymph prior to FACS analysis by using 
magnetic  beads  specific  for  CD103  (Miltenyi  Biotec)  according  to  manufacturer’s 
protocol, with minor modifications. Briefly, single cells suspensions were spun down at 
380 g x 5 min, supernatant was aspirated and the cell pellet was resuspended in 80 µl of  
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buffer per 1x10
7 total cells. Due to the fragile nature of the DC subsets being enriched, 
complete  media  supplemented  with  2  mM  EDTA  was  used  as  buffer  throughout  the 
process. 10 µl of MicroBeads per 1x10
7 total cells was then added, mixed thoroughly and 
incubated at 4°C for 15 minutes. Cells were washed with excess buffer, spun down 380 g x 
5 min and resuspended in buffer 500 µl /10
8 cells. Depending on the number of cells, either 
MS or LS columns (Miltenyi Biotec) were prepared by placing them on the magnetic 
MACS  separator  and  washing  them  with  the  buffer  using  amounts  indicated  in  the 
protocol. Cells were then applied onto the column, and it was washed three times with 
buffer, using volumes appropriate for the column size. After the unlabelled cells were 
washed away from the column, it was removed from the magnet and placed on top of a 
suitable collection tube. The appropriate amount of buffer was added on top of the column, 
and a plunger was used to flush out the magnetically labelled cells.  
2.10 Labelling of antibodies 
Monoclonal  antibodies  specific  for  rat  CD103  and  CD172a  were  conjugated  to  Alexa 
Fluor 488 and Alexa Fluor 647, respectively, using protein-labelling kits from Invitrogen, 
UK according to manufacturer’s instructions. Briefly, 50 µl of 1 M sodium bicarbonate 
was  added  to  0.5  ml  of  2  mg/ml  protein  solution  to  raise  the  pH  of  the  solution  for 
optimum labelling conditions. This solution was transferred to a vial of reactive dye, and 
stirred at room temperature for 1h. Meanwhile, the purification column was assembled and 
prepared  by  pipetting  the  purification  resin  into  the  column.  Reaction  mixture  was 
carefully added on top of the resin, and allowed to enter the column. Elution buffer was 
carefully added to the top, and the reaction mixture separated into two separate coloured 
bands  as  it  moved  through  the  column.  The  faster  moving  band  contains  the  labelled 
antibody, and it was collected from the bottom of the column. The second, slower moving 
band contains the unincorporated dye, which was discarded. 
2.11 Flow cytometry 
Cell surface staining was performed in PBS supplemented with 2 mM EDTA and 2 % FBS 
(FACS buffer) for 30 minutes on ice. Where a biotin-conjugated antibody was used, cells 
were  washed  with  FACS  buffer,  and  further  stained  with  a  streptavidin-fluorochrome 
conjugate for 15 min on ice, and washed again before analysis.   
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To determine proportions of live and dead cells, a combination of Annexin-V and DAPI 
(4',6-diamidino-2-phenylindole)  was  used  in  addition  to  surface  staining.  Cells  were 
stained with cell surface antibodies as above, washed with PBS and resuspended in an 
appropriate volume of 1x Annexin-V binding buffer (BD). 4 µl of Annexin-V antibody 
was added to each stain, and left for 15 minutes at room temperature. 50 ng/ml DAPI was 
added to the samples for 2-4 minutes before acquisition. 
For full list of monoclonal antibodies used see Table 2.1. Antibodies marked as ‘In house’ 
were provided by Neil Barclay, Cellular Immunology Unit, University of Oxford and have 
been conjugated to their fluorochromes or biotin in the laboratory either by others or by 
me. Lineage markers consist of: OX-12, OX-22, OX-33 and TCR "/#. All samples were 
acquired using either MACS Quant analyser (Miltenyi Biotec) or BD LSRII, or sorted and 
analysed by BD FACS Aria. All data analysis was carried out using FlowJo software (Tree 
Star, versions 8.8.6 and 9.3.1). 
2.12 Cell sorting 
Cells were prepared for sorting as above. When sorting fragile DC subsets, cells were kept 
at  all  times  in  complete  media  with  2  mM  EDTA  added,  on  ice.  Cells  were  kept  in 
complete media for the entire duration of the sort, and they were also sorted into media. 
Other cell types were sorted in FACS buffer.  
2.13 Cytospins 
To assess the morphological features of the three different L-DC populations in lymph, 
cytospins were performed. Migrating DCs from lymph were enriched for CD103 by using 
magnetic beads, and the MHCII
+ CD103
+ DCs were sorted into three subsets: CD11b
lo 
CD172a
hi, CD11b
hi CD172a
int and CD11b
lo CD172a
lo. Cells were then spun down and 
resuspended in 200 µl of complete medium. Slides were prepared with a filter card and a 
cuvette in a metal holder, and the 200 µl of cell suspension was loaded into the cuvette. 
Cells were spun for 6 minutes at 450 rpm to transfer them onto microscopic slides, allowed 
to air dry, and fixed in acetone for 10 minutes at -20°C. Slides were stained with Rapid 
Romanowsky  (RA  Lamb)  observed  under  light  microscope  and  analysed  and  archived 
using cell^B software (Olympus, UK).      
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Table 2.1 List of monoclonal antibodies 
Specificity  Clone  Fluorochrome/Bio  Supplier  
Dilution 
(v/v) 
CD3  G4.18  PE  BD  1:400 
CD4 
OX-38  FITC  BD  1:400 
OX-35 
PE/APC/Pe-Cy5  BD  1:200 
Biotin  In house *  1:200 
W3/25  Biotin   In house *  1:200 
CD5  OX-19  Biotin/FITC  In house *  1:200 
CD8a  OX-8  PerCP  BD/Biolegend  1:400 
CD8b  341  FITC  BD  1:400 
CD11b  OX-42  PE  BD  1:400 
CD25  OX-39  PE  BD  1:400 
CD45R  HIS24  FITC/PE  BD  1:200 
CD45RA  OX-33  Biotin  Biolegend  1:200 
CD45RC  OX-22 
FITC  BD  1:200 
Biotin  Biolegend  1:200 
CD80
  B7-1  PE  BD  1:400 
CD86  B7-2  PE  AbD Serotec  1:50 
CD103  OX-62  A488  In house *  1:400 
CD172a  OX-41  A647  In house *  1:400 
Annexin-V    PE  BD  4ul/stain 
OX-40L  ATM-2  PE  Biolegend  1:200 
HLA-B27  HLA-ABC-m3  FITC  AbD Serotec  1:200 
HLA-B7  BB7.1  FITC  AbD Serotec  1:200 
MHC class II  OX-6  PerCP   BD  1:400/600 
TCR α/β  R73  FITC/ Biotin  In house *  1:200 
Ig$ light chain  OX-12  Biotin  In house *  1:200 
CD68  ED-1  Biotin  In house *  1:200 
DAPI      Molecular Probes  1:10,000 
Streptavidin   
FITC/ APC/ APC-
Cy7/ V450 
BD  1:200-400 
Ms IgG1, κ
†  MOPC-21  PE  BD  1:400 
* See section 2.10 for details 
† Isotype control for CD25 and CD80     
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2.14 Generation of bone marrow derived DCs (BMDCs) 
Hind legs of rats were removed and placed in complete media until processed. Bones were 
separated from tissue and snapped using bone snips below the hip joint and above the 
knee, for femur, and below the knee and above the ankle for tibia. Bone marrow was 
flushed out from femurs and tibias using a 20 ml syringe and a 23G needle. Cells were 
passed through a 40 µm filter to make a single cell suspension, spun down, followed by a 
red blood cell lysis. After washing, cells were counted and resuspended at a concentration 
of 2x10
6 cells/ml. These were plated on flat-bottom 6-well plates with 5 ml/well, and 
cultured for 7 days in the presence of either 10 % mouse Flt3L supernatant, or with 100 
ng/ml recombinant human Flt3L. On occasion, cell cultures were also supplemented with 
other reagents either at D0 or at another time point, depending on the experiment. After 7 
days, cells were harvested from the plates by removing the semi-adherent layer containing 
dendritic cells with a pipette, and the wells were washed with complete media. 
2.15 Activation of BMDC in vitro 
For  some  experiments  BMDC  were  activated  with  100  ng/ml  Salmonella  enterica, 
serovar: typhimurium LPS (Invivogen) by adding it to the BMDC cultures overnight. Cells 
were then collected and analysed as before, and compared to cells grown without LPS. 
2.16 In vitro T cell proliferation assay 
To assess the ability of DCs to stimulate proliferative responses from CD4
+ T cells, mixed 
lymphocyte reactions (MLR) were performed, as previously described (184). Briefly, L-
DCs were enriched for CD103 with magnetic beads, and MHC II
+ CD103
+ lymph DCs 
were sorted from PVG (RT1
c) B27-TG animals or from non-TG littermates. For BMDCs, 
live (Annexin-V
$ DAPI
$) CD103
+ DCs were flow sorted on day 7 of BMDC cultures. 
Both L-DCs and BMDCs were cultured, at different densities in triplicate, with 1x10
5 T 
cells from DA (RT1
av1) rats: depending on the experiment, these came from either a digest 
of MLN cells without an enrichment for T cells; or from flow sorted naïve-phenotype 
(CD45RC
hi CD25
$) CD4
+ T cells from MLN. Cells were plated out on 96 well plates for 
five days at 37°C and 5 % CO2 in complete medium. 
Two different methods were used to assess T cell proliferation. In the first one, 1 µCi/well 
tritiated thymidine (
3H-TdR) (West of Scotland Radionucleotide Dispensary) was added to 
the wells for the final twelve hours of culture, and cellular DNA was harvested onto filter  
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mats  (Wallac,  UK)  before  addition  of  scintillation  fluid  and  analysis  with  Betaplate 
scintillation counter (Wallac) using the Microbeta programme.  
In the second method T cells were labelled with carboxyfluorescein succinimidyl ester 
(CFSE; Invitrogen) before plating: T cells were resuspended in 1 ml of complete media at 
2x10
7  cells/ml,  and  5  µM  CFSE  was  added  and  the  cells  were  incubated  at  room 
temperature with gentle shaking for 3 minutes. Cells were then washed with complete 
media, counted again, and finally plated out as indicated above. After 5 days, proliferating 
T cells were identified by flow cytometry by CD4 and CFSE staining.  
2.17 Luminex 
Supernatants from BMDC and L-DC MLRs were collected on day 5, and frozen at -20ºC 
until use. IFN-!, IL-17F, IL-6, IL-10, IL-2 and TNF-" levels were measured from the 
supernatants  by  Luminex  assay  (Biolegend),  according  to  manufacturers  instructions. 
Briefly, 25 µl of neat MLR supernatant was added into wells of a 96-well filter plate 
containing 25 µl of assay buffer. 25 µl of premixed beads were added into each well, and 
the plate was incubated with agitation overnight on a plate shaker at 4ºC. Following day, 
the plate was washed twice with wash buffer, and 25 µl of detection antibody was added to 
each well, and the plate was incubate with agitation on a plate shaker for 2 hours at room 
temperature. After 2h, 25µl of Streptavidin-Phycoerythrin was added into each well and 
incubated with agitation on a plate shaker for 30 minutes at room temperature. The plate 
was then washed twice, and 150 µl of sheath fluid was added into each well, and the plate 
was read with Bio-Rad Bio-Plex 200 system Luminex plate reader. 
2.18 Isolation of RNA from single cell suspensions 
Cells were isolated from tissues and washed with PBS. Samples were spun down at 400 g, 
supernatant was removed completely and each sample was resuspended in 350-600 µl of 
denaturing  RLT  Lysis  Buffer  (Qiagen),  and  either  stored  at  -80°C  or  processed 
immediately.  RNA  was  isolated  following  the  Qiagen  RNeasy  Mini  Kit  instruction 
manual.  This  included  the  optional  on-column  DNase  digestion  step  using  the  Qiagen 
RNase-Free DNase Set. Briefly, samples with added RLT buffer were homogenised using 
the QIAshredder spin columns, and 1 volume of ethanol was added to the samples to 
ensure efficient binding of RNA to the spin column membrane. Up to 700 µl of sample 
was  placed  on  the  spin  column  containing  a  silica-based  column  that  binds  the  RNA.  
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Tubes were spun 15 s at 10,000 rpm, washed once with buffer RW1 and 80 µl of DNase I 
incubation mix was added directly to the spin membrane. This was incubated for 15 min at 
room temperature and the spin column membrane was washed additional two times with 
buffer RW1, and twice with buffer RPE. Spin column was then placed to a fresh collection 
tube and 40 µl of RNase free water was added on the membrane, columns were spun down 
and  the  RNA  concentration  of  each  sample  was  determined  using  a  ThermoFisher 
Nanodrop 1000' spectrophotometer. Samples were either processed immediately for cDNA 
synthesis, or stored at -20°C until use. 
2.19 Synthesis of cDNA from RNA 
Complementary DNA (cDNA) was reverse-transcribed from RNA using SuperScript™ 
First-Strand Synthesis System for RT-PCR (Invitrogen, UK) according to manufacturer’s 
instructions.  Briefly,  equal  amounts  (50-100  ng,  depending  on  experiment)  of  starting 
RNA for each sample were made up to 10 µl with diethylpyrocarbonate (DEPC) treated 
water and 1 µl of oligo(dT) primer (0.5 µg/ul) and 1 µl of dNTP mix (10 mM). Samples 
were then incubated at 65°C for 5 minutes to remove any secondary structures in the RNA 
and then placed on ice for 5 minutes to allow primers to anneal to the RNA. To each 
sample, a 9 µl mix of the following components was added: 2 µl of 10X RT Buffer, 4 µl of 
25  mM  MgCl2,  2  µl  of  0.1  M  DTT  and  1  µl  of  RNaseOUT™  Recombinant   RNase 
Inhibitor.  Samples  were  incubated  at  42°C  for  2  minutes  to  initiate  the  reaction,  after 
which 1 µl (50 units) of SuperScript™ II Reverse Transcriptase was added, except to the 
no RT control samples, to which 1 µl nuclease free water was added. Samples were then 
incubated  at  42°C  for  50  minutes  to  extend  the  products  and  15  minutes  at  70°C  to 
terminate the reaction. Reactions were stored at either 4°C or -20°C until they were used 
for QPCR. 
2.20 Flt3 primer design 
Primers for Flt3 receptor were designed by using primer-BLAST (Primer3 and BLAST) 
program to find primers for Rattus norvegicus fms-related tyrosine kinase 3 (Flt3) mRNA 
sequence (Accession: NM_001100822). Parameters for the search were set as:  
•  PCR product size: 90-200 bp 
•  Primer Tm: 57-62°C, with 60°C being optimum and maximum Tm difference 
between primers 3°C  
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•  Primer length between 18-23 bp 
•  Primer GC content 40-65% 
•  Max self complementarity: 2 
•  Max 3’ end complementarity: 1 
Once primers were suggested by the program, the following points were taken into account 
when selecting the primers: No more than three G or C bases in last 5 at 3’ end of each 
primer, and stretches of 4 or more G or C bases were avoided. Using these parameters, 6 
primer pairs were selected and ordered. These primers were tested using BMDC from non-
TG rats and the SYBR green protocol (see section 2.21), with melt curves run at the end to 
determine the quality of the primers. All but two of the primers tested functioned well, and 
finally Flt3 1 primer pair was selected for use in experiments (Table 2.2). 
2.21 Measuring relative mRNA expression by quantitative 
polymerase chain reaction (QPCR) 
Synthesised cDNA was used to determine the expression of Flt3 receptor on BMDCs at the 
level of mRNA. TATA box binding protein (TBP) was used as a housekeeping gene. All 
information about primers is shown on Table 2.2.  
Agilent  Brilliant  SYBR
®  Green  QPCR  Master  Mix  was  used  for  the  QPCR  reaction. 
Briefly, equal amounts of 1:5 diluted cDNA were added to a 96-well MicroAmp® Fast 
Optical Reaction Plate (Applied Biosystems) in triplicate per biological sample, and the 
final volume per reaction was adjusted to 25 µl by adding a mixture of the following 
components: Nuclease free water, 12.5 µl of 2x Master Mix, forward and reverse primers 
at final concentration of 100 nM, and 0.375 µl of 1:50 diluted reference dye (300 nM final 
concentration). Plates were covered with an optical adhesive cover (Applied Biosystems) 
and were spun at 450 g for 1 min. 
Plates  were  loaded  into  a  7500  Fast  Real-Time  PCR  System  machine  (Applied 
Biosystems) and incubated at 95°C for 10 minutes followed by 40 cycles of incubation at 
95°C for 15 seconds, then 60°C for 1 minute. A melt curve was run at the end of each 
experiment to determine if the PCR reaction was successful. 
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Table 2.2 Primer sequences and other details 
Gene  Primer (5ʼ-3ʼ)  Tm (°C) 
GC content 
(%) 
Amplicon 
length (bp) 
Flt3 1 
Forward: 
GGCTGCCGCTGCTTGTTGTTT 
59.33  57.14 
143 
Reverse: 
TGGAACCATGACGTGCGACGA 
58.8  57.14 
TBP 
Forward: 
TCCTGCCACACCAGCCTCTGA 
59.49  61.90 
150 
Reverse: 
ACTGCAGCAAACCGCTTGGGA 
59.51  57.14 
 
2.22 Statistical analysis 
Data were analysed using GraphPad Prism software (San Diego, CA) by using either a 
Student’s unpaired two-tailed t test, one-way Anova or two-way Anova with Bonferroni 
post tests, as described on figure legends. Probability values of p<0.05 were considered 
statistically significant.      
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3.  HLA-B27 transgenic rats 
3.1  Introduction 
Rats transgenic for human HLA-B27 and human !2m have been used for research since 
their development in the 1990’s (223) and, as discussed in detail in the introduction, they 
provide a good model for the human SpA diseases. Mostly these rats have been used in 
their original F344 background, but in some cases they have been backcrossed into LEW 
or PVG strains. The B27-TG strain 33-3, which is used in this study, has been successfully 
backcrossed into both LEW and PVG, with few reported changes in the disease course. For 
the  purpose  of  studies  conducted  in  this  thesis,  rats  of  the  33-3  strain  on  the  F344 
background were purchased, and subsequently backcrossed onto PVG. This was necessary 
in order to be able to carry out the surgical procedures used to collect lymph DCs by 
thoracic duct cannulation (see introduction and Ch4). In rats of the F344 and LEW strain, 
the  thoracic  duct  is  anatomically  far  less  accessible  than  it  is  on  the  PVG  animals, 
considerably lowering the success rate of the surgery. In addition, the thoracic duct of 
F344  and  LEW  animals  is  crisscrossed  with  numerous  blood  vessels  that  would 
inadvertently be damaged during the surgery leading to contamination of the collected 
lymph with blood, compromising the analysis. But as B27-TG PVG animals are not as 
commonly used, it was necessary to assess the expression of HLA-B27 molecule across 
tissues used in these studies, as well as to observe the disease symptoms in the animals. 
Rats  transgenic  for  a  non-disease-associated  human  HLA-B7  molecule  were  likewise 
backcrossed from F344 to PVG in order to maintain the usefulness of these animals as 
controls. However, as these rats do not develop disease, no detailed description of these 
animals on PVG background is provided.  
3.2  Results 
For the backcrossing, most often B27-TG females were bred with WT PVG males, as male 
B27-TG rats have been reported to develop epidymitis and orchitis by 3 months of age and 
thus become sterile. However, we found that it was possible to use the young B27-TG 
males for breeding, although they did stop reproducing as they aged. The presence of 
epidymitis and/or orchitis on our male B27-TG rats was not verified in these studies. The 
infertility of B27-TG males is also the reason why even the commercially available B27-
TG F344 animals are bred as hemizygotes. The HLA-B7 animals are bred as homozygotes,  
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but as they were backcrossed onto PVG, this generated hemizygous animals. Thus, all the 
offspring from both B7-TG and B27-TG animals need to be screened for the presence of 
the corresponding HLA transgene. This was done by sampling blood from the tail vein of 
about 4-week old, weaned animals under anaesthesia, and staining the peripheral blood 
mononuclear cells (PBMCs) with anti-HLA-B27 or anti-HLA-B7 antibody. The presence 
or  absence  of  the  transgene  was  verified  by  FACS.  As  there  were  going  to  be  many 
animals to screen, the HLA-B27 antibody was first titrated to see if it could be used at a 
lower concentration than the recommended 1:25. It was noted that it was still possible to 
reliably  identify  the  transgenic  animals  even  when  the  antibody  was  used  at  1:100  or 
1:200, and thus for the rest of the experiments and screening one of these concentrations 
was used (Figure 3.1A). When 4-week old B27-TG rats were screened for the presence of 
HLA-B27, it was observed that about 50 % of all PBMCs were positive for the transgene, 
whereas non-TG animals only showed background level of staining (Figure 3.1B). About 
half of the offspring from all the litters are HLA-B27
+, as would be expected. Curiously, 
when blood was taken from 3-week old B27-TG rats, only about 10 % of PBMCs showed 
surface  expression  of  HLA-B27  (Figure  3.2A).  However,  when  these  same  rats  were 
screened again at 5 weeks, they showed increased surface expression of HLA-B27, similar 
to that observed at 4 weeks (data not shown). Screening of 8-week old rats revealed that 
about 62 % PBMCs were HLA-B27
+ (Figure 3.2B), whereas at 21 weeks over 90 % of 
PBMCs had this phenotype (Figure 3.2C). Figure 3.2D shows staining of PBMCs from 
B27-TG animals using the HLA-B7 antibody. There is no specific staining at all, proving 
that this antibody does not cross react with HLA-B27.  
As with B27-TG rats, the offspring of B7-TG rats were also screened for the presence of 
the HLA transgene by FACS. When peripheral blood from the original homozygous B7-
TG animals, aged 12 weeks, was stained with the HLA-B7 antibody, as expected a vast 
majority of PBMCs were positive for the HLA-B7 transgene (Figure 3.3A). When 4-week-
old B7-TG animals were screened, as with B27-TG animals, about 50 % of PBMCs were 
positive  for  HLA-B7  (Figure  3.3B),  and  there  was  only  a  very  slight  increase  in  the 
percentage of HLA-B7
+ cells in 8-week old animals (Figure 3.3C). It was also observed 
that the HLA-B27 antibody cross-reacts very strongly with HLA-B7, as the staining of 
PBMCs from B7-TG animals with HLA-B27 antibody resulted in almost identical staining 
pattern than staining with the HLA-B7 antibody (Figure 3.3D, E). 
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Figure 3.1 Screening of hemizygous HLA-B27 animals 
(A) The HLA-B27 antibody was titrated to find the ideal concentration, using peripheral blood from 
8-week old B27-TG animals. (B) Representative results showing screening results from peripheral 
blood of 4-week old hemizygous littermates demonstrating levels of binding of HLA-B27-specific 
antibody for B27-TG and non-TG animals.  
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Figure 3.2 HLA-B27 expression by B27-TG peripheral blood 
cells 
Peripheral blood was collected from hemizygous non-TG and B27-
TG animals, RBCs were lysed and remaining cells were stained with 
HLA-B27 antibody and cell surface expression was assessed by 
FACS. Animals at ages of (A) 3 weeks, (B) 8 weeks and (C) 21 
weeks were used. (D) Peripheral blood cells from 21-week old B27-
TG animals were stained with HLA-B7 antibody.  
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Figure 3.3 Expression of HLA-B7 by B7-TG peripheral blood cells 
Peripheral blood was collected from B7-TG animals, RBCs were lysed and cells 
were stained with HLA-B7 antibody. Blood cells were collected from: (A) 
homozygous B7-TG animals on F344 background at age of 14-weeks, (B) 4-week 
old hemizygous B7-TG rats backcrossed into PVG for 4 generations, (C) 8-week 
old non-TG and hemizygous B7-TG animals on PVG background. (D) Blood cells 
from homozygous 14-week old B7-TG animals were stained with HLA-B27 
antibody, and in (E) histogram overlay of results from B7-TG results from A, B and 
D are shown. 
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It was also decided to investigate whether cells in the various tissues that will be used in 
the following chapters express HLA-B27. Cells collected by cannulation from non-TG and 
B27-TG  animals  were  stained  with  the  HLA-B27  antibody,  and  it  was  observed  that 
almost  98  %  of  lymph  cells  were  HLA-B27
+  compared  to  only  background  level  of 
staining in the non-TG animals (Figure 3.4). Unfortunately no other stains were included 
together with HLA-B27, so it was not possible to ascertain if all the DCs were HLA-B27
+. 
However, as will be seen in the next figure, all MLN MHCII
+ cells are very strongly 
positive for HLA-B27 on 6-week old animals, and thus all lymph DCs are also likely to be 
HLA-B27
+. MLNs were collected from 6-week old animals and digested with DNase and 
liberase, and the cells were stained with antibodies specific for HLA-B27, MHCII and 
lineage markers. HLA-B27 expression on all MLN cells was first investigated, and it was 
noted that over 70 % of all MLN cells were positive for HLA-B27 (Figure 3.5A). DCs in 
the rat MLNs can be difficult to identify, as will be discussed in more detail in Chapter 5, 
but they can be recognised as LIN
$/lo and MHCII
+ cells (Figure 3.5B). When expression of 
HLA-B27 on these cells was investigated, it was noted that over 97 % of LIN
$/lo MHCII
+ 
cells were also HLA-B27
+ (Figure 3.5B), indicating that all DCs in the MLN are also 
HLA-B27
+. In fact, the cells expressing highest level of MHCII also expressed highest 
level of HLA-B27. When expression of HLA-B27 was evaluated on total MLN cells from 
21-week old animals, it was noted that at this time most of the MLN cells were HLA-B27
+ 
(Figure  3.5C),  compared  to  70  %  in  animals  of  6  weeks  of  age.  The  FCS/SSC 
characteristics of the cells that appeared not to express HLA-B27 suggested that they are 
lymphocytes, or other small cells (Figure 3.5C). 
As discussed in the introduction, the B27-TG animals present with variety of symptoms, 
such as psoriasiform skin and nail lesions, nail hyperplasia and intestinal inflammation. 
Observation of B27-TG animals, backcrossed into PVG, revealed that the animals on this 
background presented with similar symptoms as has been reported for the original F344 
strain.  Animals  experienced  hair  loss,  starting  from  the  periorbital  area  and  spreading 
towards the ears, then down towards the forepaws (Figure 3.6A). These symptoms did not 
appear until 12-16 weeks of age, and did not occur in all animals. Extensive hair loss 
shown in 3.6B was observed on a 24-week old rat, and hair loss at this scale was hardly 
ever observed on animals under 16 weeks of age. Another prominent feature of B27-TG 
animals are nail deformations. Figure 3.6C features a commonly observed nail dystrophy 
on a 24-week old B27-TG animal. None of these symptoms were observed in either non-
TG or B7-TG animals at any age.  
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Figure 3.4 Expression of HLA-B27 on thoracic duct lymph cells from B27-TG and non-TG 
animals 
Cells from thoracic duct lymph were collected from cannulated non-TG and B27-TG animals, RBC 
were lysed and remaining cells were stained with HLA-B27 antibody. Expression of HLA-B27 on 
total lymph cells from (A) B27-TG and (B) non-TG animals was analysed by FACS. (C) shows 
histogram overlays comparing HLA-B27 expression on non-TG and B27-TG lymph cells  
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Figure 3.5 Expression of HLA-B27 on B27-TG MLN cells 
MLNs were collected from B27-TG animals of different ages, and digested with DNase and 
liberase. (A) Total MLN cells from 6-week old B27-TG animals were stained with HLA-B27 antibody 
and surface expression was assessed by FACS. (B) Expression of HLA-B27 on non-TG and B27-
TG MLN DCs from 6-week old animals was assessed by staining the cells with LIN markers 
(CD45RC, CD45RA, TCRαβ, Igκ light chain), MHCII and HLA-B27. (C) Total MLN cells from 21-
week old B27-TG animals were stained with ant-HLA-B27 antibody and assessed for surface 
expression. FSC/SSC characteristics of HLA-B27
− cells were also analysed, as shown in the 
middle panel. 
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Inflammation of the small and large intestine is another reported feature of the B27-TG 
animals. Thus, it was investigated whether our animals would present with these symptoms 
as well. Small intestinal inflammation was evaluated on animals of 9 (F10 generation), 15 
(F5 generation) and 52 (F3 generation) weeks of age. When looking at the ileum (Figure 
3.7A-C), it was noted that 9-week old rats displayed a slightly changed architecture, as the 
villi appeared to be flatter, and the LP seemed more cellular when compared to non-TG 
animal.  At  15-weeks  the  ileum  has  lost  its  normal  architecture;  villi  were  fused  and 
flattened, and cellular infiltrates were visible in the LP. No visible changes are seen in the 
jejunum of 9-week old animals (Figure 3.7D-F), however again at 15 weeks increased 
cellularity and shorter and thicker villi were observed. No inflammatory changes were 
observed in the duodenum of either 9-week or 15-week old B27-TG animals  (Figure 
3.7G-I). Small intestinal sections from jejunum of 52-week old F3 generation rats revealed 
signs  of  slight  inflammation  with  flattened,  fused  villi  and  some  inflammatory  cell 
infiltrates present in the LP (Figure 3.8). Unfortunately, no sections are available from 
other parts of the small or large intestine from these animals. Histology of ascending colon 
from  9-week  old  animals  showed  no  signs  of  inflammation  with  normal  colonic 
architecture (Figure 3.9B). In contrast, histology of ascending colon from 15-week old 
animals  show  signs  of  crypt  hyperplasia  and  presence  of  inflammatory  cell  infiltrate 
throughout the lamina propria (Figure 3.9D). 
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Figure 3.6 peripheral disease symptoms on B27-TG animals 
(A) Typical pattern of hair loss on a 24-week old B27-TG animal; starting from the periorbital 
area in the head and spreading down to forepaws. (B) Alopecia and thinning of hair on the back 
of a B27-TG animal. (C) Nail dystrophy on the hindpaw of B27-TG animals. Animals used here 
are from F7 generation of backcrossing.  
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Figure 3.7 Histology of small intestinal sections  
Paraffin embedded sections from ileum, jejunum and duodenum of non-TG, B7-TG and B27-TG 
animals were stained with H&E. (A) Sections from 8-9 week old non-TG and B7-TG animals 
showed no signs of intestinal inflammation, (B) and neither did sections from 9-week old B27-TG 
animals. (C) Sections of ileum and jejunum from 15-week old animals showed signs of abnormal 
villi (arrows) and inflammatory cell infiltrates (arrowheads). No inflammation was observed in the 
duodenum. Magnification x10 and scale bars 50 μm, n=1. 
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Figure 3.8 Small intestinal histology of 52-week old animals. 
Paraffin embedded sections from 52-week old rat jejunums were stained with H&E. (A) 
non-TG animals showed no signs of inflammation, whereas B27-TG animals presented 
with inflammatory cell infiltrates (arrowheads) and flattened and fused villi (arrows). 
Magnification x10, scale bars μm, n=1.  
 
84 
 
   
C)  D)  Non-TG, 19 weeks  B27-TG, 15 weeks 
A)  B)  Non-TG, 9 weeks  B27-TG, 9 weeks 
Figure 3.9 B27-TG animals show signs of colonic inflammation 
Paraffin embedded sections from 9-15 week old non-TG and B27-TG animals were cut and stained 
for H&E. Colon sections from 9-week (A) and 19-week old (C) non-TG animals show normal colon 
structure and histology. (B) Colon sections from 9-week old B27-TG animals show normal 
structure, whereas in (D) 15-week old B27-TG animals show elongated crypts, and inflammatory 
cell infiltrate can be seen in the LP. (A, B) F10 generation, (C, D) F5 generation. Magnification x10, 
scale bars 50 μm, n=2.  
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3.3  Discussion 
In  this  chapter  the  expression  of  HLA-B27  in  various  tissues,  as  well  as  the  disease 
phenotype on the backcrossed B27-TG animals were investigated. It was first noticed that 
the surface expression of HLA-B27 increased in an age-dependent manner, from 10 % of 
HLA-B27
+ PBMCs at 3-week of age, to over 90 % on rats of 21-weeks of age. This age-
dependent increase of HLA-B27 surface expression has been reported before for splenic 
cells on the 33-3 strain on F344 background, and in the same publication it was also 
reported that the level of surface expression correlated with the disease status (226). No 
such  dramatic  age-dependent  increase  of  HLA-B7  molecule  was  noted  when  HLA-B7 
expression on PBMCs from 4-week and 8-week old B7-TG rats was compared. It was also 
noted that the HLA-B27 antibody also bound to HLA-B7 molecules as well, if not better, 
than the HLA-B7 antibody. This cross-reactivity in the HLA-B27 antibody does not pose a 
problem to us, as the rats only express one or the other HLA transgene, but for human 
work carried in our laboratory it does have an effect and was important to see. In contrast, 
the  HLA-B7  antibody  was  specific  for  HLA-B7  molecule  only.  The  age-dependent 
increase of surface HLA-B27 expression was not only limited to PBMCs, as it was also 
observed that HLA-B27 expression by MLN cells increased from about 70 % on 6-week 
old animals to over 90 % on 21-week old animals. However, it was noted that most MLN 
DCs were already expressing high levels of HLA-B27 at 6 weeks, suggesting that the 
expression of HLA-B27 is upregulated on APCs early in life. Over 97 % of lymph cells 
from 10-week old B27-TG rats were HLA-B27
+, as would be predicted when looking at 
the expression patterns elsewhere in the body. Unfortunately, no DC stain was included in 
the stain together with HLA-B27, and so it cannot be said if the DCs in the lymph express 
higher levels of HLA-B27 than other lymph cells.  
The reason for this curious effect of increasing HLA-B27 surface expression is not known. 
B27-TG animals were originally made by DNA microinjection of both HLA-B27 and !2m 
genes into fertilized rat eggs, and inserting these eggs into pseudo-pregnant females. The 
insertion of the genes is random, both in number and in location, as can be seen from the 
original publication from 1990 where several founders with different numbers of integrated 
HLA-B27 and !2m genes were identified (223). Both genes were inserted with flanking 
sequences,  but  it  is  not  known  for  sure  whether  the  promoters  of  these  genes  were 
contained  within  these  sequences,  and  it  is  not  known  where  in  the  chromosome  the 
transgenes were inserted. Thus, it could be that the transgenes are under a promoter for 
some other genes, which are only upregulated as the animals get older. Weaning of the rats  
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could potentially have an effect, as at this time the animals start eating more solid food and 
rapidly  develop  their  intestinal  microflora.  However,  the  3-week  old  rats  used  for  the 
experiments here were already weaned at the time of screening and still expressed only 
low levels of HLA-B27.  
B27-TG rats have been reported to present with a variety of psoriasiform skin and nail 
lesions, such as hyperkeratosis of digits and nail dystrophy, alopecia, edema, psoriasiform 
hyperplasia and flaking of the skin on the tail or on the body, as well as arthritis and 
intestinal inflammation. In our colony the most common symptoms were alopecia of the 
face and back skin and hyperkeratosis and dystrophy of nails. The hair loss starts at the 
periorbital area, and spreads from there and eventually the animals exhibit thinning hair all 
over. This phenomenon has also been reported for the same 33-3 B27-TG rat line on the 
original  F344  background  (269).  In  addition,  the  33-3  F344  line  has  been  previously 
backcrossed  into  PVG,  and  disease  symptoms  were  reported  to  be  the  same  as  in  the 
original F344 background (227)
1. In our colony, hair loss and nail dystrophies were rarely 
seen  on  animals  younger  than  16  weeks,  and  not  all  the  older  animals  showed  the 
symptoms  either.  This  is  not  surprising,  as  the  original  publication  detailing  the 
development of inflammatory disease on 33-3 F344 strain reported that by 12 weeks, most 
animals present with diarrhoea, but less than 10 % of animals have nail or skin lesions or 
arthritis (226). Considering most animals were sacrificed before they reached the age of 12 
weeks, it not so surprising most of the other symptoms were not frequently observed in our 
experiments. We did not detect arthritis in our animals, but this could be because the onset 
of arthritis is quite late: it has been reported that on the original F344 background at 15 
weeks only less than 20 % of males and less than 10 % of females show signs of arthritis. 
On  the  PVG  background,  the  onset  of  arthritis  is  even  later  (Joel  Taurog,  personal 
communication). We have however observed some reddening and swelling of the feet on 
some of the older animals, but no overt inflammation of the joints has been detected.  
Intestinal inflammation is another common symptom observed in the B27-TG animals. In 
our colony it was observed that most of the rats developed diarrhoea by age of 16-weeks, 
indicating  ongoing  inflammation  in  the  intestine.  Histological  sections  from  the  small 
intestine of 9-week old animals did not appear inflamed, which was to be expected, as the 
                                                 
1 Note: This paper was retracted in 1999 as the presented CTL data turned out to be fabricated. However, in 
the letter of retraction main author J. Taurog assured that all the data concerning genetics and phenotype of 
the 33-3 rats on PVG background remained accurate. This was also confirmed by personal communication 
with J. Taurog. 
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animals on the PVG background are unlikely to develop signs of intestinal inflammation 
before age of 14-weeks (Joel Taurog, personal communication). In contrast, by 15 weeks 
inflammatory infiltrates were visible in the LP of the ileum and jejunum, and the villi were 
flattened.  Sections  from  jejunum  of  52  old  week  showed  signs  of  inflammatory  cell 
infiltrates as well as fused and flattened villi. The inflammation in these old animals does 
not  seem  to  be  severe,  but  most  signs  of  intestinal  inflammation  in  these  animals  are 
detected in the ileum and the colon. Unfortunately no sections of these are available from 
these older animals. Sections from the ascending colon of 9-week old animals did not show 
signs  of  inflammation,  but  as  expected  15-week  old  animals  showed  signs  of  colonic 
inflammation. Inflammatory lesions in the stomach have also been reported for B27-TG 
animals, but it was not investigated if these were present in our animals. Together these 
results suggest that B27-TG animals on the PVG background do exhibit symptoms similar 
to those seen on the original F344 background and are thus considered suitable model to 
use in our studies.      
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4.  In vivo phenotype and function of migrating 
intestinal DCs in B27-TG rats  
4.1  Introduction  
The intestinal system is constantly exposed to vast amounts of foreign antigens – most of 
these are harmless, such as food proteins and commensal bacteria, but some are potentially 
harmful  pathogens.  Dendritic  cells  (DCs)  carry  antigens  from  the  intestine  to  the 
mesenteric lymph nodes (MLNs) where they are responsible for activating naïve T cells. 
DCs are not only involved in induction of active immune reactions, but as was discussed in 
the introduction DCs also play an important role in maintaining balance between immunity 
and tolerance in the intestine (116). Since DCs and intestinal inflammation have both been 
suggested to have a role in the disease pathogenesis in both human SpA as well as in the 
animal model of SpA (See introduction), it was decided to investigate whether intestinal 
DCs could have a role in the pathogenesis of the SpA animal model. The animal model 
makes  use  of  rats  transgenic  for  human  HLA-B27  gene  together  with  human  #2-
microglobulin (B27-TG rats), and these animals develop a spontaneous disease that shares 
many  symptoms  with  SpA  patients,  such  as  peripheral  arthritis  (223).  HLA-B27  is  an 
MHC class I gene, and while it is closely linked to SpA diseases its role in the disease 
pathogenesis is unclear (14). Data regarding DCs in the B27-TG animal model has mainly 
concentrated on functions of either splenic or BMDCs, as intestinal DCs are not as easy to 
acquire. However, in our laboratory we can make use of a sophisticated surgical method 
involving  cannulation  of  the  thoracic  duct  of  the  rats  (270),  which  allows  in  vivo 
investigation  of  DCs  migrating  in  the  lymph  from  the  intestine  towards  MLNs.  As 
inflammation in B27-TG animals and in AS patients often affects the intestine (223, 228, 
239), we hypothesised that the DCs migrating from the intestine may play an important 
role in initiating the pathogenic inflammatory responses associated with SpA. 
As DCs are very sensitive to changes in their environment, it is difficult to obtain them 
directly from the intestinal tissues as the harsh treatment needed to extract the cells from 
the tissues is likely to alter their phenotype, and function. Thus, to test our hypothesis, 
well-established surgical methods of mesenteric lymphadenectomy (MLNX) and thoracic 
duct cannulation were used to collect the DCs that migrate from the intestine to the MLNs 
in the afferent lymph (for details of this method, see Materials and Methods and (268)). 
This method allows the collection of DCs with minimum in vitro manipulation, and hence  
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the cells are able to retain their in vivo phenotype. These DCs are phenotypically MHCII
hi 
CD103
+,  and  they  have  been  found  to  divide  into  three  subsets  (113,  271):  CD11b
lo 
CD172a
hi, CD11b
hi CD172a
int and CD11b
int CD172a
lo. In this chapter, for the first time, the 
phenotype and function of these migrating intestinal DCs, or lymph-derived DCs (L-DCs), 
from the B27-TG animals are compared to L-DCs derived from non-TG littermates, or 
non-disease-prone rats transgenic for the human HLA-B7 gene and b2m genes (B7-TG).  
4.2  Results 
4.2.1  B27-TG animals have fewer L-DCs in the lymph 
As lymph cells from B27-TG animals were found to express HLA-B27 on their surface 
(CH3), it was next determined if the B27-TG and the control non-TG and B7-TG animals 
had the same number and proportion of L-DCs in their lymph. Initially, the total yield of 
lymph-derived cells from B27-TG rats was compared to that of non-TG animals to make 
sure  there  was  no  inherent  problem  with  the  general  migration  of  cells  from  tissues 
draining to the thoracic duct. In humans, and presumably in rats as well, these tissues 
include most of the body, except for right arm, right side of the chest, neck and head and 
lower left lobe of the lung. It was also assessed whether i.v. saline received by the animals 
for the first 24h after surgery had an effect on the number of cells in the lymph. To answer 
these questions, lymph was collected from individual animals at three different time points 
after cannulation: 0-24h, 24-48h and 48-72h. The volume of lymph was calculated for the 
first two time points, and as no difference was observed between non-TG and B27-TG 
animals, their results were pooled for the two time points (Figure 4.1A). As expected, 
lymph  flow  was  significantly  higher  on  the  0-24h  collection  than  on  the  24-48h  one, 
reflecting  the  i.v.  fluid  provided  for  the  animals  for  the  first  24h  after  surgery.  To 
determine if the increased lymph flow affected the number of migrating cells and if there 
were any differences in the number of cells between non-TG and B27-TG animals, the 
total number of lymph cells for non-TG, B7-TG and B27-TG animals were calculated 
separately  for  each  of  the  three  time  points  (Figure  4.1B).  No  differences  in  the  cell 
numbers were observed between any of the time points, indicating that cell migration in 
the lymph is stable for the period of observation and is not affected by extra fluid given to 
the animals. There was a trend towards a slight increase in the number of B27-TG cells 
compared to control animals, however this was not statistically significant.  
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Figure 4.1. No difference in the total number of cells in the lymph between non-TG and 
B27-TG animals. 
Lymph was collected from non-TG, B27-TG and B7-TG rats at three different time points, and 
volume of lymph at 0-24h and 24-48h are shown in (A), with results for each timepoint pooled 
from non-TG and B27-TG animals. (B) The total number of cells in non-TG, B27-TG and B7-TG 
lymph was calculated using a haemocytometer. Each dot represents an individual animal, and 
data are from 3-8 individual experiments. Horizontal line is the mean of all the values within that 
time point. Data was analysed by Studentʼs T-test (A), or 2-way Anova (B), **p<0.01. 
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Figure 4.2 B27-TG rats have fewer MHCII
+ CD103
+ L-DCs than control animals  
Lymph was collected from individual animals in three 24-hour periods following thoracic duct 
cannulation: 0-24h, 24-48h and 48-72h. Cells were stained for DC markers CD103 and MHCII 
on each collection period, and the number and percentage of DCs was determined by FACS. 
(A) Representative FACS plots from 0-24h collection showing the percentage of CD103
+ MHCII
+ 
DCs in B27-TG animals, and control Non-TG and B7-TG lymph. Data from 5-6 (Non-TG and 
B27-TG) or 1 (B7-TG) independent experiments showing percentage (B) and number (C) of 
DCs in lymph. Each dot represents an individual animal. Horizontal lines show mean values, 
and data were analysed by two-tailed Studentʼs T-test. *p<0.05. 
CD103 
M
H
C
I
I
 
 
Non-TG  B27-TG  B7-TG  A) 
B) 
C) 
%
 
M
H
C
I
I
+
 
C
D
1
0
3
+
 
L
-
D
C
 
0-24h  24-48h  48-72h 
* 
#
 
M
H
C
I
I
+
 
C
D
1
0
3
+
 
L
-
D
C
,
 
x
1
0
5
 
* 
0-24h  24-48h  48-72h 
B27-TG 
Non-TG 
B7-TG 
ns 
ns 
ns 
ns  
 
92 
As there were no differences in the total number of migrating lymph cells between B27-
TG and control animals, it was next determined if the proportion and number of lymph 
derived DCs (L-DCs) in B27-TG rats was comparable to non-TG animals. Again, lymph 
was collected from individual animals for three 24h periods after cannulation, but this time 
the cells were stained with antibodies specific for MHC class II (MHCII) and CD103, 
markers for L-DCs in the rat. The percentage and absolute number of the double positive 
MHCII
+ CD103
+ cells was determined separately for each collection period (Figure 4.2). 
Figure 4.2A shows representative FACS plots for B27-TG, non-TG and B7-TG animals 
from 0-24h collection, with gating for MHCII
+ CD103
+ cells. When data was collated from 
5-6 (B27-TG, non-TG) or 1 (B7-TG) individual experiments, it was noted that B27-TG 
animals had significantly fewer MHCII
+ CD103
+ L-DCs at the 24h collection compared to 
non-TG animals, both proportionally (mean percentage of 0.226% for non-TG vs. 0.072% 
for B27-TG) (Figure 4.2B) and in absolute numbers (mean: 6.72x10
5 vs. 2.73x10
5) (Figure 
4.2C). At 24-48h more variation in both DC percentage and number was observed, and no 
statistical significances were observed between non-TG and B27-TG derived L-DCs. Very 
few data points were available for 48-72h, and thus no firm conclusions could be drawn. 
Importantly, no differences between non-TG and B7-TG animals were observed.  
4.2.2  A population of L-DCs from B27-TG animals express more CD25 
As it was established that there were only very slight differences in the L-DC number and 
proportion between non-TG and B27-TG animals, it was next determined if there were any 
differences in the activation status of L-DCs. It was hypothesised that L-DCs from B27-
TG  animals  would  be  more  activated,  as  these  animals  might  already  present  with 
intestinal inflammation at this time. However, this has not been investigated by histology. 
If  the  hypothesis  was  proved  to  be  right,  these  DCs  could  cause  enhanced  immune 
reactions in the MLN, or present self-antigens in an inflammatory setting, and thus drive 
the disease development in the rats. To assess this, expression of classical costimulatory 
molecules CD80 and CD86 on L-DCs was determined together with CD25, or IL-2R", 
which is the most sensitive marker of activation on rat DCs (272). Rats were cannulated 
and the expression of these three molecules on MHCII
+ CD103
+ L-DCs at 0-24h (Figure 
4.3),  24-48h  (Figure  4.4)  and  48-72h  (Figure  4.5)  were  determined.  In  the  first  24h-
collection, it was noticed that about 50 % of B27-TG MHCII
+ CD103
+ L-DCs expressed 
CD25, compared to 26.2 % of non-TG L-DCs, as can be seen in the representative dot plot 
and  histogram  overlay  in  Figure  4.3A.  When  data  from  at  least  three  independent  
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experiments were pooled, there was a small but significant increase in the proportion of 
MHCII
+ CD103
+ CD25
+ cells on B27-TG lymph compared to non-TG (Figure 4.3B).  
There were no significant differences in CD80 and CD86 expression between non-TG and 
B27-TG L-DCs, although when looking at the dot plot (Figure 4.3A), there appeared to be 
slightly  more  CD80
+  cells  in  the  B27-TG  lymph.  The  trend  towards  increased  CD25 
expression  continued  when  data  from  24-48h  was  collated  (Figure  4.4),  but  was  not 
statistically significant at this time point. Again, it was noticed that there seemed to be 
more CD80
+ cells within the B27-TG  L-DCs (Figure 4.4A), but as before, it was not 
statistically significant (Figure 4.4B). Results from the final 48-72h collection resemble 
those of 0-24h and 48-72h, with slight increase in CD25 expression, and more CD80
+ cells 
on B27-TG MHCII
+ CD103
+ L-DCs (Figure 4.5A, B). Unfortunately, for non-TG there 
was only one experiment with one animal for the 48-72h data point, so no conclusions can 
be drawn. Expression of OX-40L on L-DCs at the 0-24h time point was also examined, as 
this  is  an  important  costimulatory  molecule  involved  in  T  cell  activation  (Figure  4.6). 
Neither non-TG nor B27-TG animals expressed OX-40L at a high level; in fact, there was 
only a very slight shift when compared to the isotype, and this shift was identical in both 
non-TG and B27-TG L-DCs.  
It has been reported previously that MHC class II expression on CD103
+ splenic DCs is 
lower on the B27-TG than on non-TG animals (239).  Thus, it was investigated whether 
this was also true for MHCII
+ CD103
+ L-DCs (Figure 4.7). It was noted that in most 
experiments  L-DCs  from  B27-TG  animals  did  indeed  have  a  slightly  lower  MHCII 
expression, as shown on Figure 4.7A, where representative results from one representative 
experiment  are  shown.  When  the  geometric  means  for  MHCII  on  CD103
+  cells  were 
calculated and data from 4 independent experiments combined, there was a trend towards 
B27-TG  L-DCs  expressing  less  MHCII,  but  the  difference  was  not  significant  (Figure 
4.7B).  
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Figure 4.3 A proportion of B27-TG L-DCs express significantly more CD25 than non-TG 
control DCs. 
L-DC were collected by thoracic duct cannulation for the first 24 hours (0-24h) from B27-TG and 
non-TG animals. The expression level of various costimulatory molecules on CD103
+ MHCII
+ DCs 
was determined by FACS. (A) Two upper panels show representative FACS plots of CD25, CD80 
and CD86 expression on CD103
+ MHCII
+ DCs from non-TG and B27-TG animals. Bottom panels 
show histogram overlays from figures above.  (B) Pooled data from at least 3 independent 
experiments (non-TG, n=3-4; B27-TG, n=4-6). Error bars represent SEM, and data were analysed 
by two-tailed Studentʼs T-test. *p<0.05.  
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Figure 4.4 CD103
+ MHCII
+ DCs from B27-TG animals express more CD25 also at 24-48h  
L-DC were collected by thoracic duct cannulation for the second 24 hours (24-48h) from B27-TG 
and non-TG animals. The expression level of various costimulatory molecules on CD103
+ MHCII
+ 
DCs was determined by FACS. (A) Two upper panels showing representative FACS plots of CD25, 
CD80 and CD86 expression on CD103
+ MHCII
+ DCs. Lower panels show histogram overlays from 
figures above.  (B) Pooled data from at least 3 independent experiments (non-TG, n=3-5; B27-TG, 
n=4-8). Data analysed by Studentʼs T-test. Error bars represent SEM.  
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Figure 4.5. DCs from B27-TG animals continue to express more CD25 at 48-72h than control 
non-TG DCs 
L-DC were collected by thoracic duct cannulation at 48-72h time point from B27-TG and non-TG 
animals. The expression level of various costimulatory molecules on CD103
+ MHCII
+ DCs was 
determined by FACS. (A) Two upper panels showing representative FACS plots of CD25, CD80 
and CD86 expression on CD103
+ MHCII
+ DCs. Lower panels show histograms from figures above. 
(B) Collated data from two experiments for B27-TG and one experiment for non-TG (non-TG, n=1; 
B27-TG, n=2). Error bars are SEM. 
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Figure 4.6. B27-TG and non-TG L-DCs express similar levels of OX40L 
L-DCs were collected by thoracic duct cannulation and cells were stained for MHCII, CD103 
and OX40L, and expression level of OX40L on MHCII
+CD103
+ DCs was determined by 
FACS at 0-24h. n=1. 
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Figure 4.7.  Comparison of MHCII expression level on MHCII
+ CD103
+ L-DCs from non-TG 
and B27-TG animals 
L-DCs were collected by thoracic duct cannulation from the lymph, stained with MHCII and CD103 
antibodies, and geometric mean for MHCII on MHCII
+ CD103
+ DCs from non-TG and B27-TG 
animals was determined. (A) Representative dot plots (upper panels) and histograms of MHCII 
expression on non-TG and B27-TG L-DC at 0-24h and 24-48h. (C) Pooled data + SEM from at 
least 5 independent experiments (non-TG, n=4-5; B27-TG, n=5-8). Data were analysed by 
Studentʼs T-test. 
G
.
 
m
e
a
n
 
o
f
 
 
M
H
C
I
I
 
o
n
 
C
D
1
0
3
+
 
M
H
C
I
I
+
 
D
C
s
 
0-24h  24-48h 
MHCII 
0-24h  24-48h  A) 
B) 
B27-TG 
Non-TG 
M
H
C
I
I
 
CD103 
B27-TG 
Non-TG 
ns 
ns  
 
99 
4.2.3  L-DCs from B27-TG animals are not better at stimulating allogeneic T 
cell proliferation 
As it was observed that a population of L-DCs from B27-TG animals express more CD25, 
and might thus be in a more activated state, the ability of DCs to drive T cell proliferation 
was assessed using mixed leukocyte reactions (MLRs). Lymph cells were enriched for 
CD103  using  magnetic  beads,  and  MHCII
+  CD103
+  L-DCs  from  B27-TG  or  non-TG 
animals were flow sorted as shown in Figure 4.8A. These DCs were plated out in triplicate 
in 2-fold dilutions, from 20,000 to 1,250 DCs/well, with 1x10
5 MLN cells from DA rats, 
and were cultured at 37
oC for 5 days. Thymidine was added to the wells for the final 12h 
of culture, and the level of T cell proliferation was assessed by thymidine incorporation in 
each well. The experiment was repeated 5 times; non-TG and B27-TG cells were similarly 
capable at supporting allogeneic T cell proliferation (Figure 4.8B). 
T cell proliferation was also assessed using CFSE, as using this method it is possible to 
determine the proliferation of a specific cell type in the cultures. Thus, MLN cells from 
DA rats were incubated with CFSE before plating them out with sorted L-DCs, as above, 
and the plates were cultured at 37ºC for 5 days. Cells were then harvested from the plates 
and  stained  with  a  CD4-specific  antibody  to  assess  proliferation  of  CD4
+  T  cells.  A 
representative FACS plot showing CFSE staining on all acquired cells with 12,500 DCs is 
shown in Figure 4.9A, with a gate showing the percentage of all CD4
+ cells. As can be 
seen, both non-TG and B27-TG samples appear to have similar proportion of CD4
+ cells 
(53-59%). When CFSE staining was assessed on the CD4
+ cells (Figure 4.9B), it was 
noticed that non-TG L-DC induced more T cell proliferation than B27-TG L-DCs (Figure 
4.9C).  However,  as  seen  with  the  other  proliferation  experiments  (Figure  4.8)  the 
experiment should be repeated several times before any conclusions could be drawn.  
Concentrations of various cytokines at day 5 of MLR from experiment shown in Figure 4.9 
were also measured by Luminex (Figure 4.10). IFN-! and IL-17F were present at highest 
concentrations in the cell culture supernatants, and both were higher in the cultures with 
non-TG L-DCs. IL-10 and IL-2 were also present, and IL-12 was also higher when 12,500 
non-TG L-DCs were used, whereas no obvious differences between non-TG and B27-TG 
were noted with 6,500 L-DCs. Concentrations of IL-6 and TNF" were low in both culture 
conditions, however slightly more of both were observed in the cultures with non-TG L-
DCs. 
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Figure 4.8. Mixed lymphocyte reactions revealed no consistent differences in the ability of 
L-DCs from non-TG or B27-TG animals to induce T cell proliferation 
Thoracic duct lymph was collected from non-TG and B27-TG animals in order to acquire L-DCs. 
Lymph cells were enriched for CD103 with magnetic beads, and stained with CD103 and MHCII 
antibodies, and CD103
+ MHCII
+ DCs were flow-sorted. Single cell suspension was made from 
MLNs of Dark Agouti (DA) rat, and 1x10
5 MLN cells were incubated in triplicate on 96-well plates for 
5 days with 0-20,000 flow-sorted CD103
+ MHCII
+ DCs from either non-TG or B27-TG thoracic duct 
lymph. Tritiated thymidine was added to the wells for the final 12h of the 5d incubation to assess 
cell proliferation. (A) Gating strategy for sorting MHCII
+ CD103
+ DCs from thoracic duct lymph. (B) 
5 independent MLR experiments, error bars mean±SD. 
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Figure 4.9. CFSE based MLR showed non-TG L-DCs to be more effective at inducing CD4+ T 
cell proliferation than B27-TG L-DC 
L-DC were sorted from cannulated non-TG and B27-TG animals as before, and dilutions of sorted 
MHCII
+ CD103
+ DCs were incubated in triplicate for 5d with 1x10
5 CFSE labelled MLN cells from 
DA rats. After 5d, cells were harvested from the well and stained with CD4 antibody. Proliferation of 
CD4
+ cells was assessed by FACS. (A) a representative CD4 and CFSE staining of cells incubated 
with 12,500 DCs, showing the percentage of CD4
+ cells in both non-TG and B27-TG preparations. 
(B) Percentage of proliferated CD4 T cells was assessed using a gate shown in the histogram 
overlay showing CFSE staining intensity in both non-TG and B27-TG samples from (A), and the 
results of the MLR can be seen in (C). **p<0.01 by two-way Anova. Error bars mean±SD. 
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Figure 4.10 Luminex results from MLR 
Supernatants at day 5 of MLR were collected from experiment shown in Figure 4.9, and the 
concentrations of various cytokines were measured by Luminex. Results from one experiment with 
3 technical replicates. Error bars are SEM.  
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4.2.4  B27-TG rats lack a subset of migrating intestinal DCs 
Rat MHCII
+ CD103
+ lymph DCs can be divided into three well-characterised populations 
according to their expression of CD11b and CD172a (113). These three populations are: 
CD172a
hi  CD11b
$ 
  (CD172a
hi)  CD172a
int  CD11b
+  (CD172a
int)  and  CD172a
lo  CD11b
int 
(CD172a
lo). The appearance of these three populations in non-TG rats was assessed by 
sorting the three subsets (Figure 4.11A), followed by a cytospin and staining of the subsets 
with H&E (Figure 4.11B).  
CD172a
hi cells were mainly large, mononuclear cells with a large amount of cytoplasm. 
CD172a
int cells resembled CD172a
hi cells, but were in general slightly smaller, had less 
cytoplasm,  and  a  more  regular  shaped  nucleus.  In  contrast,  CD172a
lo  cells  appeared 
different from the other two subsets: it was possible to see cells resembling activated DCs, 
many displaying dendrites on their surface. Cells like this were not seen in preparations 
from the other two subsets. Some of the cells in the CD172a
hi preparation resembled cells 
seen in CD172a
int sample, but these might be a contamination from that population that has 
occurred during cell sorting. 
Next it was investigated whether all the three MHCII
+ CD103
+ L-DC subsets were present 
in the lymph of B27-TG animals with same proportions as in control non-TG and B7-TG 
rats. B27-TG, non-TG and B7-TG animals were cannulated, and the lymph cells were 
stained with antibodies for MHCII, CD103, CD11b and CD172a, and analysed by FACS. 
As expected, all three subsets could be found in the lymph of non-TG and B7-TG animals 
(Figure 4.12A, B), with similar proportions. However, when the lymph cells from B27-TG 
animals were analysed, unexpectedly it was noted while in non-TG animals the CD172a
lo 
subset comprised about 40 % of all MHCII
+ CD103
+ L-DCs, in B27-TG animals this 
population  only  comprised  less  than  10  %  (Figure  4.12C).  This  result  is  highly 
reproducible,  as  can  be  seen  when  data  from  6  independent  experiments  with  2-3 
animals/group was analysed (Figure 4.13). Figure 4.13A shows the percentage of each 
subset from MHCII
+ CD103
+ L-DCs, and B27-TG animals had a significantly smaller 
proportion of CD172a
lo when compared to non-TG and B7-TG animals: on average, B27-
TG MHCII
+ CD103
+ DCs contained 5 % CD172a
lo cells, whereas non-TG and B7-TG 
animals had on average 28 % and 20 %, respectively. In contrast, B27-TG animals had 
significantly higher proportion of CD172a
int DCs when compared to non-TG (39 % vs. 27 
%), and also seemed to have slightly higher proportion of CD172a
hi cells, but this was not 
significant.  When  the  absolute  numbers  for  each  DC  subset  out  of  MHCII
+  CD103
+  
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population were calculated, B27-TG animals again had significantly fewer CD172a
lo L-
DCs compared to non-TG animals (Figure 4.13B). On average, B27-TG animals had 1.9 x 
10
4 MHCII
+ CD103
+ CD172a
lo lymph DCs
 compared to 2.1 x 10
5 cells in non-TG. 
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Figure 4.11 H&E staining of sorted L-DC subsets. 
Cells collected at 0-24h by thoracic duct cannulation were enriched for CD103 using magnetic 
beads, and stained with CD103, MHCII, CD11b and CD172a antibodies. (A) Three subsets of 
MHCII
+ CD103
+ L-DCs were flow-sorted as shown, and cytospins were performed for these three 
populations. (B) H&E staining of the slides from cytospins. Pictures were taken using x40 
magnification and a light microscope.
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Figure 4.12. B27-TG rats lack the CD172a
lo subset of L-DCs. 
Cells were collected at 0-24h by thoracic duct cannulation, and stained with antibodies for CD103, 
MHCII, CD11b and CD172a to identify migrating DC subsets. (A) Three CD103
+ MHCII
+ subsets of 
L-DC can be identified in non-TG rat lymph: CD11b
loCD172a
hi, CD11b
hiCD172a
int and 
CD11b
intCD172a
lo. (B) Only two L-DC subsets can be found in B27-TG rat lymph. In control B7-TG 
rats all three subsets can be found (C). Data are summarised in the next figure. 
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Figure 4.13. B27-TG rats lack the CD172a
lo L-DC subset  
Data from 6 (for non-TG and B27-TG) or 1 (for B7-TG) independent cannulation experiments 
were compiled for 0-24h timepoint, and the percentage and absolute number of DCs in each 
subset was calculated. (A) Percentage of each subset from total MHCII
+ CD103
+ DCs, and of 
each subset from total CD103
+MHCII
+ DCs. Error bars are SEM, and data were analysed by 1-
way Anova, *p<0.05, **p<0.01, ***p<0.001. Total number of animals used: 4 (B7-TG), 7 (non-TG) 
and 12 (B27-TG). 
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4.2.5  Expression of CD80 and CD25 on L-DC subsets 
As it was noticed earlier that there were small differences in the expression of CD25, as 
well as CD80, on MHCII
+ CD103
+ DCs between B27-TG and control non-TG animals 
(Figures 4.3 - 5), it was next determined if these differences could traced back to a specific 
L-DC subset. As before, rats were cannulated, and lymph cells were stained with MHCII, 
CD103,  CD11b,  CD172a,  and  either  CD25  or  CD80.  Non-TG  CD80  expression  was 
similar  between  the  CD172a
hi  and  CD172a
int  DC  subsets,  but  the  CD172a
lo  subset 
expressed a slightly lower level of CD80 both at 0-24h (Figure 4.14A) and 24-48h (Figure 
4.14B). This finding could explain the difference in CD80 expression that was observed 
when total MHCII
+ CD103
+ DCs were used (Figures 4.4 - 6), as B27-TG animals lack this 
CD172a
lo subset that on non-TG animals expresses less CD80. It was then investigated if 
the increase in CD25 expression noted earlier on B27-TG derived cells could be attributed 
to  one  subset  upregulating  the  expression  of  CD25,  or  if  both  subsets  upregulated  it 
equally. Figure 4.15 is a representative of one experiment out of two, and as can be seen on 
B27-TG derived cells, it is the CD172a
hi subset that expresses more CD25. In contrast, all 
three non-TG L-DC subsets express CD25 on an equally low level.  
4.2.6  Are B27-TG L-DCs more susceptible to apoptosis? 
As it was noted that the CD172a
lo subset was missing from the B27-TG animals, it was 
hypothesised that this could be because these cells are more susceptible to apoptosis. There 
is some evidence supporting this hypothesis, as it has been reported that the correlating 
B27-TG CD103
+ population in the spleen is more susceptible to apoptosis (239), and in 
addition it has been reported that this population survived less well than the CD172a
hi 
population when cultured with GM-CSF (273). Thus, non-TG and B27-TG animals were 
cannulated and lymph cells stained with L-DC markers CD103 and MHCII, as well as 
Annexin-V and DAPI to assess if more cells in the B27-TG animals were undergoing 
apoptosis. First, the proportion of live (Annexin-V
$ DAPI
$ ) cells in the total lymph cell 
population were compared between non-TG (Figure 4.16A) and B27-TG animals (Figure 
4.16B). No obvious differences were noticed, as the proportion of live cells was similar in 
the lymph of both non-TG and B27-TG animals. Next it was postulated that maybe the 
difference in viability of L-DCs would be too small to be seen when looking at the total 
lymph cell population, so the gating strategy was changed. This time, cells were first gated 
on  MHCII
+  CD103
+  cells,  and  Annexin-V  and  DAPI  expression  on  these  cells  was 
assessed on non-TG (Figure 4.16C) and B27-TG (Figure 4.16D) animals. There were no  
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differences  in  the  number  of  live,  apoptotic  (Annexin-V+)  or  dead  (DAPI+)  MHCII
+ 
CD103
+ cells between non-TG and B27-TG L-DCs.  
Since there were no differences in the viability of non-TG and B27-TG MHCII
+ CD103
+ 
DCs, and as it is not possible to directly investigate the CD172a
lo population from B27-TG 
animals,  it  was  decided  to  examine  whether  the  CD172a
lo  population  in  the  non-TG 
animals  would  be  more  susceptible  to  apoptosis.  As  was  mentioned  earlier,  in  culture 
CD172
lo cells survive less well than the CD172a
hi cells, and thus it was thought that maybe 
it was an inbuilt character of these cells. Thus, four non-TG rats were cannulated and their 
0-24h-collection lymph was pooled together. Lymph cells were enriched for CD103 using 
magnetic beads, stained for CD103 and MHCII and double positive L-DCs were flow 
sorted. The sort resulted in 6x10
5 L-DCs, and these were divided into two wells in a 96-
well  plate  (3x10
5  L-DCs/well)  and  were  incubated  overnight  in  complete  media.  The 
following day, cells were harvested from the wells and re-stained for CD103, MHCII, 
CD11b, CD172a and DAPI. Results for both replicates are shown on Figure 4.17. Cells 
were  first  gated  on  live  (DAPI
$)  MHCII
+  cells  (Figure  4.17A,  top  panels),  and  the 
expression of CD103 on these cells was then analysed (Figure 4.17A, bottom panels). 
Firstly,  it  was  noticed  that  majority  (>90%)  of  the  L-DCs  had  died  when  cultured 
overnight. In addition, the homogenous MHCII
+ CD103
+ population that had been sorted 
(see Figure 4.11 for an example of sorted cells), had divided into two separate populations: 
MHCII
hi CD103
+ (R1) and MHCII
int CD103
lo
 (R2). As we wanted to find out whether the 
CD172a
lo expressing cells were more prone to apoptosis, the expression of CD172a on 
these two populations was assessed (Figure 4.17C). Surprisingly, R1 and R2 populations 
also differed in their expression of CD172a: R1 cells were CD172a
hi, whereas R2 cells 
expressed only intermediate level of CD172a. When comparing the expression level of 
CD172a of all the MHCII
+ (R1+R2) cultured cells to that of freshly analysed MHCII
+ 
CD103
+ L-DCs from non-TG animals, it was noticed that actually the CD172a expression 
pattern on these two preparations was quite similar (Figure 4.17D). CD172a staining on 
B27-TG MHCII
+ CD103
+ was clearly different (Figure 4.17D). Thus, these results do not 
indicate a reduction in the non-TG CD172a
lo population after over-night culture. 
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Figure 4.14. Expression of CD80 by L-DC subsets 
Lymph cells were collected by thoracic duct cannulation as before, and the cells were stained for 
CD103, MHCII, CD11b, CD172a and CD80, and the expression level of CD80 in the different L-DC 
subsets was determined by FACS. (A) Lymph was collected for 0-24h, and CD80 expression was 
determined on the three DC subsets in both Non-TG (upper panels) and B27-TG animals (lower 
panels). (B) CD80 expression in the subsets on the 24-48h collection. Gates show the frequency of 
parent, and the gate colours on the dot plots match those on the histograms, n=1.  
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Figure 4.15. CD172a
hi L-DC subset from B27-TG animals might be the population expressing 
CD25 more highly. 
Lymph was collected from 24-48h, and the cells stained for CD103, MHCII, CD11b, CD172a and 
CD25, and the expression of CD25 on the three different L-DC subsets from non-TG (A) and B27-
TG (B) animals was determined by FACS. Gates show the frequency of the parent and the gate 
colours on the dot plots match those on the histograms. This is a representative data from 2 
independent experiments. 
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Since there were no differences in the viability of non-TG and B27-TG MHCII
+ CD103
+ 
DCs, and as it is not possible to directly investigate the CD172a
lo population from B27-TG 
animals,  it  was  decided  to  examine  whether  the  CD172a
lo  population  in  the  non-TG 
animals  would  be  more  susceptible  to  apoptosis.  As  was  mentioned  earlier,  in  culture 
CD172
lo cells survive less well than the CD172a
hi cells, and thus it was thought that maybe 
it was an inbuilt character of these cells. Thus, four non-TG rats were cannulated and their 
0-24h-collection lymph was pooled together. Lymph cells were enriched for CD103 using 
magnetic beads, stained for CD103 and MHCII and double positive L-DCs were flow 
sorted. The sort resulted in 6x10
5 L-DCs, and these were divided into two wells in a 96-
well  plate  (3x10
5  L-DCs/well)  and  were  incubated  overnight  in  complete  media.  The 
following day, cells were harvested from the wells and re-stained for CD103, MHCII, 
CD11b, CD172a and DAPI. Results for both replicates are shown on Figure 4.17. Cells 
were  first  gated  on  live  (DAPI
$)  MHCII
+  cells  (Figure  4.17A,  top  panels),  and  the 
expression of CD103 on these cells was then analysed (Figure 4.17A, bottom panels). 
Firstly,  it  was  noticed  that  majority  (>90%)  of  the  L-DCs  had  died  when  cultured 
overnight. In addition, the homogenous MHCII
+ CD103
+ population that had been sorted 
(see Figure 4.11 for an example of sorted cells), had divided into two separate populations: 
MHCII
hi CD103
+ (R1) and MHCII
int CD103
lo
 (R2). As we wanted to find out whether the 
CD172a
lo expressing cells were more prone to apoptosis, the expression of CD172a on 
these two populations was assessed (Figure 4.17C). Surprisingly, R1 and R2 populations 
also differed in their expression of CD172a: R1 cells were CD172a
hi, whereas R2 cells 
expressed only intermediate level of CD172a. When comparing the expression level of 
CD172a of all the MHCII
+ (R1+R2) cultured cells to that of freshly analysed MHCII
+ 
CD103
+ L-DCs from non-TG animals, it was noticed that actually the CD172a expression 
pattern on these two preparations was quite similar (Figure 4.17D). CD172a staining on 
B27-TG MHCII
+ CD103
+ was clearly different (Figure 4.17D). Thus, these results do not 
indicate a reduction in the non-TG CD172a
lo population after over-night culture. 
Since non-TG cells were not expected to be more prone to apoptosis, it was decided to 
repeat  the  experiment  above,  but  this  time,  induce  apoptosis  on  the  non-TG  cells.  To 
induce  apoptosis,  a  compound  called  thapsigargin  was  used.  Thapsigargin  binds  to 
endoplasmic reticulum Ca
2+ ATPases, inhibiting the function of Ca
2+ pumps, and thus 
raises the cytosolic Ca
2+ level, causing ER stress and apoptosis (274). B27-TG cells have 
been reported to undergo more ER stress compared to non-TG cells (250-252). The 24-
48h-collection of lymph from the same cannulation as in Figure 4.17 was used for the 
experiment.   
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As before, 6x10
5 MHCII
+ CD103
+ DCs were sorted, but this time they were divided into 
three  wells  of  a  96-well  plate,  2x10
5  cells/well.  Two  different  protocols  were  used  to 
induce apoptosis with thapsigargin; either 4 nM thapsigargin was incubated with the cells 
overnight (Figure 4.18B), or 400 nM thapsigargin was added to the culture for the final 3h 
of the incubation (Figure 4.18C). One well was left untreated (Figure 4.18A). The higher 
concentration of thapsigargin was selected as it was recommended by Dr Darren Asquith 
(personal communication) in the laboratory, whereas the low concentration was selected 
empirically  by  culturing  BMDCs  with  various  concentrations,  and  selecting  the 
concentration that caused similar level of reduction in cell viability as was seen with 7-day 
culture of B27-TG BMDCs without thapsigargin (see Chapter 5 for BMDC analysis). The 
cells were analysed as before, by first gating on live MHCII
+ cells, followed by CD103. As 
in Figure 4.17, two distinct populations were again found based on MHCII and CD103 
expression (Figure 4.18A-C, bottom panels). There were no differences in the proportions 
of these two populations between the groups. When the expression of CD172a on the two 
populations was compared between the treatments, no differences were noticed either in 
the R1 or R2 populations. It should also be noted that as there was no difference in the 
proportion of live cells between the groups (Figure 4.18A-C, top panels), it is possible that 
thapsigargin failed to induce apoptosis in these cells. 
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Figure 4.16. No difference in the viability of lymph derived cells from non-TG and B27-TG 
animals 
Thoracic duct lymph was collected from non-TG and B27-TG animals, and stained with DAPI, 
Annexin-V, MHCII and CD103. Data were analysed in two different ways: In (A) and (B) cell 
viability of all lymph cells was determined by gating first on Annexin-V
− DAPI
− cells, and the 
expression of MHCII and CD103 was determined on these live cells.  Viability of L-DCs was 
assessed by first selecting MHCII
+ CD103
+ cells, followed by gate for Annexin-V and DAPI (C, D). 
Numbers on plots refer to frequency of the parent. n=1. 
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Figure 4.17. In vitro culture of flow sorted L-DCs 
Lymph was collected from 4 non-TG rats at 0-24h and pooled together. Cells were then enriched 
for CD103 with magnetic beads and stained for MHCII and CD103. Double positive cells were 
sorted, and placed into 2 wells of a 96-well plate 200,000 cells/well in complete media for 12h at 
37°C. After 12h, cells were harvested, and restained for DAPI, CD103, MHCII and CD172a. (A, B) 
Cells from two replicates (DC 1 and DC 2) were gated on live (DAPI
−) MHCII
+ cells. These were 
further divided into CD103
hi (R1) and CD103
lo (R2) populations. (C) CD172a expression on R1 and 
R2 populations from both replicates was determined by FACS, and shown as histogram overlays. 
(D) Expression of CD172a on all MHCII
+ cultured DCs (R1+R2) compared to expression on freshly 
isolated and analysed MHCII
+ CD103
+ DCs from non-TG and B27-TG animals. Numbers in figures 
refer to frequency of the parent.
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Figure 4.18. In vitro culture of flow-sorted L-DCs with Thapsigargin 
24-48h lymph collection from 4 Non-TG rats was pooled together. Cells were enriched for CD103 
with magnetic beads and stained for MHCII and CD103. Double positive DCs were sorted, and 
placed into 3 wells of a 96-well plate 200,000 cells/well in complete media +/- Thapsigargin for 12h 
at 37°C. After 12h, DCs were harvested and restained for DAPI, CD103, MHCII and CD172a. (A, B, 
C) Live MHCII
+ Dapi
− cells were selected, and the expression of CD103 on these cells was 
determined in three different conditions: DCs cultured in complete media only (A), DCs treated with 
4 ηM Thapsigargin for 12h (B) and DCs treated with 400 ηM Thapsigargin for the final 3h of the 
12h culture. (C) Histogram overlays depicting expression of CD172a on MHCII
+ CD103
+ (R1) and 
MHCII
+ CD103
− (R2) cells in all three conditions shown above. Numbers shown in figures are 
frequency of the parent.  
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4.3  Discussion 
B27-TG animals have been used extensively to investigate the pathogenesis of SpA. Other 
investigators have demonstrated roles for both CD4
+ T lymphocytes (233, 234) and DCs 
(238,  239)  in  the  disease.  However,  the  mechanism  by  which  DCs  may  influence  the 
development of inflammation has been unclear. As both patients and the B27-TG animals 
present  with  intestinal  symptoms,  it  was  hypothesised  that  DCs  that  migrate  from  the 
intestine  to  the  MLN  would  have  a  role  in  the  disease  pathogenesis.  Collection  of 
migrating intestinal DCs by thoracic duct cannulation of mesenteric lymphadenectomised 
rats is an established method used to study the phenotype and properties of these cells 
(268). Here, this technique was used, for the first time, to investigate the properties L-DCs 
in B27-TG rats.  
It was first determined if the total number of cells in the lymph of non-TG and B27-TG 
animals would be the same. No differences were expected and indeed it was found that 
there was no defect in the general migration of cells as the total cell numbers collected 
from the non-TG and B27-TG animals were similar. Furthermore, it was established that 
the cell number/24h remained constant throughout the three-day collection of the lymph, 
despite the animals receiving i.v. saline for the first 24h after cannulation. As shown, this 
leads to a significantly larger volume of lymph on 0-24h-collection, compared to 24-48h.  
At the time of surgery the rats are a minimum of 10 weeks old, and some may present with 
signs of intestinal inflammation at this time point. Inflammation in the intestine leads to 
activation  of  DCs  situated  at  the  site  of  inflammation.  DC  activation  in  turn  leads  to 
increased  migration  of  these  cells  out  of  the  intestine  and  into  the  MLNs  via  lymph. 
Indeed,  it  has  been  shown  in  rats  and  mice  that  during  acute  inflammation  or  TLR 
stimulation the number of migrating DCs from the intestine increases dramatically (185). 
Thus, it was hypothesised that B27-TG animals could have increased number of DCs in the 
lymph due to inflammation in the intestine. Migrating DCs in the rat are characterised as 
MHCII
+  CD103
+,  and  they  have  been  shown  to  be  able  to  stimulate  proliferation  and 
differentiation  from  naïve  allogeneic  CD4
+  T  lymphocytes  (184),  a  DC  hallmark. 
Surprisingly, instead of increased DC numbers, it was found that the B27-TG L-DCs were 
significantly decreased both in proportion and in absolute numbers compared to non-TG 
animals at 0-24h timepoint. This observation could be caused by B27-TG animals having 
less DCs in the intestine in general, maybe due to chronic inflammation causing long-term 
increased  DC  migration  out  of  the  intestine.  However,  no  difference  in  DC  numbers  
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between B27-TG and B27-TG animals at other time points were observed, suggesting that 
this is not the case. Ideally, the number of DCs in the intestine would be determined by 
comparing the DC numbers in the intestinal tissues of non-TG and B27-TG animals to see 
if same numbers are present. This could be achieved by microscopy, as the necessary 
physical and enzymatic disruption of tissues necessary for FACS analysis would be likely 
to alter the functions and phenotype of these cells and thus make it difficult to identify 
them. Also, the animals could be treated orally with TLR7/8 ligand R848, which has been 
shown to lead to an increased migration of L-DCs from the small intestine, and to an 
almost  complete  depletion  of  DCs  within  lamina  propria  (120).  This  would  allow  a 
comparison of DC numbers present in the small intestine of non-TG and B27-TG animals. 
Also, as it was later noticed that B27-TG animals lack one of the three migrating DC 
subsets. This could lead to decreased total number of DCs if the other two subsets do not 
compensate for the loss.  
It  was  next  decided  to  determine  if  L-DCs  from  B27-TG  and  non-TG  animals  would 
express activation and costimulatory molecules similarly. It has been reported before that 
MHCII
+ CD103
+ DCs from non-TG animals express only low levels of CD80, CD86 and 
CD25 (189), thus being semi-mature cells. However, in these experiments L-DCs were 
found to express intermediate levels of CD80 and CD86, whereas the expression on CD25 
was low, as reported. The higher level of CD80 and CD86 observed here compared to 
previously published results could be explained by slight differences in the protocols used, 
such as antibody concentration or clone, or length of staining with the antibody. When 
comparing the expression of CD86 between the different time points, it was noticed that 
CD86 was expressed at a lower level at 48-72h time point compared to the other two time 
points. It is not known why this would be the case, but there were only two replicates for 
this time point, so more repeats would be required to see if the phenomenon is real. There 
was no difference, however, in the expression of CD86 between non-TG and B27-TG 
animals in any of the time points. When analysing the CD80 expression, more MHCII
+ 
CD103
+ cells from B27-TG animals compared to non-TG expressed CD80 at all the time 
points, but this was not statistically significant. In addition, there were more CD25
+ cells in 
the  B27-TG  lymph  compared  to  non-TG  in  all  the  time  points,  but  it  only  reached 
significance at the 0-24h time point. Interestingly, the pattern of CD25 expression on B27-
TG animals resembles that observed on non-TG animals after stimulation with various 
TLR2 and TLR3 ligands (189). CD25 has been reported to be a very sensitive marker of 
activation on rat DCs, and it is upregulated very quickly when the cells are exposed to 
GM-CSF in vitro (272). GM-CSF, on the other hand, is normally present in vivo at very  
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low levels, but its production it rapidly upregulated under inflammatory conditions. Thus, 
it  could  be  that  in  the  B27-TG  rat  small  intestine  more  GM-CSF  or  some  other 
inflammatory cytokines are present, due to inflammation, and the B27-TG L-DCs would 
be exposed to these factors before migrating to the MLN, leading the DCs to be more 
activated. In addition, increased numbers of Th17 cells have been reported in the colonic 
LP of B27-TG animals (252), and splenic DCs from B27-TG animals have been noted to 
preferentially induce Th17 cells (144) and GM-CSF is one of the Th17 effector cytokines 
(275). Thus, it could be that inflammation and defective DCs lead to induction of Th17 
cells, which then in turn activates DCs to upregulate CD25 expression and migrate to the 
MLN.  
In addition to markers mentioned above, expression of OX-40L was also analysed, as this 
has been shown to be an important molecule driving Th2 cell proliferation and maturation 
by intestinal DCs (276). Difference in the expression level of this molecule between non-
TG and B27-TG animals could give a hint about functional differences the DCs could 
have. However, the expression level for OX-40L was found to be low, and there were no 
differences between non-TG and B27-TG animals. It is possible, though, that this marker 
is only upregulated once the cells reach MLN and are exposed to the microenvironment 
there, and thus it would be interesting to see if OX-40L was upregulated if the DCs were 
stimulated in vitro, as indicated above. It has also been reported that splenic DCs from 
B27-TG animals express lower level of MHCII on their surface (239), and it was analysed 
if this was the case for the B27-TG MHCII
+ CD103
+ L-DCs. When analysing the results 
from individual experiments, it was often observed that MHCII was lower on B27-TG 
animals, however when data from several experiments were collated, the difference in 
MHCII expression between non-TG and B27-TG L-DCs was not statistically significant. 
There was always some variation in the intensity of the MHCII staining between individual 
experiments, probably due to slight differences in cell numbers used for each staining. 
Also, it is in general difficult to assess the level of MHCII expression on DCs as they 
express so much of it on their surface, and thus careful measurements must be made to find 
out the concentration of antibody that saturates the cells.  
As it was observed that a proportion of B27-TG DCs had a more activated phenotype with 
more CD25
+ cells, it was hypothesis that B27-TG L-DCs would be better able to stimulate 
naïve  CD4
+  T  cell  proliferation.  When  measuring  proliferation  using  total  MLN  cells 
derived from DA animals and a thymidine-based assay, there were differences within the 
individual experiments, but when comparing five individual experiments, B27-TG cells  
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were better as often as the non-TG ones. Importantly though, both non-TG and B27-TG L-
DC  were  able  to  induce  cell  proliferation,  implicating  that  the  B27-TG  DCs  are 
functioning  normally.  When  using  a  CFSE  cell  proliferation  assay,  and  specifically 
investigating the proliferation of CD4
+ cells, non-TG cells seemed to be better in this one 
experiment. However, this experiment has only been done once, so should be repeated to 
obtain consistent results. The MLR done with sorted naïve CD4
+ T cells is much more 
specific, and also one can be sure that the same number of naïve cells is added for each for 
each condition. On the other hand, when using total MLN cells, it is not sure how many 
naïve cells are actually used. Thus, variations in the number of naïve T cells in the MLN 
could have an effect on the reproducibility of the MLRs observed on the thymidine based 
assays. It could also be that non-TG and B27-TG L-DCs actually are comparable in their 
ability induce T cell proliferation, but there could be a difference in the outcome of the T 
cell activation. For example, it has been shown that B27-TG splenic DCs induce more 
Th17 T cells compared to non-TG DCs (144), which induce more IFN-! and thus Th1 type 
responses. Thus, luminex was performed to measure cytokine production by the T cells 
when activated in a MLR. Supernatants from the MLR with sorted naïve CD4
+ T cells 
were used. Contrary to our prediction, non-TG DCs induced more IL-17F as well as IFN-! 
than  B27-TG  DCs,  whereas  better  IL-6  and  IL-2  induction  from  non-TG  L-DCs  was 
expected based on the poor proliferation by B27-TG DCs. If true, these results indicate that 
intestinal migrating DCs behave differently from their splenic counterparts, and this merits 
some more investigation. However, as this is a result from just one MLR experiment, 
which itself has only been performed once, it is not sure how reliable these results are. In 
addition, in the light of experiments from other groups that have reported increased IL-23 
production  in  the  B27-TG  animals,  it  would  also  be  important  to  see  if  the  L-DCs 
themselves differ in their production of cytokines after stimulation.  
It is well established that there are three MHCII
+ CD103
+ L-DC subsets present in the rat 
lymph: CD172a
hi CD11b
lo, CD172
int CD11b
hi and CD172a
lo CD11b
int . These subsets seem 
to  differ  somewhat  morphologically.  CD172a
hi  and  CD172a
int  populations  consist  of 
mononuclear cells, with CD172a
int cells being slightly smaller in size than CD172a
hi cells. 
CD172a
lo cells, however, are smaller, and have more of a textbook DC appearance with 
visible dendrites.  
It was next established whether all three L-DC subsets were present at similar frequencies 
in  the  lymph  of  control  B7-TG  and  non-TG  animals,  as  well  as  B27-TG  animals. 
Surprisingly,  lymph  from  B27-TG  animals  lacks  the  CD172a
lo  DC  subset.  This  
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phenomenon has never been reported before, as in other models of inflammation DCs have 
been shown to maintain similar relative frequencies (185, 188). The CD172a
lo subset was 
significantly reduced both proportionally and in absolute numbers. The lack of this subset 
could  explain  the  reduction  in  the  absolute  number  of  B27-TG  MHCII
+  CD103
+  DCs 
observed  at  0-24h  timepoint  before,  however  it  does  not  explain  why  there  was  no 
difference at 24-48h timepoint. We then hypothesised that the differences in CD80, CD86 
and  CD25  expression  seen  when  comparing  total  MHCII
+  CD103
+  L-DCs    could  be 
explained by the DC subsets being present in different proportions in non-TG and B27-TG 
animals. Indeed, when the CD80 expression on each of the subsets was analysed, it was 
noticed that the CD172a
lo subset in non-TG animals seemed to express lowest level of 
CD80. As a result, B27-TG animals, which lack this subset, would appear to have more 
CD80
+ L-DCs. In contrast, when the expression of CD25 was analysed in all three subsets, 
it was noticed that it was the CD172a
hi subset in B27-TG animals that contained most 
CD25
+  cells.  Hence,  B27-TG  L-DCs  appear  more  activated  by  having  an  increased 
expression of CD25 on the CD172a
hi subset.  
In this context, it is then somewhat curious that B27-TG L-DCs were less effective at 
stimulating CD4
+ T cell proliferation when a more refined method of MLR with CFSE was 
used. It would, of course, be good to sort all three subsets separately and perform an MLR, 
and analyse if the subsets differ in their abilities. It is very difficult, however, to obtain 
enough L-DCs to perform this kind of functional analyses and it would require pooling of 
the  lymph  from  several  animals.  Even  if  we  did  not  observe  the  expected  differences 
between B27-TG and non-TG DCs in the MLRs, it does not rule out a DC defect. Indeed, 
preliminary data from our laboratory (Drs Dawn Firmin and Aude Aumeunier, personal 
communication) suggest that T cells derived from non-TG and B27-TG MLNs do express 
different levels of homing markers, such as chemokine receptors CCR4 and CCR6 on 
them. In addition, our data and data from Maxime Breban’s group (144) do indicate there 
is an increase in the number of activated CD4
+ CD25
+ T cells in the MLNs of B27-TG 
animals when compared to non-TG or B7-TG animals. Furthermore, other experiments by 
our group do indicate that B27-TG T cells sorted from the MLN, and transferred back to 
non-TG animals home preferentially in the small intestine, whereas this is not seen when 
non-TG cells are transferred to non-TG animals (preliminary data, Dr Dawn Firmin). Thus, 
it does seem DCs from B27-TG and non-TG animals do indeed induce different responses 
from T cells in vivo, even if there are no obvious differences in the ability to induce 
proliferation of CD4
+ T cells.  
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The nature of the subset that the B27-TG rats lack might also have a significant role on the 
induction or perpetuation of the disease in these animals. Previous work has revealed that 
the three subsets differ from one another in several ways. Only CD172a
hi and CD172a
int 
populations have been shown to upregulate CD25 expression after feeding with TLR7/8 
agonist R848, they both express TLR8, and secrete cytokines in response to R848 in vitro 
(120). Furthermore, CD172a
hi population has been shown to be the first subset migrating 
from the intestine to the MLN in response to feeding of TLR agonists (185), as well as 
having largest proportion of CD25
+ cells. The CD172a
lo subset has been shown to have 
some unique properties compared to the other two subsets. For example, it has been shown 
to be less effective at inducing T cell proliferation than the other two, but instead it induces 
IL-10 production (184, 273). In addition, previous work has indicated that CD172a
lo subset 
both in rats and in pigs contains cytoplasmic apoptotic DNA inclusions, and in rats also 
epithelial  cell-restricted  cytokeratins  and  non-specific  esterase-positive  inclusions  (111, 
115).  These  features  have  been  shown  to  be  present  in  DCs  derived  from  germ-free 
animals  as  well,  suggesting  that  these  cells  constitutively  endocytose  and  transport 
apoptotic intestinal epithelial to the MLNs, even in the absence of bacterial stimuli (115). 
Thus, it has been suggested that the CD172a
lo cells might be involved in the induction and 
maintenance peripheral self-tolerance to intestinal antigens. Mouse lymph also contains 
subsets of DCs, most notably CD8
+ CD103
+ CD11b
lo (referred as CD8
+), CD11b
+ CD103
+ 
CD8
lo (CD11b
+) and CD8
lo CD11b
lo CD103
$  (CD103
$) (113). Of these, CD8
+ cells have 
been suggested to resemble the CD172a
lo subset, as they also pick up and present antigen 
from apoptotic cells. As the B27-TG animals lack CD172a
lo population, they could have a 
deficiency in either maintenance or induction of self-tolerance. Taking into account that 
this CD172a
lo subset has been noted to produce more anti-inflammatory IL-10, it could be 
that a presence of two highly active L-DC populations might lead to presentation of self-
antigens  in  an  inflammatory  context,  and  to  activation  of  self-reactive  T  cells.  As 
mentioned above, preliminary data from our laboratory indicates that there might also be 
differences in the induction of homing molecules on T cells by DCs, and thus these auto-
reactive  T  cells  could  end  up  homing  to  other  places  outside  the  intestine  as  well 
explaining the systemic disease seen both in humans and in the animal model.  
Some might argue that the CD172a
lo population is just a precursor for the CD172a
hi and/or 
CD172a
int  subsets,  and  under  inflammatory  conditions  CD172a
lo  DCs  upregulate  their 
CD172a expression, and become the more inflammatory-like CD172a
hi DCs. This does 
not, however, seem to be the case, as previous elegant BrdU-labelling experiments show 
that the CD172a
lo population is not a precursor to the CD172a
hi DCs (76). In addition,  
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almost all the species investigated seem to have both CD172a
+/hi and CD172a
lo/$ subsets, 
and they do seem to have separate ontogeny and functions. One possible experiment to 
investigate  this  problem  further  would  be  to  isolate  CD172a
lo  L-DCs  from  non-TG 
animals,  and  then  adoptively  transfer  these  cells  to  the  B27-TG  rats,  and  monitor  the 
disease progression. This experiment is technically very difficult to accomplish, however, 
as the number of L-DCs needed for the transfer is very high, and the CD172a
lo subset only 
comprises maximum of 30 % of all non-TG L-DCs, which in turn comprise 0.2 % of all 
lymph cells. Thus, a very large number of animals would be needed to perform a single 
transfer. It might be more feasible to transfer total MHCII
+ CD103
+ non-TG lymph DCs to 
irradiated B27-TG recipients, and see if all three subsets could be recovered from the 
recipients. If not, it implies there could an active and very specific unknown mechanism in 
place leading to depletion of CD172a
lo L-DCs in B27-TG animals. And if all subsets were 
found,  it  could  be  that  there  is  an  inherent  and  maybe  a  genetic  problem  in  the 
development of CD172a
lo DCs in these animals. 
It  has  been  reported  that  a  population  of  CD4
$  CD103
+  DCs  in  the  spleen,  which 
correspond  to  the  CD172a
lo  DC  subset  in  lymph,  are  more  prone  to  apoptosis  (239). 
Furthermore, as was mentioned before, it has been shown that the CD172a
lo cells survive 
less well when cultured in vitro compared to CD172a
+ subsets (272). In addition, it has 
been previously shown the HLA-B27
+ molecule is prone to misfolding in the cells, leading 
to activation of unfolded protein response, and possibly to apoptosis (250). It was thus 
hypothesised that the L-DC CD172a
lo subset might be more prone to die by apoptosis, and 
that is why it is missing in the B27-TG rats. In order to find out if this was the case, lymph 
cells from both non-TG and B27-TG animals were stained with Annexin-V and DAPI to 
analyse the proportions of apoptotic, dead and live cells. It was observed that, there was no 
difference in the proportion of live cells between non-TG and B27-TG animals either when 
looking at total live cells, or when looking at the Annexin-V and DAPI stain on MHCII
+ 
CD103
+ cells.  
Since it is not possible to directly analyse properties of the missing CD172a
lo subset from 
the B27-TG animals, it was decided to see if CD172a
lo cells from non-TG animals were 
more prone to apoptosis when cultured in complete media overnight. It was noticed that 
most  of  the  sorted  DCs  died  after  overnight  culture,  and  in  addition  two  MHCII
+ 
populations could be seen: MHCII
hi CD103
hi CD172a
hi and MHCII
int CD103
lo CD172a
int. 
This already indicates that at least two CD172a expressing populations are present, and 
when expression of CD172a on all the cultured cells (MHCII
hi + MHCII
int), was compared  
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to that of freshly analysed L-DCs, no difference in the staining pattern was observed. This 
indicates that no specific loss of one subset over another has taken place. 
As the non-TG DCs are not expected to be more prone to spontaneous apoptosis, it was 
then decided to use thapsigargin to induce apoptosis in these cells, and see if this would 
make a difference to the CD172a
lo population. Two different protocols were used: low 
concentration (4 nM) of thapsigargin for the duration of culture (12h) or high concentration 
(400  nM)  for  the  last  three  hours  of  cell  culture.  Again,  we  observed  two  MHCII
+ 
populations. When the level of CD172a on these two populations was compared between 
the  treatments,  no  differences  were  observed.  More  importantly,  no  differences  in  the 
percentage of DAPI
$ cells were observed between the treatments, which might indicate 
that thapsigargin had failed to induce apoptosis on these cells using this protocol. It should 
also be noted that on both experiments mentioned above, with or without thapsigargin, 
extremely few cells survived the overnight culture (less than 10%). This could be a result 
of the treatment the cells have to go thorough before they are even plated out: RBC lysis, 
many washes and spins, enrichment with magnetic beads, and cell sorting. Any, and all of 
these could stress the cells sufficiently enough to cause the low viability observed when 
cultured overnight. In addition, L-DCs are on their way to the MLN, where they would not 
live very long even in in vivo. But in previous experiments, where L-DCs were sorted to 
use them in MLR, they were perfectly capable of supporting T cell proliferation. This 
could indicate that L-DCs need other cells, such as T cells, with them in the culture to 
provide survival signals. Thus, this experiment could be repeated by maybe co-culturing 
the DCs together with T cells. However, using non-TG DCs to try and predict what might 
be happening with B27-TG DCs is never going to give a reliable answer, however it might 
point us to the right direction and open up new avenues of research. 
In conclusion, it was observed that B27-TG animals lack the CD172a
lo subset of migrating 
DCs, and in addition a population of DCs that are left appear to be more activated. This 
however did not translate to B27-TG L-DCs being more stimulatory in an allogeneic MLR. 
Cytokine production by T cells in the MLR was surprising, as contrary to expectations 
B27-TG  DCs  induced  less  IL-17F.  However,  these  experiments  should  be  repeated  to 
confirm these observations. CD172a
lo cells have been indicated to carry self-antigens from 
the periphery to the lymph nodes in steady state conditions, and thus the lack of these DCs 
in the B27-TG animals could lead to defect in the peripheral tolerance induction and thus 
to increased number of auto-reactive T cells in the circulation. Most of the previously 
published results indicating various defects or differences in B27-TG DC function and  
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phenotype have been obtained using splenic DCs, suggesting that DC defects in B27-TG 
animals are found in several locations, suggesting systemic defects. Thus, in the following 
chapter it was decided to investigate DCs found in the MLNs, as this is where DCs would 
normally interact with T cells, leading to either induction of immunity or to tolerance. DC 
development is dependent on Flt3L, as discussed in Introduction, and it could be that the 
lack of CD172a
lo subset could be caused by a problem in the development of DCs from 
their  precursors.  Hence,  in  addition  to  MLN  DCs,  also  DCs  derived  from  their  BM 
precursors and grown under Flt3L are investigated in the following chapter.      
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5.  Mesenteric lymph node dendritic cells 
5.1  Introduction 
In the previous chapter it was shown that B27-TG animals lack one of the three subsets of 
migrating  intestinal  DCs,  the  CD11b
lo  CD172a
lo  cells.  While  this  is  an  interesting 
observation, it raises many questions: Is the loss of this L-DC subset a cause or a symptom 
of the disease? How can a defect in intestinal L-DCs lead to disease in other peripheral 
tissues? Recent findings indicating defective functions of splenic B27-TG DCs, such as a 
failure to form stable DC-T cells complexes (237), as well as an observation that splenic 
DCs induce more Th17 cells than their non-TG counterparts (144), suggest that aberrant 
B27-TG DC functions are not limited to the intestinal compartment. Most of the work 
investigating the roles of DCs in the B27-TG animal model has involved the use of splenic 
DCs. There are several reasons for this: First, splenic DCs are well characterised and are 
easy to acquire. Second, it is possible to obtain large enough numbers of them to perform 
functional analyses. However, as there are links between intestinal inflammation and SpA 
in  both  humans  and  rats  (reviewed  in  (49)  and  see  Introduction),  DCs  isolated  from 
mesenteric  lymph  nodes  (MLNs)  would  provide  more  physiologically  relevant 
information. 
L-DCs carry antigen from the intestine to the MLN, where they can activate, or tolerise, 
naïve T cells. As these important events are taking place in the MLNs, and since MLNs are 
the destination for the L-DCs observed in the previous chapter, we were interested in 
analysing  the  phenotype  of  DCs  in  the  MLNs  of  non-TG  and  B27-TG  animals.  In 
particular, we hypothesised that the CD172a
lo population that is missing in the lymph of 
B27-TG animals would also be missing from the MLN of these rats, and this could have 
consequences on the activation of T cells. Identification of migrating DCs in the MLNs 
would provide the means to analyse DCs from younger animals, and address one of the 
questions above - whether the loss of the subset is a cause or a symptom of disease in the 
animals. The MLNX-cannulation process requires at least six weeks, and can only begin 
once  animals  reach  approximately  four  weeks  of  age,  which  means  that  all  the  rats 
analysed using this approach are a minimum of 10 weeks old. At this stage, the animals 
already have established disease, and thus it is possible that inflammatory disease in these 
animals causes the loss of the subset by some unknown mechanism.  
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As was shown in the previous chapter, it is relatively easy to identify L-DCs in rat lymph, 
as they form a homogenous population of MHCII
+ CD103
+ cells. This is because there is 
no  other  cell  type  with  similar  characteristics  present  in  the  lymph  draining  from  the 
intestine.  However,  identifying  DCs  in  the  peripheral  tissues  or  secondary  lymphoid 
organs, such as spleen or MLN, can be difficult as many other cell types are present that 
share a similar phenotype to DCs. In the following pages an analysis of MLN DCs derived 
from 10-16 week old animals is provided. Unfortunately, it was not possible to include 
analysis of MLN DCs from younger animals in this thesis. This could have provided some 
insight into whether the decrease in numbers of a specific subset of DCs, noticed in the 
lymph,  precedes  the  onset  of  symptoms  in  these  animals,  or  whether  this  loss  is  a 
consequence of disease. 
5.2  Results 
5.2.1  Increased cellularity of B27-TG MLNs 
First, it was evaluated whether there were differences in the general viability or number of 
cells from non-TG, B27-TG and B7-TG MLNs. MLNs were collected from non-TG and 
B27-TG animals, digested with DNase and liberase, passed through a cell strainer and 
stained with Annexin-V and DAPI to assess cell viability (Figure 5.1A). No difference in 
the overall viability of MLN cells was observed in this experiment. However, when MLNs 
were  collected  from  B27-TG,  B7-TG  and  non-TG,  passed  through  a  cell  strainer  and 
counted, B27-TG rats had significantly more total MLN cells compared to both non-TG 
and B7-TG animals (Figure 5.1B).  
5.2.2  Identification of L-DCs in MLN preparations 
In MLNs, dendritic cells are tightly embedded in the tissue, and thus in order to extract and 
analyse them, the MLNs need to be enzymatically digested. To do this, MLNs collected 
from non-TG and B27-TG animals were digested using DNase and liberase, as indicated in 
Materials and Methods. Due to the lack of an effective CD11c-specific antibody in rats, 
which together with high MHCII expression is commonly used to identify murine DC 
populations,  it  is  difficult  to  unambiguously  identify  DC  populations  with  certainty  in 
tissues  other  than  lymph.  Unlike  lymph,  MLN  contains  a  mixture  of  resident  DCs, 
macrophages and migrating DCs, which can share similar phenotypes. Furthermore, as 
shown in the previous chapter, L-DCs only comprise about 0.4 % of all lymph cells, and as 
such their proportion of all MLN cells is very small.   
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Figure 5.1 B27-TG animals have more MLN cells 
(A)+(B) MLN cells from B27-TG and non-TG rats were collected in serum free medium, and 
digested with liberase and DNase. Cells in single cell suspension were stained with Annexin-V and 
DAPI, and the cell viability was assessed by FACS. Total MLN cell viability in a non-TG rat (A) and 
a B27-TG rat (B) are shown. Numbers refer to percentages of total cells. (C) MLNs were collected 
from non-TG, B27-TG, and B7-TG animals, passed through 40 μM cell strainer and counted. Each 
dot represents an individual animal. Results in (C) are from 7 individual experiments. Data was 
analysed by 1-way Anova. *p<0.05, **p<0.01. 
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As  shown  in  Chapter  4,  CD103,  together  with  MHCII,  is  a  very  useful  marker  in 
identifying migrating L-DCs. Thus, it was first decided to enrich the MLN cells for CD103 
in  order  to  make  it  easier  to  identify  this  small  migrating  DC  population.  Single  cell 
suspensions from non-TG MLNs were enriched for CD103 using magnetic beads, and the 
CD103
+ fraction was stained with LIN markers (Ig% chain, CD45RA, CD45RC and TCR 
"/#), DAPI, CD103, MHCII, CD11b and CD172a. Analysis of the LIN versus MHCII plot 
(Figure 5.2A) revealed two MHCII
+ LIN
$ populations: MHCII
+ (R1)
 and MHCII
hi (R2). It 
was decided to analyse these populations separately, as resident DCs and macrophages in 
the MLN express less MHCII than the arriving migratory DCs. Thus, it was hypothesised 
that  the  MHCII
hi  population  would  include  the  migratory  L-DCs.  Indeed,  it  was  first 
noticed that the MHCII
hi cells were both bigger and more granular than the MHCII
+ cells 
(Figure  5.2B),  with  MHCII
hi  cells  more  closely  resembling  L-DCs  from  Chapter  4  in 
regards  to  FSC  and  SSC  characteristics.  Our  hypothesis  was  further  supported  by  the 
observation that MHCII
hi cells were CD103
+, whereas the MHCII
+ cells expressed lower 
levels of CD103
  (Figure 5.2C). CD11b and CD172a distinguish the three L-DC subsets in 
the lymph, and thus MHCII
+ and MHCII
hi populations were analysed for their expression 
of these markers. It was found that whereas MHCII
+ cells were predominantly CD11b
+ 
CD172a
+, the MHCII
hi cells formed a more heterogeneous population (Figure 5.2D, E). 
Thus, it is likely that MHCII
hi cells contain the migratory DC population arriving from the 
lymph, whereas MHCII
+ cells might consist of MLN resident DCs.  
5.2.3  Reduced proportion of MHCII
+ CD103
+ CD172a
lo cells in B27-TG MLN  
Because it was possible that the enrichment with CD103-specific magnetic beads might 
make it more difficult to distinguish the CD103
+ and CD103
$ populations from each other 
or otherwise affect the results, it was decided to identify the DCs without the use of pre-
enrichment. As before, MLN cells were collected from 10-16 week old F10 generation 
non-TG and B27-TG animals, digested with DNase and liberase and stained without pre-
enrichment with antibodies specific for LIN, MHCII, CD103, CD11b and CD172a. As can 
be seen in Figure 5.3, it was not possible with certainty to separate the LIN
$ MHCII
+ cells 
into two populations as was done with the CD103 enriched sample before. Thus, all LIN
$ 
MHCII
+
  cells  were  included  in  the  analysis.  However,  as  was  shown  with  the  CD103 
enriched  sample,  the  MHCII
hi  and  MHCII
+  populations  could  be  distinguished,  first, 
according to their FSC and SSC characteristic, and secondly, according to their CD103 
expression. Hence, the FSC
lo SSC
lo cells were gated out of the analysis (Figure 5.3, top 
right), followed by selection for CD103
+ cells.   
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Figure 5.2 Analysis of MLN DCs – enrichment for CD103 followed by FACS analysis 
MLNs were collected from a non-TG rat, and enriched for CD103 with magnetic beads. Cells were 
then stained with antibodies for LIN markers (CD45RA, CD45RC, TCRα/β, Igκ chain), MHCII, 
CD103, CD11b and CD172a and analysed by FACS. (A) Two MHCII
+ populations were analysed 
separately: MHCII
+ (R1) and MHCII
hi (R2). FSC/SSC phenotype (B) and the expression level of 
CD103 (C) were determined for the two populations. (D) Expression of CD11b and CD172a on 
MHCII
+ and MHCII
hi populations shown as a dot plot and (E) as a histogram overlay. This 
experiment has been only been performed once. 
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Figure 5.3 Analysis of MLN DCs – without CD103 enrichment 
MLN cells were collected from both non-TG and B27-TG rats, digested with liberase and DNase, 
and stained with LIN markers (CD45RA, CD45RC, TCRα/β, Igκ chain), DAPI, MHCII, CD103, 
CD11b and CD172a. (A) Gating strategy for non-TG MLN cells. (B) Gating for B27-TG MLN cells. 
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Comparison  of  MHCII
+CD103
+  cells  from  non-TG  and  B27-TG  animals  revealed  that 
B27-TG animals had significantly fewer MHCII
+ CD103
+ cells proportionally (mean: B27-
TG 37 % vs. non-TG 52 %) (Figure 5.4B). However, when numbers of MHCII
+ CD103
+ 
cells were calculated, the difference did not reach statistical significance (Figure 5.4C).  
Even  though  it  was  not  possible  to  identify  the  three  L-DC  populations  in  the  MLN 
according  to  CD11b  and  CD172a  expression  as  in  lymph,  it  was  possible  to  examine 
CD172a
hi and CD172a
lo cells within the CD103
+ population (Figure 5.5). Indeed, it was 
observed that B27-TG animals had fewer CD172a
lo cells (Figure 5.5A, B) and comparison 
of  data  from  four  independent  experiments  revealed  that  the  B27-TG  animals  had 
significantly fewer MHCII
+ CD103
+ CD172
lo DCs proportionally than non-TG animals 
(means: 23 % vs. 37 %) (Figure 5.5C). However, again there was no significant difference 
in the absolute number of MHCII
+ CD103
+ CD172a
lo cells between non-TG and B27-TG 
animals (Figure 5.5D). B7-TG MLNs showed a slightly different pattern of staining when 
compared to non-TG MLNs, with more CD172a
lo cells (Figure 5.5B).  
In the previous chapter it was shown that B27-TG L-DCs in the lymph express a slightly 
lower level of MHCII than non-TG cells, and in addition it has been reported that splenic 
CD103
+ DCs from B27-TG animals express less MHCII than non-TG cells (239). Thus, 
the  MHCII  expression  level  on  non-TG  and  B27-TG  MHCII
+  CD103
+  DCs  was 
determined.  It  was  noticed  that  B27-TG  cells  had  significantly  lower  geometric  mean 
values for MHCII than non-TG DCs (Figure 5.6C).  
When  the  phenotype  MHCII
+  CD103
$  populations  from  non-TG  and  B27-TG  animals 
were analysed, MHCII
+ CD103
$ cells differed from CD103
+ DCs in their CD11b and 
CD172a  expression  (Figure  5.7A,  B).  In  addition,  no  difference  was  observed  in  the 
CD172a  expression  between  B27-TG  and  control  B7-TG  and  non-TG  animals  (Figure 
5.7C). However a slight decrease of MHCII expression on B27-TG DCs was observed 
(Figure 5.6A, Figure 5.7D).  
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Figure 5.4 B27-TG rats have proportionally fewer MHCII
+ CD103
+ DCs than non-TG rats 
Percentage and number of LIN
− (CD45RA, CD45RC, TCRα/β, Igκ chain), MHCII
+ CD103
+ DCs in 
MLNs of non-TG and B27-TG rats was assessed by FACS. (A) MHCII
+ cells from MLN, gate shows 
CD103
+ cells. (B) Percentage of MHCII
+ CD103
+ cells (gate in A) out of all MHCII
+ cells. (C) Total 
number of MHCII
+ CD103
+ DCs from the MLN. Horizontal bars represent mean values and data 
were analysed by unpaired Studentʼs T-test. *p<0.05
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Figure 5.5 B27-TG rats have a lower proportion of MHCII
+ CD103
+ CD172a
lo MLN DCs than 
non-TG animals 
MLN cells were collected, digested and stained as before, and the percentage and number of LIN
− 
(CD45RA, CD45RC, TCRα/β, Igκ chain) MHCII
+ CD103
+ CD172a
+ MLN DCs was assessed in B27-
TG, B7-TG and non-TG animals. (A) gate used to identify MHCII
+ CD103
+ DCs. (B) a representative 
histogram overlay of CD172a expression on MHCII
+ CD103
+ DCs (gate in (A)) from non-TG, B27-
TG and B7-TG rats. (C) Percentage of CD172a
+ cells within MHCII
+ CD103
+ DCs. (D) Number of 
MHCII
+ CD103
+ CD172a
+ cells from the total MLN cells. Horizontal bars represent mean values, 
and data were analysed by unpaired Studentʼs T-test, *p<0.05. B7-TG staining, n=1.
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Figure 5.6 MHCII
+ CD103
+ MLN DCs from B27-TG rats express lower level of MHCII than DCs 
from non-TG rats 
MLNs were collected, digested and stained as before, and the expression of MHCII on LIN
− 
(CD45RA, CD45RC, TCRα/β, Igκ chain) CD103
+ DCs was determined. (A) A dot plot overlay for 
MHCII
+ cells from non-TG and B27-TG rats. (B) Histogram overlay showing expression of MHCII on 
CD103
+ cells gated on (A), and the geometric mean is enumerated in (C). Horizontal bars represent 
mean values, and data were analysed by unpaired Studentʼs T-test. *p<0.05
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Figure 5.7 Expression of CD172a and MHCII on MHCII
+ CD103
- MLN cells 
MLNs from non-TG, B7-TG and B27-TG animals were collected, digested and stained as before, 
and the expression of MHCII and CD172a on LIN
− (CD45RA, CD45RC, TCRα/β, Igκ chain) MHCII
+ 
CD103
− cells were determined by FACS. CD172a and CD11b expression on MHCII
+ CD103
− cells 
from non-TG MLN (A) and B27-TG MLN (B), with a histogram overlay of CD172a expression on 
non-TG, B27-TG and B7-TG rats (C). (D) Expression of MHCII on MHCII
+ CD103
− cells from
 B27-
TG MLN and from B7-TG and non-TG control rats. Results are representative of 4 experiments. 
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5.3  Discussion 
Most of the evidence indicating a role for DCs in disease pathogenesis of B27-TG animals 
has been obtained using either splenic or BM-derived DCs. However, there is mounting 
evidence for the role of intestinal cells in both the human disease (277), as well as in the 
transgenic rat model. Furthermore, in the previous chapter it was shown that the B27-TG 
animals lack one subset of migrating DCs, the CD172
lo expressing subset. As discussed 
before, this subset has been implicated in transport of self- or commensal bacterial antigens 
from the intestine into the MLN (115), thus contributing to the induction and maintenance 
of peripheral tolerance. In view of this, it was decided to investigate whether it would be 
possible to identify L-DCs in the MLNs. This would allow a comparison of non-TG and 
B27-TG  migrating  DCs  that  have  arrived  in  the  MLN,  and  been  exposed  to  the  local 
microenvironment. No conclusive differences in the ability of migrating L-DCs from non-
TG and B27-TG animals to induce T cell proliferation were observed in Chapter 4, but it is 
possible  that  once  the  cells  arrive  in  the  MLN,  they  change  their  phenotype  and/or 
function. Unfortunately due to time constraints and difficulties with our animal colony, it 
was not possible to analyse the functions of L-DCs from the MLNs.  
To begin with, it was observed that B27-TG MLNs had significantly more total cells than 
non-TG or B7-TG MLNs, and there was no difference in the viability of MLN cells after 
digestion, as show by Annexin-V and DAPI staining. The increased number of cells could 
be caused by inflammation in the B27-TG animals. However, in the previous chapter it 
was observed that there was no difference in the total number of cells migrating in the 
lymph between B27-TG and non-TG animals, meaning that the increase seen in the MLN 
is more likely to be caused by cells arriving via blood or local proliferation of resident 
MLN cells. This could mean there is an increased number of circulating cells in the blood, 
or  that  the  cells  that  arrive  in  the  MLN  spend  a  longer  time  in  there,  leading  to 
accumulation of cells. It should be investigated whether there is a difference in the number 
of cells present in the blood, and if other lymph nodes in the B27-TG animals also have 
increased numbers of cells present. The possible cell type responsible for the increase of 
MLN cells number will be discussed in the next paragraph. 
We were then interested in finding out if the number of DCs would be altered in the MLNs 
of B27-TG animals. As it was noticed in the previous chapter that there were fewer L-DCs 
present in B27-TG lymph compared to non-TG at 0-24h collection, even though there was 
no obvious difference between B27-TG and B7-TG animals, it was hypothesised there  
 
137 
could be differences in the number of DCs in the MLNs as well. Analysis of L-DCs in the 
MLNs  of  rats  can  be  difficult  due  to  lack  of  specific  markers  for  DCs,  as  MHCII  is 
expressed by several other cell types, such as macrophages, and CD103 is not exclusive to 
migrating DCs as some resident DC populations in the MLN also express it. Nonetheless, 
by pre-enriching the MLN cell populations for CD103 prior to staining, two LIN
$ MHCII-
expressing populations were identified, MHCII
+ and MHCII
hi. MHCII
hi cells expressed 
more CD103 and had the same FSC/SSC characteristics as L-DCs in the previous chapter, 
thus suggesting they could include the migrating DC populations. Curiously, the MHCII
hi 
population was also slightly more positive for the lineage markers, maybe indicating that 
these cells express low levels of one or several of the markers used. Alternatively, as the 
samples  were  not  Fc  blocked  prior  to  staining,  it  could  be  that  DCs  express  more  Fc 
receptors on their surface, leading to non-specific binding of antibodies and false positive 
results. In addition, these DCs could be more autofluorescent, thus again falsely appearing 
to be positive for these markers. When CD103 enrichment was not used, the separation 
between the two MHCII expressing LIN
$ populations was not as clear. However, to avoid 
excluding  any  DC  populations  from  the  analysis,  it  was  decided  not  to  use  the  pre-
enrichment, and to include all LIN
$ MHCII
+ cells in the analysis, and then separate them 
according to CD103 expression. This way, it was noted that B27-TG MLNs had a lower 
proportion, but not absolute number, of MHCII
+ CD103
+ cells, in accordance to the data 
seen in pervious chapter about lymph DCs. Thus, the increased total number of MLN cells 
does not reflect on the number of DCs in the MLN, but must be an effect of increase in 
other cell populations. Recent data from our laboratory indicates these cells are not T cells, 
as similar numbers have been detected in both non-TG and B27-TG MLNs (Dr Aude 
Aumeunier,  unpublished  observation).  Other  studies  in  our  laboratory  have  indicated 
increased numbers of cells staining positive for rat granulocyte marker RP-1 in the spleens 
of B27-TG animals (Pamela Wright, personal communication), and thus it could be these 
cells are responsible for the increased cell numbers in the MLN as well. 
Whether or not CD103 enrichment was used, in the MLNs it was not possible to clearly 
identify the three subsets of migrating lymph DCs seen in vivo in the lymph. However, the 
proportions of MHCII
+ CD103
+ CD172a
hi and CD172a
lo DCs could be compared between 
non-TG, B7-TG and B27-TG animals, and it was observed that B27-TG animals had a 
significantly decreased proportion of CD172a
lo cells compared to non-TG CD103
+ cells. 
This decrease was much less marked than the one observed in the lymph. This could be 
because  the  CD103
+  population  examined  here  is  unlikely  to  be  formed  purely  from 
migrating L-DCs. In fact, some rat splenic CD103
+ DCs are also CD172a
$ (278), and as  
 
138 
spleen does not have lymphatic drainage, these cells must be blood derived. It is thus likely 
that similar cells would also be present in the MLNs. In addition, murine MLN-resident 
DCs consist of both CD172a
+ and CD172a
$ populations (279). There was no significant 
reduction in the number of CD172a
lo cells, again most likely reflecting the increased total 
number of cells in the B27-TG MLN.
 
The failure to clearly identify the three migrating populations seen in lymph could be 
caused  by  many  reasons.  For  example,  DCs  are  very  sensitive  to  signals  from  their 
microenvironment and could change their phenotype as they enter MLNs from lymph. 
Also, it has to be taken into account that the MLNs are subjected to harsh physical and 
enzymatic disruption prior to staining, and it is not known what effect this treatment could 
have on DCs. However, mouse lymph also contains several populations of DCs (Dr Vuk 
Cerovic, University of Glasgow, personal communication), and these DCs can also be 
identified in the MLNs after digestion, making it unlikely that rat DCs would react to 
digestion very differently. More likely, the lack of suitable markers in the rat for MLN 
DCs  makes  it  difficult  to  identify  the  specific,  small  subsets  without  them  being 
contaminated by other cells with similar characteristics. The lack of a reliable anti-CD11c 
antibody in the rat is particularly important in this context.  
Similarly  to  the  reduced  MHCII  expression  observed  by  B27-TG  CD103
+  cells  in  the 
lymph, B27-TG MLN CD103
+ DCs expressed lower levels of MHCII. As discussed in the 
previous chapter, the reason for this HLA-B27-dependent reduction of class II molecule 
expression is not known, but in a recent publication it was shown that ex vivo splenic DCs 
from B27-TG animals show reduced expression of cathepsin S enzyme (239). Cathepsin S 
is a thiol protease in the ER critical for the cleavage of the invariant chain that occupies the 
peptide-binding cleft of immature MHCII molecules (280, 281). These complexes are then 
directed to the endocytic pathway, where the invariant chain is cleaved, allowing peptide 
binding and formation of functional complexes. In addition, ER stress is thought to cause 
retention  of  MHCII-Ag  complexes  in  the  ER,  and  thus  result  in  decreased  surface 
expression (282). The functional effect of reduced MHCII on DCs and other immune cells 
is not clear, however it could lead to decreased antigen presentation to CD4
+ T cells. In 
addition,  results  presented  in  the  following  chapter  clearly  show  that  in  vitro  B27-TG 
BMDCs are less efficient at inducing proliferation of naïve CD4
+ T cells in MLRs, even 
though  the  same  phenomenon  was  not  conclusively  detected  using  in  vivo  L-DCs  in 
Chapter 4. Unfortunately it was not possible to include functional data concerning MLN 
DC  populations  in  this  study.  There  were  no  differences  in  the  expression  of  CD103,  
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CD172a or MHCII on MHCII
+ CD103
$
 cells from non-TG, B7-TG or B27-TG animals, 
further indicating that the differences between non-TG and B27-TG DCs lie within the 
CD103
+ population.  
These  results  suggest  that  the  of  B27-TG  CD172a
lo  subset  missing  in  lymph  is  also 
proportionally reduced in the MLN of these animals, even though the number of CD172a
lo 
MLN cells was not significantly different between non-TG and B27-TG animals.  As no 
difference in the T cell stimulatory capacity between non-TG and B27-TG L-DCs were 
noticed in the previous chapter, it would be important to analyse the function of these cells 
once they have arrived in the MLN. A further intriguing possibility is that they induce 
different  CD4
+  T  cell  populations,  as  indicated  in  a  recent  publication,  where  it  was 
observed that splenic B27-TG DCs induce more Th17 cells than non-TG cells (144). In 
addition, it has been shown both in mice and in humans that the CD103
+ cells in the MLN 
and small intestinal lamina propria are uniquely capable at inducing gut homing receptors 
"4!7  and  CCR9  on  T  cells,  and  they  also  have  an  important  role  in  maintenance  of 
peripheral tolerance. These functions are dependent on conversion of vitamin A to retinoic 
acid  by  these  DCs  (see  introduction).  CD103
+  DCs  express  enzyme  retinaldehyde 
dehydrogenase, which is required for this action. Another function attributed to CD103
+ 
DCs and retinoic acid is induction of FoxP3
+ regulatory T cells. Therefore, it would be 
interesting to investigate whether CD103
+ DCs from non-TG and B27-TG animals are 
both capable of converting retinol to retinoic acid at similar rates, giving an indication 
whether there is defect on either induction of homing markers on T cells, or in induction 
and maintenance of peripheral tolerance by B27-TG DCs. Defect in induction of homing 
markers is potentially interesting, as a defect in the imprinting of gut specific homing 
markers would generate populations of activated T cells that would not home to the site of 
infection, but to somewhere else in the body. This could lead to non-specific systemic 
inflammation as seen in SpA. Expression of homing markers by T cells is a subject of 
active research in our laboratory. MHCII
+ CD103
+ DCs could also be sorted from non-TG 
and B27-TG MLNs, and co-cultured with naïve CD4
+ MLN T cells. The phenotype and 
cytokine production by these T cells could then be analysed and compared between non-
TG and B27-TG animals.  
These studies have shown it is possible to identify DCs in rat MLNs, but much remains 
still  unclear.  A  more  detailed  phenotype  of  these  cells  should  be  gathered  to  make  it 
possible to use these cells for detailed studies. The precise functions of different MLN DC 
populations are still also unclear, and much work remains for the future to assess the role  
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these DCs have in the disease observed in the B27-TG animals. As results seen here are 
derived from animals of 10-16 weeks of age, it is still unclear whether the changes in DC 
subsets are a cause or a symptom of the inflammatory disease. However, preliminary data 
from 6-week old non-TG and B27-TG MLNs suggests that the proportion of CD172a
lo 
cells is already reduced in the MLNs of young B27-TG animals compared to non-TG rats 
(data  not  shown),  in  parallel  with  data  shown  here.  As  the  rats  do  not  show  signs  of 
inflammatory disease at this time, it is feasible to assume that the DC defect precedes the 
onset of disease symptoms. More work is still required to address this in more detail, and 
functional data from MLN DCs at different ages should be investigated in the future.      
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6.  Bone marrow derived dendritic cells 
6.1  Introduction 
As both lymph and MLN DCs represent cells already differentiated and influenced by the 
factors in their environment, it was also decided to investigate whether there were any 
differences between non-TG and B27-TG DCs grown from bone marrow precursors (bone 
marrow dendritic cells, BMDCs). Due to difficulty in obtaining DCs in vivo, BMDCs are 
widely used in in vitro experiments. Despite widespread use of BMDCs in experiments 
involving  B27-TG  animals,  there  have  not  been  any  reports  indicating  defects  in  the 
development of BMDCs from these animals. However, most investigators who have used 
BMDCs have used the originally developed method of growing rat BMDCs, with GM-CSF 
and IL-4 (283). But, as discussed in detail in the introduction, it has been reported that DCs 
grown  with  GM-CSF  and  IL-4  do  not  resemble  steady  state  DCs,  but  have  a  more 
inflammatory DC phenotype (60). In contrast, the L-DCs and MLN DCs in which we have 
identified  defects  represent  steady  state  populations.  Thus,  for  the  purpose  of  the 
experiments in this chapter, BM cells were cultured with Flt3L instead, which has been 
shown to induce cells that resemble steady state DCs (60, 66). In view of previous reports 
indicating several defects, or differences, in B27-TG DCs compared to non-TG DCs, it 
was hypothesised that there would be a defect in the development of B27-TG steady state 
DCs form their bone marrow precursors, and this Flt3L culture system would allow us to 
investigate this in more detail.   
6.2  Results 
6.2.1  BMDCs from B27-TG animals are less viable than non-TG BMDCs 
when grown with mouse Flt3L 
As has been shown earlier, differences in non-TG and B27-TG DCs could not only be 
found in lymph (chapter 4), but the data presented in the previous chapter also suggests 
that there might be differences in MLN DCs. Thus, it was decided to investigate whether 
there was a systemic or developmental problem associated with the observed DC defects. 
Flt3L is essential for DC development from their precursors and thus it was investigated 
whether  DCs  grown  from  BM  precursors  with  mouse  (m)  Flt3L  would  be  different 
between non-TG and B27-TG animals. BM cells were collected from non-TG and B27-TG 
animals as indicated in Materials and Methods, and grown for seven days in complete  
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media supplemented with 10 % Flt3L supernatant derived from mouse Flt3L producing 
CHO cell line (referred to as mFlt3L). 10 % mFlt3L supernatant was selected after various 
concentrations,  from  5-25  %,  were  tested  for  their  capacity  to  generate  BMDCs.  5  % 
supernatant was not sufficient for generating BMDCs, and there was no difference in the 
cell numbers when either 10 or 25 % was used (data not shown). Hence, 10 % supernatant 
was used for all the subsequent experiments. When grown under these conditions, it was 
noticed that BMDCs derived from the B27-TG animals were less viable than non-TG cells, 
as shown with Annexin-V and DAPI staining (Figure 6.1). In addition, the FSC and SSC 
characteristics of the non-TG and B27-TG cells were different, with B27-TG cells having 
more small, FSC
lo cells (Figure 6.1). As it was possible that this phenotype seen on day 
seven could be caused by, for example, overcrowding or lack of growth factors, it was 
decided to investigate the viability of BMDCs on day four. Surprisingly, there was already 
a marked difference in the proportion of live Annexin-V
$ DAPI
$ cells between non-TG and 
B27-TG animals at this early timepoint (Figure 6.2). As no defects in the viability of 
BMDCs grown with GM-CSF and IL-4 have been reported, it was decided to investigate 
whether the reduced viability observed was Flt3L dependent. Thus, BM cells from B27-
TG and non-TG animals were grown with 10 % mFlt3L supernatant supplemented with 1 
ng/ml recombinant rat GM-CSF. Surprisingly, we observed that the viability of B27-TG 
BMDCs under these conditions was the same, if not better, than that of non-TG BMDCs 
(Figure 6.3).  
When data from at least three individual experiments were combined, it was observed that 
there were indeed a significantly lower proportion of live cells present in B27-TG BMDCs 
than in non-TG BMDCs, when grown with mFlt3L (Figure 6.4A). In contrast, when GM-
CSF was added to the cultures, significantly more B27-TG BMDCs were Annexin-V
$ 
DAPI
$, compared to B27-TG BMDCs grown with Flt3L only (Figure 6.4A). In addition, 
there was no difference in the cell viability between non-TG and B27-TG BMDCs when 
the  two  growth  factors  were  both  used.  The  number  of  Annexin-V
$  DAPI
$  cells  was 
calculated per harvested well, and it showed a similar trend to the proportion of cells, 
however it did not reach statistical significance (Figure 6.4B). The percentage and number 
of live CD103
+ cells were also calculated, as these cells are phenotypically closest to in 
vivo lymph DCs. There were no obvious differences in the proportion of CD103
+ cells 
between  non-TG  and  B27-TG  animals  (Figure  6.4C),  but  there  was  a  decrease  in  the 
absolute number of B27-TG CD103
+ with Flt3L alone, which increased to the level of non-
TG mFlt3L only when GM-CSF was added to the cultures (Figure 6.4D). The proportions  
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of apoptotic (Annexin-V
+ DAPI
$) and dead (Annexin-V
+ DAPI
+, and DAPI
+) cells were 
also compared between non-TG and B27-TG animals and the two different conditions. 
 
 
 
   
Figure 6.1. Viability of B27-TG and non-TG BMDCs on day 7 of culture supplemented 
with mFlt3L 
BM cells were harvested from non-TG and B27-TG animals, and cultured for 7 days with 10 % 
mFlt3L. On day 7, the cells were harvested and stained with DAPI and antibodies for Annexin-
V, MHCII and CD103. The proportions of live (Annexin-V
− DAPI
−) cells as well as the 
proportion of CD103
+ within the live cell gate were determined for both non-TG (A) and B27-
TG (B). (A) is a representative of 10 and (B) 8 biological replicates. 
Day 7 BMDC 
A) 
Non-TG mFLT3L  
B)  B27-TG mFLT3L  
FSC-A  CD103  DAPI 
S
S
C
-
A
 
M
H
C
I
I
 
A
n
n
e
x
i
n
-
V
 
FSC-A  CD103  DAPI 
S
S
C
-
A
 
M
H
C
I
I
 
A
n
n
e
x
i
n
-
V
  
 
144 
 
   
Day 4 BMDC 
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Figure 6.2. Viability of B27-TG and non-TG BMDCs on day 4 of culture supplemented with 
mFlt3L 
BM cells were harvested from non-TG and B27-TG animals, and cultured for 4 days with 10 % 
mFlt3L. On day 4, the cells were harvested and stained with DAPI and antibodies for Annexin-V, 
MHCII and CD103. The proportions of live (Annexin-V
− DAPI
−) cells as well as the proportion of 
CD103
+  within the live cell gate were determined for both non-TG (A) and B27-TG (B). n=1.  
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A) 
Non-TG mFLT3L + GM-CSF 
B)  B27-TG mFLT3L + GM-CSF 
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Figure 6.3. Viability of B27-TG and non-TG BM cells grown with both mFlt3L and GM-CSF 
BM cells were collected from non-TG and B27-TG animals, and cultured for 7 days in the presence 
of both 10 % mFlt3L supernatant and 1 ng/ml recombinant rat GM-CSF. On day 7 the cells were 
harvested, and the viability of the cells was assessed by staining with Annexin-V and DAPI (A, B). 
Percentage of CD103
+ cells was also assessed. Figure is representative of 3 independent 
experiments.  
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Both non-TG and B27-TG BMDCs had a very low proportion, less than 5 %, apoptotic 
cells  when  cultured  with  both  GM-CSF  and  mFlt3L,  and  there  were  no  differences 
between non-TG and B27-TG BMDCs (Figure 6.4F). Not surprisingly, B27-TG BMDCs 
had more Annexin-V
+ DAPI
+ and DAPI
+ cells than non-TG animals, and these proportions 
were decreased in the B27-TG BMDC cultures when GM-CSF was used in addition to 
mFlt3L (Figure 6.4E, G). Results from B7-TG BMDCs do not deviate significantly from 
those observed from non-TG animals. If anything, they look like there are more live cells 
and less Annexin-V
+ cells than was observed on non-TG BMDC cultures. 
6.2.2  Phenotype of BMDCs cultured with mFlt3L  
The expression of surface markers on B27-TG, B7-TG, and non-TG BMDCs cultured for 7 
days with 10 % mFlt3L were assessed (Figure 6.5). The only observed differences between 
non-TG and B27-TG BMDCs were in the expression of MHCII and CD172a – all the other 
markers were expressed at similar levels. As expected, only a very small proportion of 
CD68
+ macrophages/granulocytes were found, and CD4 and CD8" were expressed by less 
than 5 % of BMDCs.  
To assess the presence of DC populations similar to in vivo DCs, non-TG and B27-TG 
BMDCs grown with 10 % mFlt3L were stained with Annexin-V, DAPI, MHCII, CD103, 
CD11b and CD172a. Three populations of live (Annexin-V
$ DAPI
$) cells were found in 
both non-TG and B27-TG BMDC preparations (Figure 6.6A, C): MHCII
$ CD103
$  (R1), 
MHCII
+ CD103
$  (R2) and MHCII
lo CD103
+ (R3). Expression of CD11b and CD172a were 
determined in all three populations (Figure 6.6B, D), but no obvious differences were 
observed between non-TG and B27-TG BMDCs in regards to those markers in any of the 
three populations. The MHCII
+ CD103
+ R3 population, that most closely resembles lymph 
DCs phenotypically, expressed uniformly high level of CD172a and CD11b, whereas the 
R1 and R2 populations were more homogeneous (Figure 6.6B, D).  
The ability to upregulate expression of MHCII and costimulatory molecules in response to 
TLR  stimulation  is  an  important  function  for  immature  DCs.  Thus,  it  was  decided  to 
investigate  whether  non-TG  and  B27-TG  BMDCs  differ  in  their  response  to  TLR4 
stimulation with LPS. When non-TG and B27-TG BMDCs grown for 7 days with mFlt3L 
were treated with 100 ng/ml LPS overnight, both non-TG and B27-TG CD103
+ (R3) cells 
strongly  upregulated  expression  of  MHCII,  creating  uniformly  MHCII
hi  CD103
+  cells 
(Figure 6.7A, C).  
 
147 
 
   
#
 
l
i
v
e
 
C
D
1
0
3
+
 
c
e
l
l
s
 
/
 
w
e
l
l
 
x
1
0
5
 
 
 
 
A)  B) 
%
 
l
i
v
e
 
C
D
1
0
3
+
 
c
e
l
l
s
 
%
 
A
n
n
e
x
i
n
-
V
+
 
D
A
P
I
-
 
C) 
E) 
D) 
F) 
%
 
A
n
n
e
x
i
n
-
V
-
 
D
A
P
I
-
 
c
e
l
l
s
 
#
 
A
n
n
e
x
i
n
-
V
-
 
D
A
P
I
-
 
 
c
e
l
l
s
 
/
 
w
e
l
l
,
 
x
1
0
5
 
 
4 
2 
Non-TG 
B7-TG 
B27-TG 
12 
8 
4 
%
 
A
n
n
e
x
i
n
-
V
-
 
D
A
P
I
+
 
%
 
A
n
n
e
x
i
n
-
V
+
 
D
A
P
I
+
 
G) 
1 
3 
0 
0 
mFLT3L 
only 
mFLT3L + 
GM-CSF 
mFLT3L 
only 
mFLT3L + 
GM-CSF 
mFLT3L 
only 
mFLT3L + 
GM-CSF 
mFLT3L 
only 
mFLT3L + 
GM-CSF 
mFLT3L 
only 
mFLT3L + 
GM-CSF 
mFLT3L 
only 
mFLT3L + 
GM-CSF 
mFLT3L 
only 
mFLT3L + 
GM-CSF 
Figure 6.4. Combined results for mFlt3L cultured BMDCs 
Combined results are shown for day 7 non-TG and B27-TG BMDC cultures supplemented 
with either only 10 % mFlt3L supernatant, or with both mFlt3L and 1 ng/ml recombinant rat 
GM-CSF. (A) Proportion of live (Annexin-V
− DAPI
−) cells out of all BMDCs, and (B) the 
number of live cells/well of culture. Percentage (C) and number/well (D) of live CD103
+ 
cells were also determined. (F) shows the proportion of apoptotic Annexin-V
+ DAPI
− cells, 
whereas dead Annexin-V
+ DAPI
+ and DAPI
+ Annexin-V
− are shown in (E) and (G), 
respectively. “mFlt3L only” shows results from 8-10 and “mFlt3L+GM-CSF” from 3 
individual experiments with one animal used in each. Data were analysed by a 1-way 
Anova, *p<0.05, ***p<0.001..  
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No obvious differences were noticed in the expression of CD11b and CD172a in any of the 
three  above-mentioned  populations  (R1-R3)  between  non-TG  and  B27-TG  BMDCs 
(Figure 6.7B, D). As addition of GM-CSF into BMDC cultures together with mFlt3L was 
shown earlier to improve viability of B27-TG BMDCs, it was decided to investigate if this 
would have an effect on LPS stimulated cells. The number and percentage of total non-TG 
and B27-TG BMDCs, either grown with mFlt3L only or with both mFlt3L and GM-CSF, 
were compared after overnight LPS stimulation. A significantly lower proportion of live 
Annexin-V
$ DAPI
$ cells were found in mFlt3L only B27-TG BMDC cultures compared to 
non-TG  BMDCs  (Figure  6.8A).  However,  an  opposite  pattern  was  observed  when  the 
proportion of live B27-TG and non-TG BMDCs cultured with both mFlt3L and GM-CSF 
were compared (Figure 6.8A). There were no significant differences in the number of live 
cells but, as with percentage, B27-TG animals had more viable cells compared to non-TG 
after LPS stimulation when both mFlt3L and GM-CSF were used (Figure 6.8B). 
As the MHCII
+ CD103
+ population is phenotypically closest to in vivo L-DCs in the steady 
state, the number and percentage of CD103
+ cells in LPS treated non-TG and B27-TG 
BMDC cultures were compared. There was no difference in the proportions of either non-
TG or B27-TG CD103
+ cells when GM-CSF was added to the cultures (Figure 6.8C). In 
addition, BMDCs from B27-TG animals contained only a slightly lower proportion of 
CD103
+ cells compared to non-TG BMDCs under both culture conditions (Figure 6.8C). 
Calculation of cell numbers revealed that as with percentages, mFlt3L cultured B27-TG 
BMDCs had fewer CD103
+ cells compared to non-TG BMDCs under the same conditions 
(Figure 6.8D). Interestingly, mFlt3L+GM-CSF cultured BMDCs from non-TG and B27-
TG animals differed slightly. The absolute number of CD103
+ cells stayed the same in 
B27-TG BMDC cultures, whereas the number of non-TG CD103
+ BMDCs was strongly 
reduced compared to mFlt3L only cultures (Figure 6.8D). In addition, the expression of 
MHCII, CD11b, CD172a and CD25 on BMDCs grown with only mFlt3L were compared 
between non-TG and B27-TG, and with and without LPS stimulation (Figure 6.8E). In this 
experiment B27-TG cells express slightly lower level of MHCII both with and without 
LPS, however this phenomenon is not consistent between individual experiments (data not 
shown). CD11b and CD172a were downregulated slightly on the B27-TG BMDCs after 
LPS stimulation, but as the experiment has only been done once, no conclusions can be 
drawn from these observations. In addition, both non-TG and B27-TG BMDCs expressed 
only low levels of the activation marker CD25, and its expression was not upregulated 
after LPS stimulation.   
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Figure 6.5 Phenotype of mFlt3L cultured BMDCs 
BM cells from non-TG, B27-TG and B7-TG animals were incubated with 10 % mFlt3L for 7 days to 
obtain BMDCs. On day 7, semi-adherent cells were harvested and stained with various markers as 
indicated in the figure. This experiment has been performed once, n=1.  
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Figure 6.6. Phenotype of non-TG and B27-TG BMDCs generated with mFlt3L 
Non-TG and B27-TG BMDCs were grown as before with 10 % mFlt3L cell culture supernatant for 7 
days. On day 7 cells were harvested and stained with Annexin-V, DAPI, MHCII, CD103, CD11b 
and CD172a. Cells were were pre-gated on live (Annexin-V
− DAPI
−) cells, and analysed for the 
expression of MHCII and CD103. Three populations were identified in both non-TG (A) and B27-TG 
BMDCs (C): MHCII
− CD103
− (R1), MHCII
+ CD103
− (R2) and MHCII
lo/int  CD103
+ (R3). Each of these 
subsets were further analysed for their expression of CD11b and CD172a (B, D). N=1.  
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Figure 6.7. Phenotype of mFlt3L derived BMDCs activated with LPS. 
Non-TG and B27-TG BMDCs were grown with 10 % mFlt3L for 6 days and treated with LPS 
overnight. On day 7 cells were harvested, and stained with Annexin-V, DAPI, MHCII, CD103, 
CD11b and CD172a. Three subsets were identified on both non-TG (A) and B27-TG (C) live 
BMDCs: MHCII
− CD103
− (R1), MHCII
+ CD103
− (R2), and MHCII
+ CD103
+ (R3). All three subsets 
were analysed for the expression of CD11b and CD172a (B, D). (A, C) are representatives of 3 
individual experiments with one non-TG and B27-TG animal used in each, (B, D) n=1.   
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6.2.3  Caspase inhibitor Q-VD can rescue B27-TG BMDCs 
In the previous figures it was shown that B27-TG BMDCs cultured with 10 % mFlt3L 
contain a large proportion of Annexin-V
+ cells, indicating they are dying by apoptosis. 
Thus, it was investigated whether this loss of viability was caspase-dependent by inhibiting 
caspase activation in the BM cultures, and observing if this would rescue the cells. As it 
was not known which caspase pathway would be activated, pan-caspase inhibitor Q-VD-
oph (Q-VD) was selected because it has been reported to inhibit all three major caspase 
pathways, caspase 9/3, caspase 8/3 and caspase 12, and in addition it is not toxic to the 
cells even when used at very high concentrations (284). To investigate the effects of Q-VD 
on BMDC cultures, non-TG and B27-TG BM cells were treated at day zero with various 
concentrations of Q-VD, and the viability of the cells was determined by Annexin-V and 
DAPI staining at day seven of culture. When treated with a small concentration of Q-VD 
(0.01 µM), about 60 % of non-TG BMDCs were live Annexin-V
$ DAPI
$ on day 7 (Figure 
6.9A, top panels), compared to only about 13 % of B27-TG BMDCs (Figure 6.9A, bottom 
panels). However, when the concentration of Q-VD was raised to 10 µM, 60-70 % of both 
non-TG  and  B27-TG  BMDCs  were  viable,  and  in  addition  both  non-TG  and  B27-TG 
BMDCs  had  similar  FSC/SSC  characteristics  (Figure  6.9B).  When  data  from  2-5 
individual experiments were pooled, it was noticed that when supplemented with 10 µM 
Q-VD, B27-TG BMDCs survived as well as the non-TG BMDCs. In fact, there was a 
significant increase in the proportion of viable B27-TG BMDCs between non-treated cells 
and cells treated with 10 µM Q-VD, with mean percentage of 27 % viable cells with no Q-
VD, and 61 % with 10 µM Q-VD (Figure 6.9C). There was no significant difference in the 
absolute number of Annexin-V
$ DAPI
$ cells, however the number of B27-TG live cells did 
increase in a Q-VD concentration dependent manner (Figure 6.9D). 
In addition to Q-VD, it was also investigated if the elF2" inhibitor salubrinal would have 
an effect on the survival of B27-TG BMDCs. elF2" is a key signalling molecule involved 
in the ER stress response, and has been reported to specifically inhibit apoptosis driven by 
cell stress and UPR (285), and this process is different from the caspase driven apoptosis 
Q-VD inhibits. As splenic cells and BM derived macrophages in rats have been shown to 
undergo the UPR more than non-TG cells (250, 251, 286), it was thought that use of elF2" 
inhibitor might be a more specific way to inhibit apoptosis on B27-TG cells. As with Q-
VD, non-TG and B27-TG BM cells were treated at day zero with various concentrations of 
salubrinal.   
 
153 
 
 
 
4.5 
3 
1.5 
6 
0 
%
 
A
n
n
e
x
i
n
-
V
-
 
D
A
P
I
-
 
c
e
l
l
s
 
#
 
A
n
n
e
x
i
n
-
V
-
 
D
A
P
I
-
 
c
e
l
l
s
/
w
e
l
l
,
 
x
1
0
5
 
B27-TG 
Non-TG 
mFlt3L  mFlt3L +  
GM-CSF 
mFlt3L  mFlt3L +  
GM-CSF 
A)  B) 
1.5 
1 
0.5 
2.5 
0 
2 
%
 
C
D
1
0
3
+
 
c
e
l
l
s
 
o
u
t
 
o
f
 
A
n
n
e
x
i
n
-
V
-
 
D
A
P
I
-
 
c
e
l
l
s
 
#
 
C
D
1
0
3
+
 
c
e
l
l
s
/
w
e
l
l
 
x
1
0
4
 
mFlt3L  mFlt3L +  
GM-CSF 
mFlt3L  mFlt3L +  
GM-CSF 
C)  D) 
B27-TG 
Non-TG 
Non-TG + LPS 
B27-TG + LPS 
MHCII  CD11b  CD172a  CD25 
E)  R3: CD103+ 

Figure 6.8. Effect of LPS on non-TG and B27-TG BMDCs 
BM cells were grown with either 10 % mFlt3L only, or with 10 % mFlt3L + 1 ng/ml GM-CSF for 6 
days, and treated with 100 ng/ml LPS. On day 7 BMDCs were harvested and stained with Annexin-
V, DAPI, MHCII and CD103. The percentage and number of viable (Annexin-V
− DAPI
−) cells were 
calculated (A. B), as well as the percentage and number of live CD103
+ BMDCs (C, D). (E) 
Comparison of MHCII, CD11b, CD172a and CD25 expression levels on non-TG and B27-TG 
CD103
+ BMDCs cultured with mFlt3L before and after (+LPS) LPS treatment. mFlt3L, n=4; 
mFlt3L+GM-CSF, n=2-4; (C) has been performed once, n=1. Error bars are SEM, and data were 
analysed by a Studentʼs T test, *p<0.05.  
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No effect was seen in the proportion (Figure 6.9E) or in the number (Figure 6.9F) of 
Annexin-V
$ DAPI
$ B27-TG BMDCs in any of the concentrations investigated. Salubrinal 
had no effect on the viability of non-TG BMDCs (data not shown).  
6.2.4  B27-TG BMDCs are not as efficient as non-TG cells at inducing CD4
+ 
T cell proliferation  
It was now established that B27-TG BMDCs were less viable than non-TG cells, and that 
addition of pan-caspase inhibitor Q-VD to the BM cultures inhibited the cell death. No 
obvious differences were noted in the phenotype of non-TG and B27-TG BMDCs either 
with  or  without  LPS  stimulation.  The  function  of  non-TG  and  B27-TG  BMDCs  was 
investigated next. Thus, the capacity of non-TG and B27-TG BMDCs to induce T cell 
proliferation was assessed by way of allogeneic mixed leukocyte reaction (MLR). 
To obtain BMDCs, BM cells from PVG-strain (RT1c) were grown in the presence of 10 % 
Flt3L for 7 days, as before, and stained for Annexin-V and DAPI. Live Annexin-V
$ DAPI
$ 
cells were flow sorted, and plated out at various concentrations with 1x10
5 CFSE labelled 
MLN cells from a DA-strain (RT1
av1) rat. These co-cultures were incubated for 5 days at 
37°C,  and  on  day  five  cells  were  stained  with  CD4  antibody  and  the  percentage  of 
proliferated (CFSE
lo) CD4
+ cells was determined by FACS (Figure 6.10). Surprisingly, 
even when 1x10
4 BMDCs were used, only about 10% of CD4
+ cells had proliferated in 
response to the B27-TG DCs, compared to over 40 % with the same number of non-TG 
BMDCs (Figure 6.10A, B). Although no obvious differences were noticed in the FSC/SSC 
characteristics of non-TG and B27-TG cells from the co-cultures, it was proposed that 
B27-TG BMDCs might not survive sufficiently long in the MLR co-culture. To find out if 
this was the case, the DC-T cell co-cultures were supplemented on day zero of the MLR 
with  10  µM  Q-VD,  which  was  shown  earlier  to  effectively  rescue  B27-TG  BMDCs. 
However, the Q-VD treated B27-TG BMDCs did not induce more proliferation from CD4
+ 
cells  compared  to  non-treated  cells  (Figure  6.10C).  Importantly,  neither  Q-VD  nor  its 
vehicle (DMSO) had an inhibitory effect on CD4 cell proliferation in the non-TG cultures 
(Figure 6.10C). 
We then tested whether it was too late to treat the BMDCs with Q-VD at the time of MLR 
set-up, even though live cells were sorted prior to culturing them. As was shown earlier in 
this chapter, the phenotype of B27-TG BMDCs is already different on day four of BMDC 
culture (Figure 6.2), indicating an inherent problem in the generation of Flt3L dependent 
cells.   
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Figure 6.9 Caspase inhibitor Q-VD rescues B27-TG BMDCs 
BM cells were harvested from non-TG and B27-TG animals, and cultured for 7 days in the 
presence of 10 % mFlt3L supernatant. In addition, some wells were further supplemented on day 0 
with various concentrations of Q-VD (0.01-10 μM). On day 7, cells were harvested and stained with 
Annexin-V and DAPI, and the viability of the cells was determined by FACS. Representative dot 
plots for cells treated with either 0.01 μM Q-VD (A) or 10 μM Q-CD (B), with non-TG on top and 
B27-TG on bottom rows. (C, D) Summary of results, with (C) showing percentage of live 
Annexin
−V
− DAPI
− cells, and (D) the absolute number. Results are from 2 (non-TG 0.01-1μM Q-
VD), 3 (B27-TG 0.01-1μM Q-VD, non-TG 10 μM) or 5 (no Q-VD, B27-TG 10 μM) individual 
experiments. (E, F) BM cells were treated on day 0 with various concentrations of elf2α-inhibitor 
Salubrinal, and cultured for 7 days in the presence of 10 % mFlt3L. On day 7 cells were harvested 
and stained with Annexin-V and DAPI, and the cell viability was assessed by FACS. (E) percentage 
and (F) absolute number of live (Annexin-V
− DAPI
−) cells. Results from 2-3 individual experiments 
with 1-2 animals in each. Error bars are SEM, and data were analysed by 1-way Anova, **p<0.01.  
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Thus, non-TG and B27-TG BMDCs were grown in the presence of either 10 % mFlt3L 
alone, or with both mFlt3L and 10 µM Q-VD for 7 days. On day 7, live BMDCs were flow 
sorted  as  before,  and  plated  out  at  various  concentrations.  On  this  occasion,  naïve-
phenotype CD4
+ CD25
$ CD45RC
+ T cells were sorted from MLNs of DA rats, stained 
with CFSE and 1x10
5 of these cells were cultured with the DCs. In addition, some wells 
with the Q-VD treated B27-TG BMDCs were further treated with 10 µM Q-VD. After 5 
days of co-culture, cells were stained with CD4, and again the percentage of proliferating 
CD4
+ T cells was assessed by FACS. Using this system, B27-TG BMDCs that had not 
received Q-VD (media only) were again significantly worse than the non-TG BMDCs at 
inducing proliferation from CD4
+ naïve T cells (Figure 6.11A, B). Furthermore, even the 
additional Q-VD added to the DC-T cell cultures at the time of MLR set up (Q-VD+Q-
VD) was not sufficient to induce more CD4
+ T cell proliferation from cultures with B27-
TG BMDCs (Figure 6.11C). 
As was shown earlier, BMDCs could be divided into three populations: CD103
+ MHCII
+ 
(R3),  CD103
$  MHCII
+  (R2)  and  CD103
$  MHCII
$  (R1)  (Figure  6.12A).  For  the  MLR 
experiments above, total live BMDCs had been used. However, it was next decided to 
investigate if these three populations would differ in their ability to induce naïve T cell 
proliferation. It was hypothesised that the CD103
+ DCs would be the best, as they were the 
only  population  to  strongly  upregulate  their  MHCII  expression  upon  LPS  stimulation 
(Figure 6.7). MLRs were set up as before with 1x10
5 flow sorted CFSE labelled CD4
+ 
CD25
$ CD45RC
+ naïve T cells. In Figure 6.12B, live BMDCs were flow sorted into two 
populations:  i)  R3  and  ii)  R1+R2  combined.  After  5  days  of  co-culture  CD103
+  DCs 
induced a robust proliferation, whereas CD103
$ DCs failed to induce T cell proliferation. 
The experiment was then repeated, but this time CD103
+ (R3) and CD103
$ MHCII
+ (R2) 
DCs  were  used  (Figure  6.12C).  Again,  CD103
+  DCs  induced  more  proliferation  than 
CD103
$  MHCII
+  DCs,  but  the  difference  was  less  pronounced  than  before  when  all 
CD103
$ cells were used.  
To assess whether there would be a difference in the T cell populations non-TG and B27-
TG DCs induce, the concentration of cytokines in the BMDC MLR co-culture supernatants 
were also measured. The supernatants from MLRs performed with flow sorted CD103
+ 
DCs with sorted naïve T cells were used. The cytokines were measured in triplicate from 
individual  experiments,  and  representative  results  are  shown  for  one  experiment.  The 
results are shown in Figure 6.13. Consistently, B27-TG BMDC co-culture wells contained  
significantly more IL-17F than non-TG co-cultures.   
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Figure 6.10 B27-TG BMDCs are less capable at inducing T cell proliferation than non-TG 
BMDCs 
BM was harvested from both non-TG and B27-TG animals, and cultured for 7 days in the presence 
of 10 % mFlt3L supernatant. On day 7, BMDCs were harvested, stained with Annexin-V and DAPI, 
and the live (Annexin-V
− DAPI
−) cells were flow sorted and plated out in triplicate at various 
concentrations, as shown. MLN cells from DA rats were labelled with CFSE, and 1x10
5 labelled 
cells were added to the cultures with BMDCs. After 5 days of co-culture, the cells were harvested 
and stained with anti-CD4 antibody, and the proliferation of CD4 cells was assessed by FACS (A-
C) shows an example of proliferation with no DC control and 10,000 DCs. (D) CD4
+ T cells 
proliferation shown in graph format. Using another approach, day 7 BMDCs were co-cultured with 
CFSE labelled MLN cells, as above, but this time either DMSO (vehicle) or 10 μM Q-VD was added 
to the co-cultures for the 5-day incubation. On day 5, cells were harvested from the plate, and 
stained as above, and the proliferation of CD4
+ cells was again assessed by FACS (E). All MLR 
reactions were performed in triplicate. (A-D) are a representative of 3 individual experiments (n=3), 
whereas C has only been performed once (n=1). Error bars are SD.  
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Figure 6.11 B27-TG BMDCs are less able to induce proliferation from naïve T cells 
compared to non-TG BMDCs 
As before, BM cells from non-TG and B27-TG animals were cultured for 7 days in the presence of 
10 % mFlt3L supernatant, and additionally some wells of the B27-TG cells were supplemented with 
10 μM Q-VD. On day 7, BMDCs were harvested, stained with Annexin-V and DAPI, and the live 
(Annexin-V
− DAPI
−) cells were flow sorted and plated out in triplicate at various concentrations, as 
indicated. Naïve CD4
+ CD25
− CD45RC
hi MLN T cells from DA rats were also flow-sorted, labelled 
with CFSE and 1x10
5 labelled cells were added to the wells with BMDCs. Some wells of the B27-
TG BMDCs grown with Q-VD were further supplemented with 10 μM Q-VD for the duration of the 
co-culture. After 5 days, cells were harvested and the proliferation of CD4
+ T cells was assessed by 
FACS. (A) and (B) show the results without Q-VD treatment, and (C) shows results with BMDCs 
either treated with Q-VD for 7 days (Q-VD) or 7+5 days (Q-VD+Q-VD). (A) and (B) are results from 
3 experiments, (C) has only been performed once. Error bars are mean +/
− SD, and the data was 
analysed by a 2-way Anova, *p<0.05, ***p<0.001.
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Figure 6.12 CD103
− DCs are not as efficient at inducing proliferation of 
naïve CD4
+ T cells  
Annexin-V
− DAPI
− BMDCs grown with mFlt3L for 7 days were sorted into two 
different populations in two separate experiments according to MHCII and 
CD103, either R1+R2 and R3, or R2+R3 as show in (A). 2-fold dilutions of DCs 
in triplicate were incubated for 5 days with 1x10
5 sorted, CFSE stained naïve 
CD4
+ T cells from DA rats. (B) is experiment one, where R3 (CD103
+) (i) and 
R1+R2 (all CD103
−) (ii) BMDCs were sorted, as shown in (A), and the 
proliferation of T cells was assessed on day 5 by FACS. (C) is experiment 2, 
where R3 population (i) and R2 (CD103
− MHCII
+) (ii) BMDCs were sorted, and 
T cell proliferation was assessed as before. Data were analysed by 2-way 
Anova, *p<0.05, **p<0.01, ***p<0.001. Experiments were performed in 
triplicate; (B, C), n=1.
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The IL-17F concentration was also dependent on the number of B27-TG BMDCs used. In 
contrast, more IFN-! was found in the non-TG co-cultures, especially when 1x10
4 or 5x10
3 
DCs were used There was some variation in the concentration of the cytokines between 
experiments, however the trend was always similar to that indicated in the figure. Non-TG 
BMDCs induced more of IL-6, IL-2 and TNF" compared to B27-TG DCs, however there 
was no difference in the IL-10 level. No IL-12p70, IL-4, IL-1 or IL-5 were detected. 
6.2.5  B27-TG BMDCs grown with hFlt3L are more viable than cells grown 
with mFlt3L  
There have been no reports to indicate that rat BM cells would not respond properly to 
mouse derived Flt3L, and indeed results shown earlier in this chapter with non-TG BMDC 
developing  normally  when  grown  with  mFlt3L  supports  this.  Nonetheless,  as  many 
investigators have used recombinant human Flt3L (hFlt3L) instead of mFlt3L cell culture 
supernatant, the effect of hFlt3L on BMDCs was investigated.  
The concentration of hFlt3L used in literature for culturing either murine or rat BMDCs 
ranges  from  100-200  ng/ml  (60,  66).  It  was  decided  to  use  100  ng/ml  as  the  initial 
concentration for culturing BMDCs. Non-TG and B27-TG BM cells were and cultured for 
7 days in the presence of 100 ng/ml hFlt3L. As before, cells were harvested on day seven, 
and stained for Annexin-V, DAPI, MHCII and CD103. When the viability of the cells was 
assessed by FACS, the difference between non-TG and B27-TG BMDCs was no longer 
apparent (Figure 6.14). First, FSC and SSC characteristics of the BMDCs looked similar in 
both non-TG (Figure 6.14, top panels) and B27-TG cultures (Figure 6.14, bottom panels). 
Second, viability of the cells was similar, as measured by Annexin-V and DAPI staining. 
In addition, there seemed to be a slight decrease in the proportion of B27-TG CD103
+ cells 
in the B27-TG cultures compared to the non-TG.  
Since it had been noted earlier that addition of GM-CSF to mFlt3L BMDC cultures had a 
positive effect on the proportion of live cells, it was decided to see how the addition of 
GM-CSF would affect the hFlt3L BMDC cultures. Thus, non-TG and B27-TG BM cells 
were cultured for seven days in the presence of 100 ng/ml hFlt3L and 1 ng/ml GM-CSF, 
and the viability was assessed by FACS (Figure 6.15). It was noticed that under these 
conditions that the viability of both non-TG and B27-TG BMDCs seemed to be lower than 
with 100 ng/ml hFlt3L alone. However, there were no differences between non-TG and 
B27-TG  BMDCs  in  terms  of  Annexin-V  and  DAPI  staining,  nor  in  the  proportion  of 
CD103
+ cells, or in the FSC and SSC characteristics.  
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Figure 6.13. B27-TG BMDCs induce more IL-17 and less IFN-γ than non-TG BMDCs  
CD103
+ mFlt3L BMDCs from non-TG and B27-TG animals and naïve CD4
+ T cells from DA 
rats were flow sorted, as described before, and co-cultured for 5 days. On day 5, the cell 
culture supernatants were collected, and frozen at -20ºC until use. Luminex was performed 
in triplicate (20 and 5x10
3 DCs) or in duplicate (10x10
3 DCs), and results here are a 
representative of 3 (20 and 5 x10
3 DCs) or 2 (10 x 10
3 DCs) biological replicates. Data were 
analysed by Studentʼs T-test, *p<0.05. 
A)  B) 
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Figure 6.14 Viability of non-TG and B27-TG BMDCs cultured with 100 ng/ml hFlt3L 
BM cells were harvested from non-TG and B27-TG animals, and cultured for 7 days in the 
presence of 100 ng/ml recombinant human Flt3L. On day 7 cells were harvested, and stained with 
Annexin-V, DAPI, MHCII and CD103 and analysed by flow cytometry. The percentages of live 
(Annexin-V
− DAPI
−) and CD103
+ cells were assessed for both non-TG (A) and B27-TG (B) 
BMDCs. Frequencies in the figure relate to frequency of the parent. Figure is a representative of 7 
individual experiments with 1-3 animals/experiment.  
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As the viability of B27-TG BMDCs was improved with 100 ng/ml hFlt3L compared to 
mFlt3L, it was decided to use a higher concentration of Flt3L to see if this would have an 
additional effect on the BMDCs. When BM cells were cultured in the presence of 10 ug/ml 
hFlt3L for 7 days, and analysed as above, it was noticed that the higher concentration of 
hFlt3L did not further increase the proportion of live B27-TG BMDCs, nor were there any 
differences in the FSC and SSC characteristics (Figure 6.16).  
When data from several individual experiments and the three conditions were combined 
and compared, no significant differences were observed either in the proportion or absolute 
number of live Annexin-V
$ DAPI
$ cells between non-TG and B27-TG BMDCs (Figure 
6.17A, B). It was observed, however, that on average 48 % of B27-TG hFlt3L derived 
BMDCs were live (Annexin-V
$ DAPI
$), compared to 34 % with mFlt3L (Figure 6.17 and 
Figure 6.4). When comparing the proportion and number of CD103
+ BMDCs, more were 
present in both non-TG and B27-TG BMDC hFlt3L cultures than when either GM-CSF 
was added to the cultures, or when a higher concentration of hFlt3L was used (Figure 
6.17C,  D).  Again,  as  with  mFlt3L,  there  was  a  relatively  low  proportion  of  cells 
undergoing  apoptosis  (Annexin-V
+  DAPI
$)  in  both  non-TG  and  B27-TG  preparations 
(Figure 6.17E). There was a slight increase in the percentage of apoptotic cells when GM-
CSF was added to the culture, but this was not significant. Furthermore, the proportion of 
late apoptotic/dead (Annexin-V
+ DAPI
+) cells was not different between non-TG and B27-
TG BMDCs, between any of the three conditions (Figure 6.17F). As with mFlt3L+GM-
CSF grown BMDCs, also with hFlt3L+GM-CSF the proportion of DAPI
+ Annexin-V
$ 
cells was lower, but this time the difference was not significant (Figure 6.17G).  
6.2.6  Phenotype of hFlt3L derived BMDCs 
It was also investigated if hFlt3L grown BMDCs would share a similar phenotype to that 
seen when mFlt3L was used. As before, non-TG, B27-TG and B7-TG BMDCs on day 7 
were stained with various surface markers (Figure 6.18). The staining pattern was identical 
to that seen on mFlt3L derived BMDCs, with only a small proportion of CD68
+ cells, and 
even  smaller  proportion  of  CD4
+  or  CD8"
+  cells.  I  also  determined  whether  BMDCs 
cultured  with  hFlt3L  would  respond  similarly  to  LPS  stimulation  as  cells  grown  with 
mFlt3L. As before, BMDCs were treated with LPS on day 6, and on day 7 the cells were 
harvested and stained with DAPI and antibodies to Annexin-V, MHCII and CD103.  
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Non-TG 100 ng/ml hFLT3L + GM-CSF  
B27-TG 100 ng/ml hFLT3L + GM-CSF  
Figure 6.15. Viability of non-TG and B27-TG BMDCs grown with both 100 ng/ml hFlt3L and 
GM-CSF 
BM cells were harvested from non-TG and B27-TG animals, and cultured for 7 days in the 
presence of both 100 ng/ml recombinant human Flt3L and 1ng/ml recombinant rat GM-CSF. On 
day 7 cells were harvested, and stained with Annexin-V, DAPI, MHCII and CD103 and analysed by 
flow cytometry. The percentages of live (Annexin-V
− DAPI
−) and CD103
+ cells were assessed for 
both non-TG (A) and B27-TG (B) BMDCs. Frequencies in the figure relate to frequency of the 
parent. Figure is a representative of 3 individual experiments.  
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Figure 6.16 Non-TG and B27-TG BMDC viability with 10 μg/ml hFlt3L 
BM cells were harvested from non-TG and B27-TG animals, and cultured for 7 days in the 
presence of 10 μg/ml recombinant human Flt3L. On day 7 cells were harvested, and stained with 
Annexin-V, DAPI, MHCII and CD103 and analysed by flow cytometry. The percentages of live 
(Annexin-V
− DAPI
−) and CD103
+ cells were assessed for both non-TG (A) and B27-TG (B) BMDCs. 
Frequencies in the figure relate to frequency of the parent. Figure is a representative of 3 individual 
experiments.  
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Figure 6.17. Combined results for hFlt3L cultured BMDCs 
Combined results are shown for non-TG and B27-TG BMDC cultures supplemented with 100 ng/ml 
hFlt3L, 100 ng/ml hFlt3L+ 1 ng/ml GM-CSF, or with 10 μg/ml hFlt3L. (A, B) proportion and 
number/well of live (Annexin-V
− DAPI
−) cells out of all BMDCs. Percentage (C) and number/well (D) 
of live CD103
+ cells were also determined. Proportion of apoptotic Annexin-V
+ DAPI
− cells are 
shown in (F), whereas dead Annexin-V
+ DAPI
+ and DAPI
+ Annexin-V
− are shown in (E) and (G), 
respectively. Results from 3-7 individual experiments, and data were analysed by 1-way Anova, 
*p<0.05, ***p<0.001. Error bars mean+SEM. 
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As  with  mFlt3L  derived  BMDCs,  CD103
+  cells  showed  the  strongest  upregulation  of 
MHCII after LPS stimulation in hFlt3L cultures (Figure 6.19). No differences were noted 
between non-TG and B27-TG BMDCs.  
Since B27-TG derived BMDCs were shown to be deficient when grown with mFlt3L, it 
was  tested  whether  non-TG  and  B27-TG  BM  cells  express  similar  levels  of  the  Flt3 
receptor. In the absence of suitable antibody reagents, expression of Flt3 receptor transcript 
was measured by RT-qPCR. Freshly isolated BMDCs were lysed with RBC lysis buffer to 
deplete red blood cells, and RNA was isolated from the cells. RNA was reverse transcribed 
into cDNA, and the amount of Flt3 receptor RNA was assessed, during the PCR reaction, 
by  SYBR  green  incorporation.  The  experiment  was  repeated  twice,  and  no  significant 
difference was observed in the amount of Flt3 receptor RNA present in B27-TG and non-
TG freshly isolated BM cells (Figure 6.20A). In addition, it was investigated whether cells 
grown  with  either  10  %  mFlt3L  supernatant  or  with  100  ng/ml  hFlt3L  would  express 
different amount of Flt3 receptor after 7 days of culture. Not surprisingly, it was found that 
both  B27-TG  and  non-TG  BMDCs  grown  with  Flt3L  had  more  Flt3  receptor  when 
compared to freshly isolated BM cells (Figure 6.20B, C). Furthermore, both non-TG and 
B27-TG BMDCs grown with hFlt3L expressed about 20-fold more Flt3 receptor than cells 
grown with mFlt3L (Figure 6.20B, C). 
6.3  Discussion 
As DC development is dependent on the growth factor Flt3L, and defects in both intestinal 
and in splenic B27-TG DCs have been observed by others (144, 237, 239, 287) and by us, 
it  is  possible  that  there  is  an  inherent  developmental  problem  with  DCs  in  B27-TG 
animals. Thus, we investigated whether the development of DCs from bone marrow with 
Flt3L would be the same between non-TG and B27-TG animals. 
When  BMDCs  were  grown  for  7  days  with  10  %  mFlt3L  supernatant,  a  significantly 
reduced viability of B27-TG BMDCs compared to either B7-TG or non-TG BMDCs was 
seen.  This  defect  was  already  present  on  day  4  of  the  culture,  indicating  that  lack  of 
cytokines or nutrients in the medium was unlikely to be the cause for this loss of viability. 
This observed reduced viability of B27-TG BMDCs has not been reported before, but as 
described in the introduction, there are no previous reports of Flt3L being used to culture 
BMDCs from B27-TG rats.   
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Figure 6.18 Phenotype of BMDCs cultured with hFlt3L  
BM cells from B27-TG, B7-TG and non-TG animals were cultured with 100 ng/ml hFlt3L for 7 days, 
and on day 7 cells were harvested and stained for various markers as shown in figure. The 
expression level of these markers were compared between the animals. This experiment has only 
been performed once.  
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Figure 6.19. Viability and phenotype of BMDCs cultured with 100 ng/ml hFlt3L and 
stimulated with LPS 
BM cells were collected form non-TG and B27-TG animals, were cultured for 6 days in the 
presence of 100 ng/ml hFlt3L, and were treated with LPS on day 6. On day 7, the cells were 
harvested and stained with DAPI and antibodies for Annexin-V, MHCII and CD103. The phenotype 
and viability of both non-TG (A) and B27-TG (B) BMDCs were analysed by FACS. Figure is a 
representative of 3 individual experiments.  
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Figure 6.20 No difference in the Flt3 receptor RNA expression between non-TG and 
B27-TG animals  
mRNA was isolated from either freshly isolated BM cells or from BMDCs grown for 7 days 
with either 10 % mFlt3L or 100 ng/ml hFlt3L, and reverse transcribed into cDNA. The level of 
Flt3 receptor RNA was analysed by Q-PCR for both non-TG and B27-TG cells. (A) Two 
individual experiments showing the expression of Flt3 receptor on freshly isolated BM cells 
from non-TG and B27-TG animals. Figure shows the fold change for B27-TG BM cells when 
non-TG BM sample has been set to 1. Expression of Flt3 receptor was also analysed on 
BMDCs grown with either mFlt3L or hFlt3L for non-TG (B) and B27-TG (C). In both cases 
Flt3L receptor RNA expression in the freshly isolated BM sample has been set to 1, and 
other values indicate the fold change shown as fold change.   
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The alternative method of using GM-CSF and IL-4 generates DCs of a more inflammatory 
type, not the steady state DCs that the lymph DCs represent (60). Curiously, when GM-
CSF  and  Flt3L  were  used  together,  B27-TG  BMDCs  showed  significantly  improved 
viability compared to BMDCs grown with only mFlt3L. This could indicate there is a 
defect in the development of Flt3L dependent DC populations, but that the development of 
inflammatory DCs would not be affected in these animals.  
Phenotypic analysis revealed no great differences between non-TG and B27-TG BMDCs. 
Even though Flt3L cultured BMDCs are said to more closely resemble the steady-state DC 
populations (288), they are not identical to DC populations in vivo. One notable difference 
to in vivo DCs is the expression of CD4. In vivo, a population of rat DCs express CD4, and 
in L-DCs CD4 is co-expressed with CD172a (273). Only a very few CD4
+ cells were seen 
in mFlt3L BMDC cultures. However, it should not be attempted to draw direct correlations 
between in vitro and in vivo DCs, as in vivo DCs receive a constant flow of information in 
the form of chemokines, cytokines and interactions with other cells, whereas in vitro the 
conditions are much more restricted.  
BMDCs from both non-TG and B27-TG animals can be divided into three populations 
according  to  their  expression  of  MHCII  and  CD103:  MHCII
$  CD103
$  (DN),  MHCII
+ 
CD103
$  (CD103
$)  and  MHCII
+  CD103
+  (CD103
+)  populations.  Further  phenotypic 
characterisation  of  Flt3L  derived  BMDCs  revealed  that  the  three  BMDC  populations 
differed somewhat in their expression of L-DC subset markers CD11b and CD172a. Only 
the CD103
+ population was positive for both CD11b and CD172a, whereas the other two 
populations  were  more  homogeneous.  As  all  lymph  DC  subsets  are  positive  to  some 
degree for CD172a, it is likely that the CD103
+ population most closely resembles the in 
vivo L-DCs. No differences, however, were seen between non-TG and B27-TG BMDCs. 
The percentage and number of CD103
+ cells were compared between the non-TG and 
B27-TG animals and between the different culture conditions. It was hypothesised that 
Flt3L would induce more CD103
+ cells than the combination of Flt3L and GM-CSF, but 
this was not the case as B27-TG BMDC cultures with both Flt3L and GM-CSF contained 
more CD103
+ cells than Flt3L only cultures. However, BMDCs cultured with GM-CSF 
and IL-4 contain very few CD103
+ cells (Milling, unpublished data), suggesting that the 
CD103
+ DC population is indeed derived from Flt3L-dependent precursors. These results 
indicate, therefore, that in B27-TG animals Flt3L alone is not sufficient to support the 
survival and development of DCs, but addition of GM-CSF rescues the cells and augments 
their  survival.  Or  alternatively,  GM-CSF  could  be  working  on  its  own  and  generating  
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inflammatory-type DCs. In fact, examination of mice deficient in both Flt3L and GM-CSF 
revealed that these mice had fewer DCs than either single knockouts, and also the numbers 
of BM precursors were reduced (289). In the same publication it was observed that GM-
CSF and Flt3L are both required for steady state regulation of dermal DC populations, 
especially  the  CD11b
+  subset,  in  the  skin  (289).  Furthermore,  it  has  also  been 
demonstrated  that  CD103
+  CD11b
+  LP  DCs  are  reduced  both  in  GM-CSF  and  Flt3L 
deficient mice, suggesting they need both cytokines for their differentiation (290). As the 
dermal CD11b
+ cells can also be identified in the LNs, and CD103
+ DCs consist of DCs 
migrating from LP into MLN, these data indicate that some migrating DC populations 
require both Flt3L and GM-CSF for their development. The molecular mechanisms by 
which GM-CSF affects DC differentiation have been recently reviewed elsewhere (291). 
Curiously, as shown in chapters 4 and 5, it is the CD103
+ CD172a
lo migratory DC subset 
that is reduced in B27-TG animals. Thus, it could be possible that the B27-TG DCs have a 
defect in Flt3 signalling, but they can be rescued by GM-CSF. It would be important to 
determine the levels of circulating Flt3L and GM-CSF in these animals to establish if there 
differences between non-TG and B27-TG animals. As it is difficult to reliably identify DC 
subsets in other rat tissues, it could be that there are missing or reduced DC subsets in 
other tissues as well. Thus, at the present it is not known how exactly Flt3L and GM-CSF 
affect in vivo DC populations in the rat. 
LPS treatment of BMDCs revealed that the CD103
+ cells from both non-TG and B27-TG 
animals upregulated their expression of MHCII, thus further supporting the fact that these 
cells could be the in vitro equivalent of migrating L-DCs. The number of CD103
+ cells 
was not different between LPS treated and non-treated cultures, indicating that CD103
+ 
DCs do not proliferate in response to LPS, but just upregulate their MHCII expression. As 
could be expected because of the reduced overall viability of B27-TG BMDCs, after LPS 
stimulation B27-TG BMDCs had significantly decreased proportion of live cells compared 
to non-TG cells, but there was no difference in the absolute number of live cells/ well 
between non-TG and B27-TG BMDCs. However, when Flt3L+GM-CSF cultured BMDCs 
were stimulated with LPS, B27-TG DCs again demonstrated differential responsiveness to 
GM-CSF when compared to non-TG. Thus, B27-TG cells seem to respond differently to 
GM-CSF than non-TG cells, again indicating there could be a developmental problem with 
Flt3L-dependent B27-TG BMDCs, but not with the GM-CSF derived DCs. There were no 
great  differences  in  the  phenotype  of  B27-TG  and  non-TG  CD013
+  BMDCs  when 
expression of MHCII, CD11b, CD172a and CD25 were analysed before and after LPS 
stimulation. B27-TG CD103
+ DCs did seem to have constantly lower levels of all markers  
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investigated, but they did respond to LPS stimulation as non-TG cells. Expression levels of 
CD80  and  CD86  were  not  measured,  however,  so  it  is  not  clear  if  there  could  be  a 
difference in the expression of these markers between non-TG and B27-TG animals after 
LPS stimulation.  
It has been reported that the unusual biochemical properties of the HLA-B27 molecule can 
lead to accumulation of misfolded HLA-B27 protein in the ER, as discussed in detail in the 
Introduction. An increase in incorrectly assembled proteins can lead to ER stress, and to 
activation of unfolded protein response (UPR) where the cells try to re-establish normal 
homeostasis (247). However, if ER stress is severe or chronic, these responses can lead to 
apoptosis  or  increased  inflammatory  signalling  (282).  Thus,  it  could  be  that  B27-TG 
BMDCs were under ER stress and dying by apoptosis. Caspases are central molecules for 
the initiation of apoptosis, and a compound called Q-VD can inhibit three main caspase 
pathways: 9/3, 8/10 and 12 (284). We tested whether B27-TG BMDCs could be rescued by 
treatment with Q-VD. Indeed, when cells were treated with various concentrations of Q-
VD, we observed that the proportion of viable B27-TG cells increased in a concentration 
dependent manner. The best results were achieved when 10 µM Q-VD was used, with a 
significant improvement in the viability of B27-TG BMDCs compared to non-treated cells, 
and in addition the FSC and SSC characteristics of the cells became similar to non-TG 
cells. Even when using this very high concentration of Q-VD, no increased cell death was 
observed in the non-TG BMDCs, indicating that Q-VD is not toxic.  
Another compound called salubrinal was also tested. Salubrinal inhibits dephosphorylation 
of a molecule called elF2", which is involved in the activation the UPR pathway, and thus 
salubrinal  can  inhibit  ER-induced  apoptosis  (285).  No  improvement  in  the  viability  of 
B27-TG BMDCs was noticed when salubrinal was added to the cultures, despite a wide a 
range of concentrations used. However, it has been reported that salubrinal is not effective 
at inhibiting apoptosis in all cell types or cell lines, and thus it could be that it does not 
work effectively on the BMDCs (292). Since Q-VD improved the viability of cells and 
salubrinal did not, it could be argued that in the B27-TG BMDCs apoptosis is not caused 
by  ER  stress.  However,  ER  stress  has  been  suggested  to  activate  especially  the 
mitochondrial intrinsic caspase pathway as well, connecting these two mechanisms (293). 
It is also possible that I failed to discover the right concentration of salubrinal to use, and 
that is why no improvement in the viability of B27-TG BMDCs was seen. As Q-VD was 
so effective at inhibiting cell death in vitro and it did not show signs of toxicity even at 
very high concentrations, it might be possible to use it for treatment of B27-TG animals in  
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vivo, and to observe if this would have an effect on disease symptoms, or even if it would 
rescue the missing CD172a
lo L-DC subset. 
As was mentioned before, ER stress does not always lead to apoptosis, but it can also 
affect the functions of APCs either directly or indirectly. For example, co-culture of cells 
treated  with  the  ER  stress-inducing  agent  thapsigargin  with  mouse  BMDCs  leads  to 
increased production of inflammatory cytokines IL-6, IL-23 and IL-12p70 by the DCs, 
although  the  latter  two  are  only  induced  if  LPS  is  also  added  to  the  cultures  (294). 
Furthermore, thapsigargin-induced ER stress in human monocyte derived DCs induced 
increased production of IL-23 when LPS was added to cultures (295), and in addition 
increased  IL-23  production  by  LPS  treated  macrophages  from  AS  patients  has  been 
observed (253). A similar phenomenon has also been observed in B27-TG rats, where 
increased LPS dependent IL-23 production by macrophages (252), as well as increased 
Th17 cells have been noted (144, 252). Taking into account that all these results suggest a 
function-modifying role for ER stress, rather than apoptosis induction, the functions of 
surviving B27-TG and non-TG BMDCs were investigated, using the MLR as readout. 
Unlike L-DCs from B27-TG animals, B27-TG BMDCs grown with mFlt3L were very 
poor at driving CD4 T cell proliferation. Even when Q-VD was added to the cultures for 
the  duration  of  the  5-day  MLR  co-culture  to  increase  viability,  no  improvement  was 
noticed in the capability of B27-TG BMDCs to drive cell proliferation. A more refined 
MLR method was also used, where DCs were co-cultured with flow sorted naïve T cells. 
In this instance, the B27-TG BMDCs were grown in the presence of Q-VD for 7 days, and 
Q-VD was also added to the DC-T cell co-cultures for the duration of MLR. However, 
B27-TG DCs again did not succeed in driving proliferation on naïve T cells.  
Taking into account the information above suggesting that DCs and macrophages only 
show  increased  production  of  cytokines  when  also  stimulated  with  LPS,  it  would  be 
interesting to find out if the situation would change if these BMDCs were activated with 
LPS before the MLR. Migrating L-DCs from B27-TG were as good as non-TG L-DCs at 
inducing T cell proliferation, as shown in the previous chapter, which might be explained 
by the different microenvironments the L-DCs and BMDCs develop in. Also, taking into 
account the observed improvement in viability of B27-TG BMDCs when GM-CSF was 
used together with mFlt3L, it would be interesting to compare DCs grown with mFlt3L 
only to cells grown with both mFlt3L and GM-CSF. However, these results do suggest a 
specific  HLA-B27  dependent  defect  of  mFlt3L  cultured  BMDCs  in  inducing  T  cell  
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proliferation, as non-TG BMDCs were perfectly capable at driving T cell activation and 
proliferation.  
In the above experiments total flow sorted live DCs were used. However, it was noted 
earlier that when LPS was added to the BMDC cultures, only the CD103
+ cells upregulated 
their expression of MHCII. Thus, when the three BMDCs subsets were sorted and used for 
MLRs individually, it was noted that, as expected, the CD103
+ cells were far more capable 
at inducing proliferation of naïve T cells than the two other populations. But as the three 
BMDC populations also differed in their abilities to induce T cell proliferation, it is clear 
that these are indeed separate populations. In the previous chapter it was shown that B27-
TG L-DCs were less capable at driving proliferation of sorted naïve T cells, and thus these 
results indicate that both in vivo and in vitro CD103
+ DCs from B27-TG animals behave in 
a similar fashion.  
The concentrations of cytokines produced from the MLRs with CD103
+ DCs were also 
measured to assess whether B27-TG and non-TG BMDCs induce differentiation of T cell 
with different phenotypes. It was noted that B27-TG BMDCs induced significantly more 
IL-17F  and  lower  levels  of  IFN-!  compared  to  non-TG  cells.  The  concentrations  of 
cytokines varied between individual experiments, but always showed the same trend; B27-
TG  BMDCs  induce  more  IL-17,  even  though  they  stimulate  much  less  CD4
+  T  cell 
proliferation. In contrast, non-TG BMDCs induce more IFN-!. Of course, some of these 
MLR cytokines could be DC derived, such as IL-6, as it is not possible to differentiate 
which cytokines come from what cells exactly. Thus, to confirm the findings indicated 
above, and to confirm the cytokines are truly T cell derived, T cells from the MLR co-
cultures could be stained intracellularly with antibodies for IFN-! and IL-17. However, we 
have  not  been  successful  with  either  rat  IL-17  or  IFN-!  intracellular  staining  in  our 
laboratory, despite attempts over a number of years, with a number of protocols using 
published antibodies.  
The cytokine results differ from those seen in the previous chapter when ex vivo L-DCs 
were used, but that result was from one experiment and should be repeated to evaluate 
whether BMDCs and L-DCs truly differ in their functions. These functional experiments 
do reveal that not all BMDCs are equally capable of inducing proliferation of naïve CD4
+ 
T  cells,  and  thus  in  the  future  greater  care  should  be  taken  when  using  BMDCs  for 
experiments.  Also,  B27-TG  BMDCs  are  significantly  less  capable  at  inducing  T  cell 
proliferation  than  non-TG  BMDCs,  and  non-TG  and  B27-TG  BMDCs  stimulate  
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production of different cytokines. These results add to the existing knowledge about how 
defects in B27-TG DCs may induce inflammatory disease in B27-TG animals. 
As many investigators use recombinant human Flt3L instead of mouse Flt3L to culture rat 
BMDCs, it was also decided to see if it the species of origin of Flt3L would affect the 
viability B27-TG BMDCs. hFlt3L and mFlt3L have differences at both nucleic acid and 
protein level. The mFlt3L gene is about 4 kb long, whereas the hFlt3L gene is 5.9 kb, and 
the main translational product for both mFlt3L and hFlt3L is a transmembrane protein, 
which is cleaved to generate the soluble, bio-active form of Flt3L (296). The human and 
mouse Flt3L proteins are of similar length, with 235 and 231 aa respectively, and have 72 
% homology (296). However, while the extracellular domains of human and mouse Flt3L 
are similar, the cytoplasmic domains only share 52 % sequence homology. Furthermore, 
mice have an additional membrane-associated isoform of Flt3L that is biologically active, 
and resistant to proteolytic cleavage (296). Flt3LR is also structurally different between the 
two species (296). In spite of these differences, hFlt3L has been successfully used in mice 
both in vivo and in vitro to expand DC populations (60, 69).  
When BM cells were cultured with 100 ng/ml hFlt3L, it was immediately noticed that the 
viability of B27-TG BMDCs was better than when mFlt3L was used. B27-TG BMDCs 
still had a lower proportion and number of live cells, but the difference to non-TG animals 
was much less marked than when mFlt3L was used. In addition, when a much higher 
concentration (10 µg/ml) of hFlt3L was used, the difference between B27-TG and non-TG 
BMDCs was smaller still.  This led us to hypothesize that the 10 % mFlt3L used had a 
lower than 100 ng/ml concentration of Flt3L, and thus maybe B27-TG BMDCs require a 
higher concentration of Flt3L to develop properly. Unfortunately I did not analyse the 
concentration of Flt3L in the cell culture supernatant that was used for the experiments, nor 
did I use a lower concentration of hFlt3L, which could have also addressed this issue. 
However,  data  from  a  colleague  (Laura  Ford,  University  of  Glasgow,  personal 
communication)  indicated  that  the  10  %  mFlt3L  used  for  the  experiments  here  has  a 
concentration of about 160 ng/ml. If this is true, it indicates that B27-TG BMDCs respond 
differently  to  mFlt3L  and  hFlt3L,  and  importantly  B27-TG  cells  have  a  defect  in 
responding to the mFlt3L. There is some data to support a different response of murine 
DCs to human and murine Flt3L (297). In this study, mice were given in vivo the same 
concentration of either mFlt3L or hFlt3L, and splenic DC populations were compared. It 
was observed that hFlt3L caused a much bigger increase in DC numbers compared to 
mFlt3L. The authors could not provide an explanation for this observation. However, no  
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differences  in  the  yield  or  viability  of  non-TG  BMDCs  grown  with  either  mFlt3L  or 
hFlt3L were noticed, suggesting that at least non-TG rat cells are perfectly capable of 
responding to both mFlt3L and hFlt3L. Furthermore, there are no differences between cells 
grown with mouse or human Flt3L in the response to LPS treatment, and in addition the 
phenotype of mFlt3L and hFlt3L grown cells is very similar, suggesting again that rat cells 
are capable of using both human and mouse Flt3L. As it was mentioned at the beginning of 
this section, mFlt3L and hFlt3L are indeed different, and thus it could be that there is a 
difference in Flt3R between B27-TG and non-TG animals, causing B27-TG to be less 
responsive to mFlt3L. Unfortunately, there was not enough time to carry out functional 
studies to compare the ability of hFlt3L and mFlt3L derived BMDCs to induce T cell 
proliferation and cytokine production. 
Since experiments with mFlt3L did suggest there might be difference in the way non-TG 
and B27-TG BMDCs respond to Flt3L, it was decided to investigate by Q-PCR if the 
receptor for Flt3L was expressed at the same level on both non-TG and B27-TG animals. 
There was no difference in the level of Flt3 receptor on freshly isolated non-TG or B27-TG 
BM cells. However, it still possible that there could be differences between DC precursors 
from non-TG and B27-TG animals, but unfortunately it is not possible to identify and sort 
these  pre-cursors  from  rats  to  carry  out  more  detailed  studies.  When  BM  cells  were 
cultured  with  either  mFlt3L  or  hFlt3L,  and  the  expression  of  Flt3  receptor  was  then 
determined  on  these  mature  BMDCs,  it  was  first  noticed  that  Flt3  receptor  was  more 
highly expressed on cells from both Flt3L cultures when compared to fresh BM samples. 
But, in addition, it was also observed that both non-TG and B27-TG cells grown with 
hFlt3L showed about 20-fold higher level of Flt3 receptor expression than cells grown with 
mFlt3L. Again, this could indicate that the 10 % mFlt3L supernatant used contains less 
than 100 ng/ml of Flt3L. Or that mFlt3L is not as effective as the human equivalent. 
However  these  experiments  should  be  carried  out  several  more  times  to  obtain  more 
biological replicates, and thus confirm if this pattern is consistent. It would also be useful 
to determine the levels of Flt3L and maybe also GM-CSF in the serum of the animals to 
see if there are any differences between non-TG and B27-TG animals. 
In conclusion, these experiments have revealed a possible developmental problem in the 
mFlt3L-derived  B27-TG  BMDCs,  which  can  be  alleviated  by  GM-CSF.  This 
developmental problem was revealed when a significantly higher number of BMDCs from 
B27-TG  animals  were  observed  to  be  either  dead  or  undergoing  apoptosis  in  mFlt3L 
cultures. This phenomenon could be reversed by addition of caspase inhibitor Q-VD into  
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the  cultures,  providing  evidence  that  B27-TG  BMDCs  were  dying  by  apoptosis. 
Furthermore, it was shown that mFlt3L-derived B27-TG BMDCs also had a functional 
defect, as B27-TG MHCII
+CD103
+ DCs were significantly worse at inducing proliferation 
of naïve T cells in a MLR compared to non-TG cells. Despite this defect, more IL-17 and 
less IFN-! were found in the supernatants collected from the MLR co-cultures with B27-
TG DCs than with non-TG DCs. These data agree with a recent publication demonstrating 
that B27-TG splenic DCs induce more Th17 cells than non-TG splenic cells in vitro (144). 
In addition, it was also recently shown that increased numbers of Th17 cells are present in 
the colonic lamina propria of B27-TG animals compared to non-TG animals (252). Thus, 
as  in  many  other  inflammatory  diseases,  Th17  cells  have  also  been  implicated  in  the 
pathogenesis of B27-TG animal model of SpA. As an increased concentration of IL-17 
was observed in the B27-TG DC co-cultures, it could be that a defect in these DCs could 
drive differentiation of increased numbers of Th17 cells, and thus lead to inflammatory 
disease. However, discovering the exact role of these cells in the B27-TG animal model is 
not straightforward due to the lack of available antibody reagents, and the absence of 
knockout or additional transgenic animal models commonly used in murine research.  
Also, it is important to understand how these data could relate to the human disease. In 
humans in vitro, only monocyte derived DCs can be examined, and thus it is not possible 
to  directly  translate  the  findings  made  here  about  rat  BMDCs  into  humans.  Nor  is  it 
feasible, at least not in our laboratory, to test BMDCs from humans. In addition, due to the 
difficulty  in  obtaining  tissue  samples,  in  humans  circulating  blood  DCs  are  most 
commonly studied. In rodents however, these DCs are present in much lover frequency 
than in humans and are rarely studied, and in rats it is not possible to identify them, further 
limiting direct comparison of results from rat and human studies. However, much progress 
has been made recently in the identification of various human blood DC populations, their 
functions  and  possible  similarities  with  DCs  from  other  species.  In  our  laboratory,  in 
addition  to  detailed  phenotypical  analysis  of  human  blood  DCs,  DC  populations  from 
healthy controls and AS patients are being compared. We are hoping these exciting studies 
will add to the current knowledge of human DC biology, as well as hopefully reveal the 
role HLA-B27 has in DC function and disease pathology in patients with SpA.      
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7.  Final discussion 
In the preceding chapters several aspects of the SpA inflammatory disease both in humans 
and in B27-TG animals have been discussed in detail. In addition, I have discussed the 
relevance of my results to published data. Thus, in this final chapter I would like to present 
two models to address how HLA-B27 could contribute to development of inflammatory 
disease  both  in  the  animal  model  and  in  HLA-B27
+  SpA  patients.  These  models  are 
consistent with the data presented in previous chapters, but are not necessarily directly 
related and aim to take a wider view of the events leading to overt disease. The first model 
focuses on the cellular events that could lead to inflammatory disease in rats, but some 
aspects could also be relevant to human disease. As several events at the molecular level 
have been proposed to contribute to development of inflammatory disease, especially in 
the animal model, the second model aims to combine several aspects of these events in to a 
framework to aid in the design of future experiments. 
7.1  Model 1: Loss of a tolerogenic DC subset drives or 
exacerbates disease in B27-TG animals 
As shown in chapter 4, migrating intestinal DCs in rats can be divided into three subsets, 
which all migrate from the intestine into the MLN even in steady state. All subsets are 
MHCII
+ CD103
+, but differ in their expression of CD11b and CD172a. These subsets are: 
CD11b
lo  CD172a
hi  (CD172a
hi),  CD11b
+  CD172a
int  (CD172a
int)  and  CD11b
int  CD172a
lo 
(CD172a
lo). B27-TG rats lack the CD172a
lo subset of these DCs in the intestinal draining 
lymph, as shown in chapter 4, and the proportion of this same subset was also decreased in  
the MLNs of B27-TG animals (Chapter 5). The lymph defect was detected on rats over 10 
weeks  old,  when  these  animals  already  have  established  disease,  raising  the  question 
whether  the  DC  defect  is  caused  by  the  inflammatory  disease  in  these  animals.  The 
reduced proportion of CD172a
lo DCs in the MLNs was also originally observed on animals 
over 10 weeks old, however, I have subsequently discovered that the subset was already 
reduced  in  6-week  old  animals.  Animals  of  this  age  do  not  display  inflammatory 
symptoms,  suggesting  that  the  DC  defect  precedes  the  onset  of  clinical  inflammation. 
Thus, the lack of this subset could contribute to disease development in these animals. As 
has been discussed in detail throughout this thesis, the CD172a
lo subset is thought to be 
involved in induction and maintenance of peripheral tolerance, as it has been noted to carry 
self-antigen from the intestine to the MLN. In the absence of inflammation, DCs migrating  
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from the intestine are in a semi-mature state, expressing high MHCII, but only low or 
intermediate levels of co-stimulatory molecules. In the MLN, these DCs could present 
these “non-pathogenic” Ags to T cells without engaging co-stimulatory molecules, leading 
to induction of anergy or Treg cells in the responding Ag-specific naïve T cells. This 
phenomenon of peripheral tolerance is illustrated in Figure 7.1 (points 1-3), which depicts 
the situation in non-inflamed intestine of a non-TG animal. Both mice and human CD103
+ 
MLN DCs have been shown to be uniquely capable of inducing generation of FoxP3
+ Treg 
cells, and rat DCs have also been shown to be able to do this. In addition, CD103
+ DCs in 
the MLN are able to imprint the responding T cells with gut homing molecules CCR9 and 
"4#7. This aspect of CD103
+ DC function has not yet been investigated on rat DCs, but 
on-going studies in our laboratory are addressing this issue. After interacting with T cells, 
DCs remain in the MLN and probably die there. T cells and other lymphocytes, on the 
other hand, leave the MLN via efferent lymphatics, and return to circulation (Figure 7.1; 
point  4.).  As  these  cells  have  been  imprinted  with  gut  homing  molecules,  they  will 
eventually  home  back  to  the  intestinal  sites  (Figure  7.1;  5.).  These  events  create  a 
homeostatic balance in the healthy intestine, where DCs maintain tolerance to harmless 
pathogens, but are still able to mount a rapid response to pathogenic antigens.  
Figure 7.2 depicts the possible events taking place in B27-TG intestine. B27-TG animals 
lack  the  CD172a
lo  subset  of  DCs  in  lymph,  which  has  been  implicated  in  tolerance 
induction and maintenance (Figure 7.2; 1). At present, it is not known if this subset is 
present in intestinal tissue, but fails to migrate out to the MLN, or if there is a problem in 
the development of this specific DC subset from DC precursors. In either case, the result is 
that this subset is significantly reduced both in lymph, and in the MLN of B27-TG animals. 
The two remaining DC subsets have been previously shown to have a more activated 
phenotype compared to CD172a
lo subset, and also respond differently to TLR stimulation, 
indicating that these DCs are more immunogenic. Thus, it could be that these two subsets 
carrying antigen from self, food or commensal bacteria in to the MLN could present these 
harmless antigens in an immunogenic fashion, leading to development of active immune 
response rather than tolerance (Figure 7.2; 2+3). Th17 cells specifically have been recently 
linked to development of inflammatory disease both in B27-TG rats and in humans, and 
thus it could be that these DCs induce Th17 differentiation over Th1 or Th2 differentiation. 
Supporting this are the results from chapter 6, where B27-TG CD103
+ BM derived DCs 
stimulated less proliferation, but more IL-17F production from naïve CD4
+ T cells than 
non-TG DCs. In addition, splenic DCs from B27-TG animals have been shown to induce  
 
181 
more IL-17 production (144). We have not yet investigated the function of CD103
+ DCs 
from the B27-TG MLN.  
In addition to skewing towards Th17 induction, several other B27-TG DC defects have 
been reported, and these seem to specifically centre around DC – T cell interactions. Thus, 
it  could  be  that  B27-TG  CD103
+  DCs  have  additional  defect  in  imprinting  homing 
molecules on T cells. As was discussed above, DCs in MLNs would normally induce gut 
homing molecules on the cells they activate. However, defective DCs could induce other 
homing molecules, such as CCR4 for skin homing. This would lead to cells activated in 
response to intestinal antigens leave the MLN, and home to other tissues where they could 
potentially be involved in pathogenesis (Figure 7.2; 4). This would explain the various 
symptoms  observed  both  in  SpA  patients  and  B27-TG  rats.  Some  evidence  for  this 
defective  function  of  B27-TG  DCs  has  emerged  from  studies  in  our  lab  (Drs  Aude 
Aumeunier and Dawn Firmin, unpublished observations). However, some effector cells 
would also home back to the intestine, and contribute to development of the intestinal 
pathology  (Figure  7.2;  5).  Supporting  this,  increased  colonic  Il-17
+  APCs  have  been 
observed in B27-TG rats compared to non-TG animals (252). This could lead to a positive 
feedback loop, where Th17 cells induce more intestinal inflammation, leading to increased 
activation and migration of DCs to MLNs, and further generation of inflammatory cells. 
Data in chapter 4, however, demonstrates that there is in fact decreased number of DCs in 
the B27-TG lymph at 0-24h timepoint. This could be a result of chronic inflammation, 
where increased DCs did migrate at the acute phase, are not subsequently replenished 
properly from the precursors. As SpA patients often present with intestinal inflammation or 
lesions, it could be that some microbial events in the intestine, together with a susceptible 
phenotype, lead to development of inflammatory disease. This has been shown to be the 
case for development of reactive arthritis, but no direct evidence exists for other SpA 
disease.  Understandably,  investigation  of  human  DC  functions  is  more  complicated  as 
intestinal  tissue  samples  are  not  readily  available.  Thus,  research  is  mostly  limited  to 
peripheral  blood  DCs,  whose  relationship  with  their  tissue  counterparts  is  not  entirely 
clear. However, increased circulating IL-17
+ CD4
+ T cells have also been reported in AS 
patients, thus indicating that these cells might have a role in the human disease as well. 
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Figure 7.1 Hypothetical non-TG intestine 
(1) In a non-TG healthy intestine, CD172a
lo, CD172
int and CD172a
hi rat DC subsets are all 
present. There is a balance between all the cell types, and no overt inflammation. (2) DCs migrate 
continuously from the intestine into the MLN via lymph, where they present Ag derived from self, 
food or commensal bacteria to naïve T cells. Specifically, the CD172a
lo subset has been shown to 
carry self-Ag to MLNs. (3). As these DCs are not activated and express low levels of co-
stimulatory molecules, they induce T cells to either enter a state of anergy, or to differentiate into 
Tregs. Both these events contribute to peripheral tolerance to harmless antigens. Some effector T 
cells might also be generated. DCs in the MLN also induce expression of gut homing molecules, 
such as CCR9 and α4β7, on responding T cells. (4) T cells leave the MLN via efferent lymph, and 
return to the circulation. (5) Eventually, cells activated in the MLN return to intestinal sites. 
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Figure 7.2 Hypothetical B27-TG intestine 
1) B27-TG animals lack the subset of tolerogenic CD172a
lo DCs. In the absence of these cells, the 
remaining CD172a
+ DC subsets carry Ag from the intestine into the MLN (2) and present Ag from 
self, food or commensal bacteria to naïve T cells. (3) The remaining DCs could be more activated, 
and can induce immune responses rather than tolerance, as Ag are presented to T cells together 
with co-stimulatory molecules. Specifically, Th17 cell differentiation can be induced. DCs can 
induce gut homing molecules on these cells, however defective B27-TG DCs could also imprint 
expression of homing molecules to tissues other than intestine, such as CCR4 for skin. (4) Thus, 
effector T cells primed with intestinal Ag can leave the MLN, and home back to various tissues, 
such as skin or synovium, explaining the emergence of peripheral inflammation in the rat. (5) 
Effector T cells homing back to the intestine can exacerbate the intestinal inflammation, and lead to 
even more inflammation. 
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7.2  Model 2: Molecular events leading to SpA disease 
pathogenesis 
The cellular events presented above do not describe how the B27-TG DCs acquire their 
defective phenotype. In this section, I suggest molecular events that could lead B27-TG 
DCs and other cells to behaving differently from non-TG DCs. This model is unashamedly 
DC-centric. Thus, Figure 7.3 aims to demonstrate some of the molecular events that could 
contribute  to  either  development  or  maintenance  of  inflammatory  disease  in  rats  and 
humans. The model is based on published results. However, some of the events have been 
published to take place outside SpA diseases, or in other systems, and have been brought 
together to illustrate events that could take place.  
Firstly, HLA-B27 is a class I MHC molecule that behaves normally even in the transgenic 
animal system, and can thus present peptides on its surface to T cells. MHCI molecules 
normally interact with CD8
+ T cells, but as these cells appear to be redundant for disease in 
the animal model, alternative explanations have been proposed. For example, it has been 
shown that CD4
+ T cells from AS patients can bind to HLA-B27 molecules (257). In 
addition, it has been shown that HLA-B27 heavy chains can be expressed as !2m-free 
dimers on the cell surface (denoted B272) (249). These dimers are thought to be derived 
from heterotrimeric surface HLA-B27 molecules that are recycled through the endocytic 
pathway (298) (Figure 7.3; 1). It has been noted that KIR3DL1 and KIR3DL2 receptors 
expressed by NK cells and some T cells can recognise these unusual structures on the cell 
surface.  KIR3DL1  can  also  bind  to  intact  HLA-B27  molecules,  in  which  case  the 
interaction is dependent on the bound peptide. In contrast, interaction of both of these 
receptors with B272 is independent of the bound peptide sequence (264) (Figure 7.3; 2). 
Numbers of both CD4
+ T cells and NK cells expressing KIR3DL2 are increased in SpA 
patients  compared  to  healthy  controls  (265,  299).  KIR3DL2  is  an  inhibitory  receptor 
shown to decrease IFN-! production by NK cells upon binding their ligands (264, 299). In 
addition, KIR3DL2
+ cells from SpA patients are more activated, and in vitro culture with 
B272-expressing cells was shown to enhance their survival (265). As activated NK cells 
are potent killers, it could be that the increased resistance to apoptosis leads to increased 
numbers of NK cells in the tissues, which could contribute to pathogenesis in peripheral 
tissues. In addition, activated NK cells may induce DC maturation at sites of inflammation 
by a phenomenon called DC editing (300), and thus NK-DC interaction could lead to 
activation and maturation of DCs. The decreased IFN-! secretion could be of importance 
as  well  in  the  context  of  Th17  versus  Th1  polarisation,  as  IFN-!  is  needed  for  Th1  
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polarisation, but not to Th17 cell differentiation. This would lead back to the proposed role 
of Th17 cells in SpA disease pathogenesis, which will also be discussed more below. 
It has been shown that HLA-B27 molecule is prone to misfolding in the ER due to its slow 
maturation rate (248). This misfolding can create unusual heavy-chain homodimers in the 
ER, leading to accumulation of misfolded proteins in the ER, which has been demonstrated 
to cause ER stress in rats cells (250). ER stress triggers a specific cellular machinery, 
collectively called the UPR, which attempts to restore homeostasis in the cell (247). The 
UPR re-establish homeostasis, for example by decreasing protein translation in order to 
reduce  the  protein  load  in  the  ER.  If  these  remedies  are  not  successful,  the  cells  can 
eventually die by apoptosis. However, in some cases ER stress can lead to production of 
pro-inflammatory cytokines via the NF-%B pathway. The molecular events leading to this 
outcome are not known at present. TLR activation can be linked to these events as well, as 
it has been noted that macrophages from B27-TG animals treated with the TLR4 ligand 
LPS firstly show more signs of UPR, and secondly produce increased levels of IL-23 
(252). In addition, increased levels of IFN-! have been seen from TLR activated B27-TG 
macrophages  (301).  Furthermore,  monocyte  derived  macrophages  from  AS  patients 
showed markedly increased production of IL-23 upon LPS stimulation (253). However, the 
UPR has not been detected in human HLA-B27
+ cells. These events are depicted in Figure 
7.3 at points 3 and 4. Thus far, no study has been conducted using DCs from either AS 
patients  or  B27-TG  animals  to  investigate  the  effect  ER  stress  has  on  these  cells.  In 
addition, we did not look for IL-23 in our experiments presented here, so it is not clear if 
similar events could be taking place in DCs. In addition, rat L-DCs have been shown to be 
hyporesponsive  to  TLR4  stimulation  (189).  These  data  do  not  however  exclude  the 
possibility that events like those described above could take place in DCs, perhaps driven 
by several TLR agonists. Intestinal DCs have constant exposure to several TLR ligands, 
and  thus  it  could  be  that  TLR  ligation  leads  to  increased  DC  activation,  and  thus  to 
increased protein translation. In B27-TG cells, this would lead to accumulation of aberrant 
dimeric molecules in the ER, and would eventually lead to ER stress response. 
Activated  DCs  can  produce  the  cytokine  IL-6,  which  is  important  in  Th17  T  cell 
differentiation (see introduction). In addition to IL-6, Th17 differentiation requires TGF-!, 
which is also required for differentiation of FoxP3
+ Tregs. However, in the presence of IL-
6, Treg differentiation is inhibited, leading to induction of Th17 cells instead (Figure 7.3; 
5a, b). As mentioned above, HLA-B27
+ cells can secrete more IL-23 in response to TLR 
stimulation, and increased expression of IL-23 has been detected in macrophages/DCs in  
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the colon of B27-TG animals (252), and also in the terminal ileum of SpA patients (302). 
IL-23 is an important cytokine involved in maturation and activation of Th17 cells (Figure 
7.3; 6). Thus, aberrant behaviour of DCs and production of IL-23 can lead to increased 
numbers of Th17 cells. In fact, splenic DCs from B27-TG animals have been shown to 
induce more Th17 differentiation than non-TG DCs (144), and in addition, I noticed an 
increase in IL-17F cytokine concentration from MLRs with B27-TG BMDCs (chapter 6). 
Furthermore, increased numbers of IL-17
+ CD4
+ cells have been found in the colons of 
B27-TG animals (252). In humans, increased numbers of circulating IL-17
+ CD4
+ IL-23R
+ 
T  cells  have  been  found  in  the  peripheral  blood  of  SpA  patients  compared  to  healthy 
controls (267). In addition, these cells also express the KIR3DL2 receptor, and were shown 
proliferate when incubated in vitro in the presence of B272 expressing cells. Curiously, 
many  of  these  cells  were  also  shown  to  secrete  IFN-!  in  addition  to  IL-17,  and  the 
production of both cytokines was increased in response to IL-23. Recently, reports have 
emerged to suggest that Th17 cells differentiated in the presence of IL-6, IL-23 and IL-1# 
may acquire an “alternative” phenotype, and produce IFN-! and IL-17 (303). In fact, it is 
these “double producers” that are often found at inflammatory sites, and are proposed to be 
more  inflammatory  than  the  “classical”  Th17  cells  (303).  IL-23  can  also  have  Th17-
independent roles, as both DCs and macrophages can express IL-23R, leading to autocrine 
activation of the cells by IL-23, and leading to further inflammatory cytokine production 
(304). 
Th17  cells  produce  several  cytokines  that  have  been  indicated  to  have  a  role  in 
pathogenesis. Firstly, Th17 can produce the growth factor and pro-inflammatory cytokine 
GM-CSF. In a recent publication it was shown that in the mouse model of EAE, IL-23 
drives GM-CSF production by Th17 cells, and GM-CSF in turn drives IL-23 secretion by 
DCs (153) (Figure 7.3; 7). This would create a positive feedback loop, and lead to further 
increased  numbers  of  Th17  cells.  In  addition,  GM-CSF  can  drive  the  maturation  and 
activation of both DCs and macrophages, thus leading to increased production of other 
inflammatory cytokines (275). In addition, GM-CSF can act on monocytes, which can 
differentiate into inflammatory DCs, further perpetuating the inflammatory response. It is 
also not known at present if there are differences in the concentration of serum GM-CSF 
between HLA-B27
+ SpA patients and healthy controls. Other Th17 derived cytokines can 
have widespread effects on a variety of cells types, leading to activation and IL-6 and TNF 
production from these cells, which would further drive the inflammatory response in a 
variety of target organs (Figure 7.3; 8).       
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Figure 7.3 Molecular events leading to SpA pathogenesis 
(1) HLA-B27 can form β2m free heavy chain homodimers (B272) on cell surface, and these are 
thought to be generated in the endosomes from recycled intact HLA-B27 surface molecules. (2) NK 
cells can express KIR3DL1 and KIR3DL2 receptors, which can bind both intact HLA-B27 molecules 
as well as B272 dimers. These interactions, with other activating factors such as IL-15, can lead to 
increased survival and proliferation of NK cells. (3) HLA-B27 molecule has a propensity to misfold 
in the ER, leading to accumulation of HLA-B27 heavy chain dimers in the ER. TLR stimulation 
increases the misfolding rate, and can lead to ER stress and UPR. (4) ER stress can also result in 
production of pro-inflammatory cytokines such as IL-6 and IL-23. (5a) IL-6 produced by DC can 
inhibit differentiation of naïve T cells into Tregs, even in the presence of TGF-!, and instead they 
can differentiate into Th17 cells (5b). Presence of IL-1β can lead to generation of “alternative” Th17 
cells, identified by their co-production of IFN
−γ and IL-17. (6) In addition, Th17 cells can express 
KIR3DL2 receptor, which can bind B272 dimers. IL-23 produced by the DC can induce proliferation 
and survival of Th17 cells. (7) Th17 cells can produce GM-CSF, which induces increased IL-23 
production by the DC, thus creating a positive feedback loop. In addition, Th17 cells can produce 
other inflammatory cytokines, such as IL-21 and IL-17. (8) Th17 cytokines, and IL-23 alone, induce 
inflammatory changes in target cells and thus contribute to disease pathogenesis. 
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7.3  Conclusion 
Experiments presented in this thesis have added to the existing pool of knowledge about 
role of DCs in the B27-TG rat model of SpA. Specifically they have provided intriguing 
new evidence for the possible role of intestinal dendritic cells in the HLA-B27-associated 
disease pathogenesis. Hopefully in the future we will be able to further investigate the role 
these DCs have in the animal model, and perhaps also confirm whether similar events 
could take place in the human SpA. The immunological events leading to the development 
of human SpA are far from clear, and very little is known about the role DCs have in this 
process. Taking into account the evidence that has emerged from the animal model, it 
would not be surprising to find out DCs have a central role in the human SpA pathogenesis 
as well. SpA treatment at present is not always very successful, and it is heavily relaying 
on  the  therapeutics  used  for  treatment  of  RA  or  IBD,  which  are  related,  but  different 
diseases  with  different  immunological  fingerprints.  Thus  it  would  be  important  to 
investigate if DCs could be targeted to offer more specialised next generation therapeutics 
for treatment of SpA.       
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